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Abstract 
The physiology of the vasculature in the central nervous system (CNS) which 
includes the blood–brain-barrier (BBB) and other factors, prevents the transport of 
most anticancer agents to the brain and restricts delivery to infiltrating brain tumors. 
The heterogeneous vascular permeability in tumor vessels (blood-tumor barrier; BTB), 
along with several other factors, creates additional hurdles for drug treatment of brain 
tumors. Different methods have been used to bypass the BBB/BTB, but they have 
their own limitations such as being invasive, non-targeted or requiring the formulation 
of new drugs. Magnetic Resonance Imaging guided Focused Ultrasound (MRIgFUS), 
when combined with circulating microbubbles, is an emerging noninvasive method to 
temporarily permeabilize the BBB and BTB. The purpose of this thesis was to use this 
alternative approach to deliver chemotherapeutic agents through the BBB/BTB for 
brain tumor treatment in a rodent model to overcome the hinderances encountered in 
prior approaches tested for drug delivery in the CNS. 
The results presented in thesis demonstrate that MRIgFUS can be used to 
achieve consistent and reproducible BBB/BTB disruption in rats. It enabled us to 
achieve clinically-relevant concentrations of doxorubicin (~ 4.8±0.5 µg/g) delivered 
to the brain with the sonication parameters (0.69 MHz; 0.55 MPa; 10 ms bursts; 1 Hz 
PRF; 60 s duration), microbubble concentration (Definity, 10 µl/kg), and liposomoal 
doxorubicin (Lipo-DOX) dose (5.67 mg/kg) used. The resulting doxorubicin 
concentration was reduced by 32% when the agent was injected 10 minute after the 
last sonication. Three weekly sessions of FUS and Lipo-DOX appeared to be safe in 
the rat brain, despite some minor tissue damage. Importantly, the severe neurotoxicity 
seen in earlier works using other approaches does not appear to occur with delivery 
via FUS-BBB disruption. The resuls from three weekly treatments of FUS and Lipo-
DOX in a rat glioma model are highly promising since they demonstrated that the 
method significantly inhibits tumor growth and improves survival. Animals that 
received three weekly sessions of FUS + Lipo-DOX (N = 8) had a median survival 
time that was increased significantly (P<0.001) compared to animals who received 
Lipo-DOX only (N = 6), FUS only (N = 8), or no treatment (N = 7). Median survival 
for animals that received FUS + Lipo-DOX was increased by 100% relative to 
untreated controls, whereas animals who received Lipo-DOX alone had only a 16% 
improvement. Animals who received only FUS showed no improvement. No tumor 
cells were found in histology in 4/8 animals in the FUS + Lipo-DOX group, and only 
a few tumor cells were detected in two animals. Tumor doxorubicin concentrations 
increased monotonically (823±600, 1817±732 and 2432±448 ng/g) in the control 
tumors at 9, 14 and 17 days respectively after administration of Lipo-DOX. With 
FUS-induced BTB disruption, the doxorubicin concentrations were enhanced 
significantly (P<0.05, P<0.01, and P<0.0001 at days 9, 14, and 17, respectively) and 
were greater than the control tumors by a factor of two or more (2222±784, 3687±796 
and 5658±821 ng/g) regardless of the stage of tumor growth. The transfer coefficient 
Ktrans was significantly (p<0.05) enhanced compared to control tumors only at day 9 
but not at day 14 or 17. These results suggest that FUS-induced enhancements in 
tumor drug delivery for Lipo-DOX are relatively consistent over time, at least in this 
tumor model. These results are encouraging for the use of large drug carriers, as they 
suggest that even large/late-stage tumors can benefit from FUS-induced drug 
enhancement. Corresponding enhancements in Ktrans were found variable in large/late-
stage tumors and not significantly different than controls, perhaps reflecting the size 
mismatch between the liposomal drug (~100 nm) and Gd-DTPA (molecular weight: 
938 Da). Overall, this thesis research provides pre-clinical data toward the 
development of MRIgFUS as a noninvasive method for the delivery of agents such as 
Lipo-DOX across the BBB/BTB to treat patients with diseases of the central nervous 
system. 
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Chapter 1: Introduction 
1.1 Motivation 
Since the time immemorial there researchers have pondered over the vast 
empire of the brain. The central nervous system (CNS) has remained a focus of 
research and continued to hold some of the greatest mysteries in science and in 
medicine because it is challenging to utilize most drugs due to the presence of 
vascular barriers that prevent their delivery. For the treatment of brain-borne ailments 
in general, and tumors in particular, several techniques have been investigated to 
overcome these barriers, and new innovations are yet in process. In these other 
techniques, there have been significant shortcomings, such as invasiveness, non-
targetedness, or the requirement and expense of new drug formulation. The central 
inclination of this dissertation was to study an alternative approach with the potential 
to overcome the hinderances encountered in these other techniques to deliver a 
chemotherapeutic agent across the blood-brain barrier (BBB) and the blood-tumor 
barrier (BTB) for brain tumor treatments in a rodent model..  
1.2 The Blood-Brain Barrier 
The blood-brain barrier (BBB) is a specialized non-permeable barrier in 
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cerebral microvessels consisting of endothelial cells connected together by tight 
junctions, a thick basement membrane, and astrocytic endfeet. The tight junctions 
between the endothelial cells, together with an ensemble of enzymes, receptors, 
transporters, and efflux pumps of the multidrug resistance (MDR) pathways, control 
and limit access of molecules in the vascular compartment to the brain by paracellular 
or transcellular pathways  [1]. The BBB normally protects the brain from toxins and 
helps to maintain the delicate homeostasis of the neuronal microenvironment. 
However, it also excludes 98% of all small-molecule drugs and approximately 100% 
of large-molecule neurotherapeutics from reaching the brain parenchyma  [2,3]. Only 
small-molecule drugs with high lipid solubility and a molecular mass under 400-500 
Daltons (Da) can cross the BBB in pharmacologically significant amounts, resulting 
in effective treatments for only a few diseases such as depression, affective disorders, 
chronic pain, and epilepsy. Given the paucity of small-molecule drugs that have been 
shown to be effective for the majority of CNS disorders, it is clear that the BBB is a 
primary limitations for the development and use of drugs in the brain. Overcoming 
this hindrance could mean potential therapies for a wide range of disorders, including 
Alzheimer’s and Huntington’s disease, amytrophic lateral sclerosis (ALS), neuro-
AIDS, stroke, brain or spinal cord trauma, autism, lysosomal storage disorders, fragile 
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X syndrome, inherited ataxias, and blindness.  
1.3 The Blood Tumor Barrier 
Tumors of the brain, also face challenges for effective drug delivery. While 
the blood vessels of primary and metastatic brain tumors are often somewhat 
permeable from the lack of a fully formed BBB, infiltrating cancer cells at the tumor 
margins and small metastatic seeds may be protected by the BBB of the surrounding 
normal tissue  [4]. Glioblastomas in particular, are highly infiltrative, and commonly 
recurring after localized treatments such as conformal radiotherapy or surgery. 
Relapse usually occurs within a few centimeters of the treatment site  [5–7]. 
Furthermore, their vasculature permeability is heterogeneous, and additional barriers 
to drug delivery include increased interstitial pressures  [8] and drug efflux pumps 
that contribute to their multidrug resistance phenotype  [9]. As for metastatic tumors, 
work in mice suggests that the BTB is only partially compromised in breast 
adenocarcinoma brain metastases, and that toxic concentrations of chemotherapy 
agents are only achieved in a small subset of tumors that are highly permeable  [10]. 
Also, systemic drug accumulation in brain metastases can be substantially less than in 
extracranial metastases  [10]. Thus, the BTB is a hindrance of effective drug delivery 
in addition to the BBB.  
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1.4 Methods for Drug Delivery in the Brain 
In order to overcome these limitations, it is necessary to either bypass these 
vascular barriers altogether, or to facilitate passage across it via controlled 
exploitation of endogenous transport mechanisms. Different methods have been 
explored to bypass the BBB (or the BTB) (Table 1.1)  [11–13]. While these methods 
are promising, they also have limitations. 
1.4.1 Invasive Approaches to Brain Drug Delivery 
High local drug concentrations can be achieved by inserting a needle or 
catheter into the brain and directly injecting or infusing drugs or by implanting drug-
exuding devices. With such techniques, therapeutic benefits have been shown for 
brain tumors and other disorders  [14–17]. Because of their invasiveness, there are 
some risks of infection or brain trauma, and they may not be amenable for repeated 
treatments or for drug delivery to large areas of the brain. It can also a challenge to 
control the drug distribution, as drug concentrations decrease exponentially from the 
injection or implantation site  [18]. When convection-enhanced diffusion is used, the 
infused agents are delivered preferentially along white matter tracts  [19], which may 
not be desirable.  
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Another approach for bypassing the BBB is to introduce drugs into the 
cerebrospinal fluid (CSF) via intrathecal or intraventricular routes. It then follows the 
flow patterns of the CSF and enters the brain parenchyma via diffusion. This approach 
has been successful in cases where the target is in the subarachnoid space  [20], but 
drug diffusion drops off exponentially from the brain surface and penetration into the 
brain parenchyma can be limited  [11]. It is also possible to deliver drugs transnasally 
from the submucus space into the olfactory CSF  [21–24]. This approach has 
advantages of being noninvasive and being relatively easy to administer. However, 
only small drug volumes can be delivered and interindividual variability and other 
factors may pose challenges to this procedure  [24]. Nevertheless, the technique is a 
promising route to bypass the BBB and is currently being investigated by numerous 
researchers.  
1.4.2 Transvascular Brain Drug Therapy: Biopharmaceutical 
Approaches 
A number of approaches have been investigated to develop drugs that can 
cross the BBB or to modify or encapsulate existing drugs so they can. While these 
methods are highly promising and offer the ability to easily administer drugs to the 
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CNS as in other organs, they do require the expense and time of developing new 
agents, and they result in drugs being delivered to the entire brain, which may not 
always be desirable. Converting water-soluble molecules that would not ordinarily 
cross the BBB into lipid-soluble ones is one approach to brain drug therapy. This can 
be achieved by the addition of lipid groups, or functional groups such as acetate to 
block hydrogen bonding. The molecule would then undergo passive diffusion across 
the BBB. An example of this is the conversion of morphine to heroine by the 
acetylation of two hydroxyl groups, which results in the removal of the molecule from 
hydrogen bonding with its aqueous environment  [25]. Although utilized by the 
pharmaceutical industry, this approach has limited applicability to drugs greater than 
400-450 Da  [26,27] .  
Another approach involves utilizing the large variety of solute carrier proteins 
(SLC) on the endothelial surface that specifically transport many essential polar and 
charged nutrients such as glucose, amino acids, vitamins, small peptides, and 
hormones transcellularly across the BBB  [28]. These transporters move the solute 
into the cytoplasm where they await another SLC at the opposite cell membrane to 
exocytose them into the brain parenchyma. An example of an SLC used for brain drug 
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therapy is the large neutral amino acid transporter type 1 (LAT1), which transports the 
amino acid Parkinson’s drug L-dopa across the BBB. Once across, it is converted to 
dopamine by aromatic amino acid decarboxylase, and can then bind to its target 
receptor. Dopamine being water-soluble cannot cross the BBB  [26,29].  
Finally, the molecular targeting of endothelial-surface receptors, colloquially 
termed the “Trojan Horse” approach, is yet another paradigm in drug transport across 
the BBB. This involves using a targeting ligand such as a serum protein, monoclonal 
antibody, or other high affinity targeting molecule that binds to its receptor and 
activates endocytosis of the complex into a vesicle that is transported across to, and 
released from the opposite pole (i.e., transcytosis). In theory, if the ligand is 
chemically linked to a drug or drug carrier, it too is transported across the BBB. Over 
the last two decades, a number of animal studies have suggested the transport of 
antineoplastic drugs, fusion proteins, genetic therapies (plasmid vectors, siRNA), 
liposomes, and nanoparticles by this mechanism  [30–33] . For transcytosis to occur, 
it requires that the endosome not fuse with lysosomes while in the cytoplasm, which 
would degrade the internalized macromolecules. Unlike other tissues, endothelial 
cells in brain capillaries appear to have low levels of endosome fusion with lysosomes, 
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facilitating transport of necessary substances through the transcellular route  [34–36]. 
1.4.3 Transvascular Brain Drug Therapy BBB Disruption 
Others have investigated methods to temporarily disrupt the BBB to enable 
CNS delivery of circulating agents. One such technique investigated intensively for 
several decades is the use of intraarterial injection of a hyperosmotic solutions such as 
mannitol. This causes shrinkage of the endothelial cells and consequent stretching of 
the tight junctions  [37–40], through which drug may pass. This method has been 
shown repeatedly to enhance delivery of therapeutic agents to brain tumors, and 
several promising clinical trials have been performed  [41–46] . Other agents, such as 
bradykinin, have also been investigated  [47–50]. While such methods can be an 
effective means to deliver drugs to large brain regions, they are invasive procedures 
that require general anesthesia, and can have side effects. For example, one study 
reported focal seizures in 5% of osmotic BBB disruption  [41], and others have noted 
vasovagal response with bradycardia and hypotension  [40]. As I describe below, to 
overcome limitations of invasive and biopharmaceutical approaches of brain drug 
delivery, focused ultrasound (FUS) combined with circulating microbubbles has been 
investigated by numerous researchers.  
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Table1. 1 Different methods investigated to get around the BBB to deliver drugs to the brain 
 
Method Advantages Disadvantages 
Direct injection, convection-
enhanced delivery, implantable 
devices 
High local drug concentrations can 
be achieved; systemic 
administration avoided. 
Invasive; side effects; 
challenging to control; not 
readily repeatable. 
Intrathecal, intraventricular 
injection 
Effectively delivers drugs to 
subarachnoid space, brain surface. 
Little drug penetration beyond 
brain surface; invasive. 
Trans-nasal delivery Noninvasive; easy to administer; repeatable. 
Small volume of drug delivered; 
interindividual variability. 
BBB disruption via arterial 
injection of osmotic solution or 
other agents 
Effectively delivers drugs to large 
brain regions; large clinical 
experience. 
Invasive; requires general 
anesthesia; side effects; not 
readily repeatable. 
Modification of drugs to cross 
barrier through endogenous 
transport mechanisms 
Easily administered; delivered to 
whole brain. 
Requires systemic 
administration; expensive; each 
drug requires new development; 
clinical data lacking. 
BBB disruption via FUS and 
microbubbles 
Noninvasive; readily repeatable; 
can target drug delivery to desired 
volumes; can control "magnitude" 
of disruption; can be combined 
with drug-loaded microbubbles or 
magnetic particles for additional 
targeting. 
Requires systemic 
administration; currently 
technically challenging; large 
volume/whole brain disruption 
unproven; no clinical data. 
 
1.5 Ultrasound 
Ultrasound is a mechanical wave which can be generated by applying an 
oscillating electrical voltage to a piezoelectric material, such as certain crystals or 
ceramics, which respond with mechanical deformation in proportion to the applied 
voltage. The expansion or contraction of the material due to the electric potential 
causes the compression or rarefaction of its surrounding medium, such as air or water. 
When an oscillating voltage produces pressure waves with frequencies higher than 
upper limit (~18 kHz) of human hearing frequency, it is called ultrasound. The 
piezoelectric effect also works in reverse:  mechanical stress can conversely induce an 
electric voltage across the material. Thus piezoelectric transducers can be used both to 
generate and receive ultrasonic signals. In medical ultrasound, these frequencies 
typically range between 200 kHz and 10 MHz. The wavelength λ of the ultrasound is 
determined by the frequency f  
 fc /   1. 1 
where c is the speed of sound in the tissue. Typically sound velocity in soft 
tissue is c ≈ 1540 m/s. In soft tissues, this wave is primarily longitudinal, but shear 
waves can be generated under some circumstances, such as at soft tissue-bone 
interfaces.  
When ultrasound wave propagates through a medium (tissue) its amplitude 
(P(z)) is attenuated according to:  
    1. 2 
zePzP  0)(
where μ is the amplitude attenuation coefficient per unit path length and P0 is 
the incident peak rarefactional pressure amplitude at the surface. The attenuation 
coefficient depends on both absorption (µa) and scattering (µs) coefficients as  
 sa     1. 3 
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Both the absorption and scattering of ultrasound energy can produce heating in 
the medium  [51]. Ultrasound has a relatively low absorption rate in soft tissue, 
enabling it to propagate into even deep tissue strucutres. For example ultrasound with 
1.0 MHz, having an approximate wavelength of 1.5 mm, can penetrate up to 10 
cm  [52].  
1.5.1 Focused Ultrasound 
Focused ultrasound is an application of ultrasound in which the wave energy is 
concentrated to provide high gains and localized energy deposition. Ultrasound can be 
focused using a curved transducer geometry, a lens or reflector, or via electronic 
focusing. A diagram of a single element spherically curved transducer is as shown in 
Figure1. 1 
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Figure1. 1 Diagram of a focused ultrasound transducer 
In this case, intensity at point x on its axis can be written as 
 2
2
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where I(0) is the average intensity over the radiating surface, d is the diameter of the 
transducer, and R is the radius of curvature  [51]. 
At the geometrical focus, x ~R, the intensity can be approximate as  
 2
2
)
8
)(0()( 
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R
dIxI     1. 5 
The acoustic pressure profile near the focal plane can be approximated by  
 
z
zJRpRp )(2)0,(),( 1    1. 6 
where sinkaz  ,  is the acoustic pressure on the axis, and J1 is the first order 
Besel function  [51] 
)0,(Rp
The shape of the focus is long and narrow, and these dimensions depend on 
the focusing properties of the transducer, i.e. the transducer’s F-number (F = R/d), and 
the ultrasound frequency  [51]. For constant values of ultrasound frequency and 
transducer diameter, the position of focus and intensity gain can be changed with R. 
The maximum intensity can be pushed deeper into the tissue by increasing R. 
However, a high value of R reduces the focusing effect of transducer as a result the 
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focal region becomes longer and peak intensity smaller. Finally, the value of intensity 
becomes less than 1. Figure1. 2 shows the distribution of intensity along the axis of 
focused transducer with fixed value of d and frequency for different value of R. 
Moreover, the sharpness of the focus depends on the frequency. Ultrasound with 
higher frequencies can achieve tighter foci, while lower frequencies can produce 
wider focal regions.  
 
 
Figure1. 2 The axial intensity distribution from a focused transducer (diameter 60mm, frequency 
1MHz) for various values of radius of curvature calculated in tissue (attenuation 10 Npm-1). 
 
1.5.2 Application 
Ultrasound technology has been used for both diagnostic as well as therapeutic 
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applications. In diagnostic imaging, it is most notably used for fetal imaging and 
echocardiography. Low acoustic pressures (< 0.5 MPa peak-rarefactional) and short 
pulse lengths are used for this application. Typically, pulses are only a few cycles 
long, but are rapidly emitted to acquire real-time images at a rate of 10 to 30 frames 
per second. For current medical applications, diagnostic ultrasound is considered a 
safe imaging device that is routinely used to diagnose disease. Therapeutic 
applications of FUS can be achieved with both thermal and mechanical effects. For 
thermal application, the induced temperature is raised high enough over a short period 
of time (~ seconds) to cause cell death by protein denaturization and coagulative 
necrosis (tissue ablation), while in hyperthermia, an induced temperature change of 
only a few degrees for an extended period of time (~ minutes) can sensitize tissue to 
radiation and chemotherapy.  
In addition to thermal effects, it can induce mechanical effects in biological 
tissue. In cavitation, the interaction of a gas bubble with the acoustic field, whether by 
radial oscillation (stable cavitation) or violent collapse (inertial cavitation), can 
significantly enhance absorption and heating effects in tissue  [53]. Gas bubbles can 
form spontaneously in tissue during exposure to high intensity FUS, or pre-formed 
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gas bubbles, such as those found in ultrasound contrast agents, can be introduced into 
the acoustic field by intravenous injection. The microbubbles formed in the tissue 
concentrate the ultrasound effects in the microvasculature, thus greatly reducing the 
FUS exposure levels needed to produce bioeffects. The success of this technique has 
prompted its investigation in diverse medical applications, including tumor and tissue 
ablation  [54,55], hemostasis  [56], vessel occlusion  [57], thrombolysis  [58] and 
BBB disruption for drug and gene therapy in brain tissue. The specific application 
across the BBB will be discussed in greater detail in section 1.8. 
1.6 Ultrasound and Microbubble 
When microbubbles interact with ultrasound, different phenomena take place 
such as scattering, absorption of ultrasound and bubble oscillation. The oscillation 
will be either linear or nonlinear depending on the magnitude of applied acoustic 
pressure. At low acoustic pressures, the instantaneous radius oscillates linearly with 
amplitude of the applied external pressure field. For higher amplitudes of the external 
field, the pulsation of the bubbles becomes nonlinear. 
1.6.1 Linear Bubble Vibration 
In tissues, microbubbles are constrained within blood vessels or in small 
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regions of water within different tissue structures. Modeling the bubble behavior 
under such constraints is complex. A good understanding can be achieved by making 
some simple assumptions:  
1. A bubble is considered spherical and surrounded by a liquid of infinite extent and 
a constant viscosity. The bubble volume is defined by a single variable, the radius, 
and the motion of bubble is spherically symmetric.  
2. The wavelength of the ultrasound field is much larger than the bubble diameter, 
and only the motion of the bubble surface is of interest. The vapor pressure 
remains constant during the compression and expansion phase, and that there is no 
rectified diffusion during the short period of exposure to ultrasound.  
3. The gas inside the bubble is assumed to be ideal and compression and expansion 
takes place according to the gas law.  
4. At small excitation levels, the displacement of the bubble wall can be compared to 
the displacement of a simple one-dimensional mass spring oscillator. The 
oscillator is defined by its mass, restoring force, damping, and applied force.  
The equation of bubble motion can be modeled as:  
 drivFSxdt
dx
dt
xdm  2
2
  1. 7   
where m is the mass of the bubble–liquid system,   is the mechanical resistance 
related to the dissipation, S is the stiffness of the system, Fdriv(t) is the driving force, 
and x(t) is the radial displacement of the bubble wall relative to the initial radius R0, 
according to x(t) = R(t) - R0.  
For undamped simple harmonic oscillation the resonance frequency of bubble 
can be written as 
 
m
S
R
fR 2
1    1. 8 
For gas bubbles in a liquid, the stiffness is that of the enclosed volume of gas 
that acts like a spring when the bubble is disturbed from its equilibrium radius. The 
inertia is principally due to the mass of the liquid surrounding the bubble that 
oscillates with it. The derived value of the mass, the mechanical resistance, and the 
stiffness are  [59] 
 ,  304 Rm  mtot  , 0012 RPS    1. 9   
where   is the density of the surrounding medium, tot is the total damping,   is the 
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angular frequency,   is the heat capacity ratio (Cp/Cv), and P0 is the ambient pressure. 
The total damping tot  is sum of reradiation damping ( tot rad), damping due to 
viscosity of the surrounding fluid ( tot vis) and thermal damping ( tot th) i.e.  
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tot  = tot rad+ vis + tot th   1. 10 tot
The damping coefficients depend on the bubble size and the frequency of the 
acoustic field and are nominally on the order of 0.1 for bubbles with a diameter 
between 1 and 10 m . Exact expressions for the different damping components can be 
found in  [60]. 
Substitution of value m,  , and S into equation 1.8 above gives the final 
expression for the resonance frequency for a bubble motion without losses. 
 
3
RfR 2
1 P    1. 11 
This equation shows that the resonant frequency is inversely proportional to 
the radius. 
For an encapsulated bubble, the surrounding shell causes an additional 
restoring force. This can increase the resonance frequency  [61] of the bubble. 
 
m
shellS
Rfref 24
22

   1. 12   
where  is the resonance frequency of the encapsulated bubble,  is the resonance 
frequency for a free gas bubble, and Sshell the stiffness due to the shell. The shell is 
assumed to be homogeneous, of constant thickness, and perfectly elastic. The shell 
influences the surface tension and probably also the thermal damping. 
re Rf f
1.6.2 Nonlinear Bubble Vibration 
For large acoustic pressure fields equation 1.7 it is thought to be inadequate to 
fully model the bubble vibration phenomenon and a more sophisticated model is 
needed. In developing the initial model Rayleigh made following assumptions:  
5. The bubble is spherical, and is surrounded by an incompressible liquid with 
constant viscosity to infinite extent.  
6. The gas in the bubble is compressed and expanded according to the gas law with 
the polytropic exponent remaining constant during the vibration.  
7. Pressure at the bubble wall is at equilibrium. Combining the Rayleigh–Plesset 
equation and the polytropic gas law with the boundary condition, Nico-de Jong 
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where R, dR/dt, dR2/dt2 represent the radius, velocity and acceleration of the bubble 
wall, 1  is the density of the liquid, p0 is the ambient pressure,   is the surface 
tension,   is the polytropic gas exponent,   is the viscosity of the surrounding water, 
c is the speed of sound, and Pac(t) is the applied acoustic field. For simplicity only the 
viscous damping caused by the surrounding liquid has been taken into account. 
1.6.3 Coated Bubble Vibration 
Encapsulation of the bubbles dramatically changes their acoustical behavior. 
The shell causes an increase in resonance frequency due to its stiffness and an 
increase in damping due to its viscosity. Encapsulated microbubbles were first 
modeled by De Jong et al.  [61] and De Jong and Hoff  [62] incorporating 
experimentally determined elasticity and friction parameters into the Rayleigh–Plesset 
model. Church  [63] used linear visco-elastic constitutive equations to describe the 
shell. Since then many models have been defined to investigate the influence of the 
shell on the bubble’s vibration, e.g.  [64–67] including Marmottant model for 
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phospholipid-coated bubbles  [68] where he proposed three parameters to describe the 
properties of the shell: a buckling radius, the compressibility of the shell, and a break-
up shell tension. These three regimes can be expressed as following which add   
term in equation 1.13, )(R  is equal to zero if R ≤ Rbuckling, 


  1)( 2
2
bucklingR
RR   if 
Rbuckling ≤ R≤ Rbreak-up and )(R  becomes )(water  if R ≥ Rruptured. Buckling radius 
(Rbuckling) is a state that naturally occurs with dissolution of gas, or that can be 
accelerated by repeated pulses.  
1.7 Acoustic Characterization 
As mentioned previously, when bubbles interact with ultrasound they absorb 
as well as scatter energy. Both absorbed and scattered energy can be determined by 
using different kinds of measurement techniques  [69]. The scattered power of a free 
microbubble can be determined by its scattering cross-section and can be expressed 
as  [61]: 
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where s is scattering cross-section and f is applied ultrasound field. 
In case of coated bubble, there exists an additional damping constant due to 
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shell viscocity  [70]  
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0
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S 
     1. 15 
The expressions for other three damping constants are the same as equation 
1.10. However, the resonance frequency of the bubble depends on the shell properties, 
and this alters the value of damping constant. It was observed that encapsulated 
bubbles could scatter energy with different harmonics such as n-harmonics, sub-and 
ultraharmonics  [69] Like in case of scattering, absorption cross section also depends 
on damping coefficient as:  
 )1( 
rad
sa 
   1. 16 
where a  is absorption cross section. The total energy loss for an acoustic beam 
travelling through bubble solution is determined by the sum of scattering and 
absorption cross sections.  
1.8 Application in the Brain 
FUS has been investigated since the 1940’s for noninvasive ablation in the 
brain as a potential alternative to surgical resection and radiosurgery  [71–74]. Until 
recently, clinical testing required a craniotomy to allow for ultrasound propagation 
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into the brain  [75,76] because of ultrasonic heating of the skull bone and beam 
aberration caused by the skull’s irregular shape and large acoustic impedance. In the 
past decade, FUS thermal ablation systems have been developed that overcome these 
obstacles produced by the skull  [77]. They reduce skull heating through active 
cooling of the scalp and a transducer design with a large aperture to distribute the 
ultrasound energy over a large skull region, and they correct for beam aberrations 
using a phased array transducer design. When combined with methods that use 
acoustic simulation based on CT scans of the skull bone to determine the phase and 
amplitude corrections for the phased array  [78,79] and MRI temperature imaging 
(MRTI) to monitor the heating  [80], a completely noninvasive alternative to surgical 
resection in the brain becomes possible. These systems, use very high intensities to 
enable thermal ablation through the human skull, and are currently in initial human 
trials  [81,82], .  
1.8.1 Ultrasound-Induced BBB Disruption 
Since the early years of investigation into ultrasound bioeffects on the brain, 
several studies have noted localized BBB disruption, either accompanied with tissue 
necrosis or without evident tissue damage  [73,83–88]. None of these early studies 
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however, elucidated sonication parameters that could repeatably and reliably produce 
BBB disruption without occasionally producing lesions or necrosis. 
In 2000 our laboratory discovered that if short ultrasound bursts are preceded 
by an intravenous injection of a microbubble ultrasound contrast agent, the BBB can 
be consistently opened without the production of lesions or apparent neuronal 
damage  [89]. The circulating microbubbles appear to concentrate the ultrasound 
effects to the blood vessel walls, causing BBB disruption through widening of tight 
junctions and activation of transcellular mechanisms, with little effect on the 
surrounding parenchyma  [90]. Furthermore, the opening occurs at acoustic power 
levels orders of magnitude lower than was previously used, making this method 
substantially easier to apply through the intact skull. For BBB disruption, the 
sonications have been typically applied as short (~1-20 ms) bursts at a low duty cycle 
(1-5%) for 0.5-1 min. With a few simple modifications to enable low-intensity bursts, 
existing clinical brain FUS systems can be used for BBB disruption  [91]. Clinical 
translation may also be possible using simpler FUS systems  [92].  
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1.8.2 Effect of Ultrasound Parameters and Other Factors on BBB 
Disruption 
A number of sonication parameters can be varied in ultrasonic BBB disruption. 
Each parameter variation may impact the threshold pressure amplitude needed to 
disrupt the BBB, along with the magnitude of its disruption, and the resultant drug 
quantity delivered to the brain parenchyma. As determined from a number of studies, 
parameter variations and their effects are listed in Table1. 2. These studies used an 
MRI contrast agent, fluorescent probe, or drug to evaluate the BBB disruption. Given 
the large parameter space, and different techniques and criteria used to evaluate the 
disruption (each with different sensitivities), it can be challenging to compare results 
from different laboratories. Such comparisons are additionally confounded by 
uncertain accuracies in estimates of acoustic pressure amplitude when sonicating 
through the skull  [93]. However, general trends can be observed. 
For a fixed set of parameters, as one increases the pressure amplitude, the 
magnitude of the BBB disruption increases, and at some level it appears to 
saturate  [94–96]. Below some value, no disruption is detected, and at some higher 
pressure threshold, vascular damage is produced along with the disruption (see below). 
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Such studies repeated while varying a different parameter have shown that the 
threshold for BBB disruption depends strongly on the ultrasound frequency  [97] and 
burst length  [98]. Most experiments have been done with commercially-available 
ultrasound contrast agents that consist of microbubbles with a wide range of diameters. 
Experiments with microbubbles with narrow size distributions suggest that the BBB 
disruption threshold can also be reduced by using larger microbubbles  [99–101]. 
Pulse repetition frequency can also influence the magnitude of disruption up to a 
point  [102,103], but other studies have seen no dependence  [98]. Finally, the 
magnitude of the disruption can be increased by increasing the sonication 
duration  [96] or by repeating the sonication after some delay  [104,105], but 
excessive durations may result in tissue damage  [105,106] . Factors such as using an 
infusion instead of a bolus injection of microbubbles  [107] and choice of anesthesia 
protocol  [108] may also influence the resulting disruption. Other factors such as the 
delay between the microbubble injection and the start of sonication, and whether the 
drug or tracer is administered before or after the sonication may also be expected to 
have an effect. Additive effects have been observed when FUS-induced BBB 
disruption is combined with agents that affect vascular permeability  [109–111]. 
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These trends observed in parametric studies are difficult to interpret with 
confidence since the exact mechanism by which microbubble-enhanced FUS induces 
BBB disruption is currently unknown (see below). They are perhaps consistent with 
the following notions. First, for BBB disruption to occur, the microbubbles 
oscillations may need to reach a certain minimal radius, which can be achieved by 
increasing the pressure amplitude or by using larger microbubbles, and assuming the 
bubbles grow during each burst via rectified diffusion, by decreasing the ultrasound 
frequency or increasing the burst length. Next, in addition to depending on the bubble 
size during its oscillation, the magnitude of the disruption depends on the number of 
sites on which the microbubbles interact with the vasculature. The number of these 
sites can be increased by increasing the microbubble dose, or by increasing the 
sonication duration and/or number of bursts. Data showing a strong dependence on 
burst length may also suggest that the threshold and magnitude of the disruption 
depend on the amount of time the microbubbles interact with the blood vessels during 
each burst. Pulse repetition frequency may have an influence if the microbubbles are 
being fragmented or destroyed-time may be needed to replenish them if that is the 
case  [112]. Finally, it appears that the magnitude of the disruption can saturate at 
some level, and increasing the different parameters has no additional effect. 
Table1. 2 Reported effects of different parameters on BBB disruption via FUS and microbubbles. 
 
Parameter Effect on BBB disruption 
Pressure amplitude 
Increase in BBB disruption magnitude as pressure amplitude increases; 
saturation at some point  [94–96] ; vascular damage produced at high 
pressure amplitudes. 
Ultrasound frequency Decrease in BBB disruption threshold as frequency decreases; some evidence of improved safety for lower frequencies  [97]  
Burst length 
For burst lengths less than 10 ms, BBB disruption threshold increases and 
BBB disruption magnitude decreases as burst length is 
reduced  [98,102,103,113]; little or no increase in disruption magnitude for 
longer bursts  [93,102,114]. 
Pulse repetition frequency 
BBB disruption magnitude increases as repetition frequency increases up 
to a point  [102]. Other works have observed no effect on BBB disruption 
magnitude  [98]. 
Ultrasound contrast agent dose Magnitude of BBB disruption increases with dose  [102,115–117] ; other experiments have reported no effect  [98]. 
Sonication duration 
Longer durations  [96] or repeated sonication  [105,118], increase 
magnitude of BBB disruption; damage reported with excessive 
sonication  [96,105] . 
Microbubble diameter Threshold for BBB disruption lower for larger microbubbles; disruption magnitude increased with larger microbubbles  [100,101,119] . 
Ultrasound contrast agent 
Similar outcomes reported for Optison® and Definity® 
microbubbles  [120]. Sonovue® microbubbles and research agents are also 
commonly used. 
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1.8.3 Optimal Parameters for BBBD 
Overall, these studies have made it clear that BBB disruption is possible over a 
wide range of exposure parameters. Disruption has been demonstrated at frequencies 
between 28 kHz  [121] and 8 MHz  [113], burst lengths as low as a few ultrasound 
cycles  [102,103,122] up to 100 ms  [114], and over a range of pulse repetition 
frequencies, microbubble doses, and sonication times. It is not clear what the 
“optimal” parameters are, or what criteria to use to establish them. In our view, the 
primary consideration could be to find parameters that maximize the window in 
acoustic pressure amplitude where robust BBB disruption is possible without 
producing vascular damage. It will be challenging to precisely estimate the pressure 
amplitude in the human brain after transcranial sonication, and having the widest 
safety margin possible will be desirable for clinical translation. How close the FUS 
frequency is to the “resonant size” of the microbubbles may have an impact on the 
width of this safe window. Additional important criteria would be to optimize the 
frequency and transducer geometry to produce the desired focal spot size, to 
effectively focus through the skull with minimal distortion, and if a phased array 
transducer is used, to be able to steer the focal region throughout the brain. It may also 
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be desirable to find parameters that enable BBB disruption in the shortest possible 
sonication time so that multiple targets can be targeted in a reasonable amount of time, 
and to maintain a safe dose of microbubbles. 
1.8.4 Potential Mechanisms  
Even though FUS exposures combined with microbubbles have been 
investigated to disrupt the BBB in numerous studies, the exact mechanism to open 
BBB still remains unknown. It does appear that two known effects that can be 
induced by FUS, bulk heating and inertial cavitation, are not responsible. Initial 
studies on the method utilized MRI-based temperature imaging  [114] during the 
sonications, and no measureable heating was observed. Studies that recorded the 
acoustic emissions during the sonications  [123–125] have found that BBB disruption 
can be achieved without wideband acoustic emission, which is a signature for inertial 
cavitation  [74]. It may not also be the same mechanism utilized for so-called 
“sonoporation”, where transient pores in cell membranes created by sonication with 
microbubbles enable drugs to enter  [126]. Those pores are rapidly resolved, while 
FUS-induced BBB disruption lasts for several hours.  
Fundamentally, one does not know if the FUS/microbubble interactions 
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physically modify the vessel walls, or if they are triggering a physiological response 
that includes temporary BBB breakdown. As described below, electron microscopy 
studies have shown delivery of tracers through widened tight junctions  [90,127], 
which could be consistent with a direct physical force pulling them apart, as well as 
active transport  [90,128]. Other work has shown the sonications can induce vascular 
spasm  [129,130]. While the role of this spasm is not clear, it does make clear that the 
sonications can trigger a physiological response. 
In the absence of bulk heating and inertial cavitation, mechanical effects 
induced during the microbubble oscillations in the ultrasound field are likely sources 
for the disruption. A number of effects are produced with potential to induce the 
observed BBB disruption. Microbubbles tend to move in the direction of the wave 
propagation via acoustic radiation force  [131], which will bring them in contact with 
vessel endothelium. During oscillation, the shell of the microbubble can break, the 
bubbles can be fragmented into smaller bubbles, and they can grow via rectified 
diffusion. Microstreaming due to microbubble oscillations can induce biologically-
significant shear stresses on the neighboring endothelium, and the oscillations 
produce inward forces that in extreme cases can pull the vessel wall inward  [132]. 
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Clearly, the behavior of a microbubble in an acoustic field is complex, and it can be 
different in free fluid than when constrained within a capillary  [133].  
1.8.5 Bioeffects Induced by FUS and Microbubbles 
The BBB disruption occur almost immediately with sonication  [130] and 
appears to decay exponentially over several hours thereafter  [94,114,118,134]. The 
amount of agent delivered across the barrier appears to be much larger in grey matter 
than in white matter, presumably due to differences in vascular density  [91]. Several 
studies have found that the barrier appears to be largely restored in approximately 4-6 
hours  [94,114,118,128,134,135]; other experiments have observed low-level 
disruption at 24 hours after sonication or longer  [101]. The source of this discrepancy 
is not clear, but it could be simply that more sensitive detection methods such as high-
field MRI combined with large doses of MRI contrast agent are capable of detecting 
low-level disruption missed in other works. The duration of the opening to different 
tracers appears to be reduced for larger tracers  [134]. 
This window in time where the barrier is open is thought to be good for the 
prospect of delivering even long-circulating drugs, but not so long as to produce 
concern of toxicity arising from chronic BBB breakdown. Indeed, the appearance of 
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the brain after BBB disruption in light microscopy appears to be normal  [136], even 
after repeated weekly sessions  [91]. The only major feature that has been observed in 
many studies is the presence of tiny clusters of extravasated red blood cells 
(petechiae)  [137,138]. It is thought that these petechiae are formed during inertial 
cavitation, and experiments where no wideband emissions (a signature for inertial 
cavitation) were observed, no such extravasations were observed  [139]. Some have 
suggested that wideband emissions can be observed without producing such 
petechiae  [140]. While the presence of these petechiae is undesirable, their impact on 
the brain may be minimal. Investigations looking for apoptosis or ischemia, which 
may be expected if serious vascular damage were occurring, failed to anything more 
than a few individual damaged neurons, and long-term effects have not found 
evidence of neuronal damage with such sonications  [137,138,141]. However, as I 
show in section 4.1.2, this vascular damage might be exacerbated by a chemotherapy 
agent. At excessive exposure levels, more severe vascular damage, parenchymal 
damage, and neuronal loss can occur  [114,142].  
Transmission electron microscopy (TEM) investigations have demonstrated an 
increase of cytoplasmic vesicles in endothelium and pericytes (suggestive of 
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transcytosis), formation of trans-endothelial fenestrae, widened tight junctions, and 
transport of serum components across the BBB  [90]. The use of a 44 kDa tracer 
molecule helped elucidate arterioles as the major sight of trans-endothelial vesicle 
transport (followed by capillaries then venules), and showed extensive tracer 
deposition in the endothelial paracellular space, basement membrane, and surrounding 
brain parenchyma  [128]. Finally, using immunogold labeling, the disappearance of 
tight junction (TJ) proteins occludin, claudin-5, and ZO-1 were shown, along with 
opened endothelial junctions and tracer leakage at 1-4 hours post-sonication  [127]. 
The TJ proteins reappeared at 6 and 24 hours. Other work has shown down-regulation 
of the same TJ proteins along with their mRNA, and recovery to normal levels at 12 
hours post-sonication  [143]. Reorganization of connexin gap junction proteins have 
also been reported  [144]. An increase of endothelial vesicles in normal  [145] and 
tumor microvessels  [146] have also been observed on TEM with an up-regulation of 
caveolin proteins/mRNA, suggesting that caveolae-mediated transcytosis (CMT) as a 
contributing mechanism for permeability. These researchers also found increased 
phosphorylation of Src and caveolin-1/2, noting that Src-induced phosphorylation of 
caveolins is a trigger for CMT  [147]. 
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Intracellular signaling cascades in response to mechanical stimulation by FUS-
induced BBB disruption is likely, but has only recently been addressed. Increased 
phosphorylation of Akt and its downstream molecule GSK3β has been shown in 
neurons flanking the BBB disruption at 24 hours, well after tight junction 
reassembly  [148]. Akt phosphorylation has been implicated in neuroprotection after 
stroke  [149], while activation of the p38 JNK MAP kinases promote neuronal 
apoptosis  [150,151] . Alonso et al. showed increased protein ubiquitination in 
neurons not glia post sonication, no increase in heat shock proteins, and limited 
neuronal apoptosis at 24 hours in areas staining positive for extravasated 
albumin  [152]. Ca2+ signaling has also been suggested as being stimulated by FUS-
induced BBB disruption. Specifically, temporary disruption of the endothelial plasma 
membrane (i.e., sonoporation) can induce immediate transient changes of intracellular 
Ca2+ concentration in cells with direct contact with microbubbles, and delayed 
fluctuations in nearby cells  [153]. When factoring in fluid shear induced in an in vitro 
flow channel (intended to mimic cerebral vessels), the membrane disruption and Ca2+ 
transients were much lower  [154]. 
Multiphoton microscopy (MPM) has provided useful insights into the 
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bioeffects of FUS-induced BBB disruption. Initial work with this technique 
demonstrated arteriolar vasospasm in 14/16 mice lasting up to 5 minutes, and 
interrupted cerebral blood flow  [129]. Although this could cause ischemic injury, it 
has been noted that mice have enhanced vasomotor excitability over other rodents, 
such as rats  [155]. Indeed, a similar study in rats showed vasospasm in only 25% of 
the vessels examined  [130]. Initial work has also noted two forms of vessel dye 
leakage, rapid focal microdisruptions (3-9 seconds) that were prevalent at vessel 
bifurcations, and slow disruptions that were observed as a gradual increase in 
extravascular signal intensity  [156]. Subsequent work noted three rather than two 
leakage types: (1) fast, characterized by rapid increase to peak intensity and rapid 
decrease, (2) sustained, described as rapid increase to peak which persisted for up to 
an hour, and (3) slow, a gradual increase to peak intensity  [130]. The authors noted 
that differing vessel calibers have preferences for different leakage types, and 
interestingly, that distinct peak negative pressures also show preference for leakage 
types. Continuing work suggested correlation between fast leakage, common with 
high pressure amplitudes, and detachment of astrocyte endfeet from the vessel 
walls  [157]. 
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1.8.6 Delivery of Imaging/Therapeutic Agents and Tests in Animal 
Disease Models 
1.8.6.1 Delivery of Imaging Tracers 
One advantage of this method for targeted drug delivery in the brain is that it 
appears to be “drug neutral” – that is, it appears that many agents with a wide range of 
properties can be successfully delivered across the BBB and/or the BTB. A large 
number of imaging tracers Table1. 3 and therapeutic agents Table1. 4 which normally 
do not cross the BBB have been delivered to the brain or to brain tumor models with 
FUS and microbubbles. The amount of substance delivered and the distance from the 
blood vessels that it penetrates appears to depend on its size. For example, less 
delivery of an albumin-bound MRI contrast agent (MW: ~67 kDa) was evident 
compared to a standard agent (MW: 928 Da) in a macaque  [91]. This is even clearer 
in another study, where fluorescent Dextrans with different molecular weights are 
delivered to the mouse hippocampus. For 3,000 Da Dextrans, a relatively uniform 
fluorescence was observed; for the larger 70 kDa tracer, it was more concentrated 
near the blood vessels, and a 2000 kDa was found not to penetrate at all  [158]. This 
result points to a need for close examination of how the delivery of large agents 
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occurs – it may not be enough to look for the presence of the agent, but to also 
investigate whether it is delivered far enough from the vasculature at a high enough 
concentration to reach the desired target at a therapeutic level. Low-resolution 
methods such as MRI may not be sufficient for this purpose. It may be possible, for 
example, for agents to make it past the endothelial cells but get trapped at the 
basement membrane  [159].  
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Table1. 3 Example different tracers that have been delivered across the BBB 
 
Agent Size Use 
Lanthanum chloride 139 Da Electron microscopy tracer  [127]  
99mTc-Diethylenetriaminepentaacetic 
pentaacetate  
492 Da SPECT agent  [160]  
Omniscan® (Gd-DTPA-BMA) 574 Da MRI contrast agent  [101]  
Magnevist® (Gd-DTPA) 928 Da MRI contrast agent  [114]  
Trypan blue, Evans blue ~67 kDa Tissue dyes (binds to albumin)  [91,161]  
Ablavar® (Gadofosveset trisodium) ~67 kDa MRI contrast agent (binds to albumin)  [91]  
Horseradish peroxidase 40 kDa Electron microscopy tracer  [90]  
Dextran 3-70 kDa Fluorescent tracer  [158]  
Immunoglobulin G ~150 kDa Endogenous antibodies  [162]  
pCMV-EGFP¹ ? Plasmid DNA  [163]  
MION-47 20 nm MRI contrast agent  [141]  
Gold nanoparticles 50 nm Carrier for drugs or imaging  [164]  
Gold nanorods 10×40 nm Photoacoustic imaging contrast agent  [165]  
Dotarem, P846, P792, P904, P03680 1-65 nm MRI contrast agents  [134]  
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1.8.6.2 Delivery of Therapeutics 
A large number of therapeutic agents have also been delivered to the brain and 
to brain tumor models (Table 4). Many of the studies so far have investigated the 
delivery of chemotherapy agents, such as BCNU  [166], doxorubicin  [118], 
methotrexate  [167], cytarabine  [168], and temozolomide  [169]. Enhanced delivery 
of chemotherapy packaged in liposomes  [95,170] , targeted liposomes  [171] and 
magnetic particles  [172–174], which allow for MRI-based tracking and enhanced 
delivery via magnetic targeting have also been demonstrated. Other works have 
shown Trastuzumab, an antibody-based agent used for HER2-positive breast 
cancer  [175,176], and boronophenylalanine, which is used for boron neutron capture 
therapy, can be delivered to the brain and to brain tumor models  [177,178]. FUS-
induced BBB disruption has also been shown to improve the delivery of natural killer 
cells in a brain tumor model  [179]. Finally, a number of experiments have loaded 
chemotherapy and other agents into the microbubbles used for the 
disruption  [163,174,180–182], which offers the possibility of achieving even higher 
local payload at the targeted region. Delivering agents for neurodegenerative diseases, 
such as Alzheimer’s, Huntington’s, and Parkinson’s disease, have also been an active 
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area of research by several groups. A number of therapies for neurodegenerative 
diseases such as neuroprotective agents  [181,183] , antibodies  [162,184], plasmid 
DNA  [163], and siRNA  [157] have all been successfully delivered across the BBB 
using FUS and microbubbles. Other investigations have shown that circulating neural 
progenitor cells  [185] or viral vectors for gene therapy  [186–188] can be delivered to 
the sonicated regions after FUS-induced BBB disruption. 
 
1.8.6.3 Disease Models 
While delivery of these agents is promising, one also needs to demonstrate 
that the amount of drug delivered – and the drug penetration – is sufficient to produce 
a therapeutic response. In some cases it is also important to demonstrate that the drug 
reaches the desired target and is active after it is delivered  [183]. Several studies have 
shown that FUS enhancement of the BTB can slow tumor growth and/or improve 
survival in orthotopic murine models of primary or metastatic brain 
tumors  [166,170,172,173,189–191] . While in some cases the response has been 
modest, several of these studies have seen substantial improvements. Using multiple 
treatments may be necessary to achieve a pronounced improvement  [170]. One factor 
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that has not been investigated in depth so far is to confirm that drugs can successfully 
be delivered to infiltrating tumor cells, which are a major feature in glioma and other 
primary tumors, and to metastatic “seeds”. Both can be protected by the normal BBB. 
The orthotopic models investigated so far do generally not have large infiltrating 
zones, and the benefit observed in studies so far may have been primarily due to FUS-
enhanced permeability of the BTB. It may be challenging to get therapeutic levels to 
distant regions that are protected by the BBB. Some agents may have neurotoxic 
effects on the normal brain that may limit this ability.  
Beyond brain tumors, a study by Jordao et al. showed that delivery of 
antibodies targeted to amyloid plaques can reduce the plaque burden in Alzheimer’s 
disease model mice  [192]. While the decrease was modest, with multiple treatment 
sessions this may be an effective treatment strategy. In an intriguing follow-up study, 
the same group recently showed that FUS-induced BBB disruption alone can reduce 
the size of the plaques, perhaps through the delivery of endogenous antibodies [193]. 
We anticipate that these studies are only the beginning, and that FUS has a large 
potential for Alzheimer’s disease and other neurodegenerative disorders. Issues 
regarding the feasibility and safety of disrupting the BBB in large brain regions (or 
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the whole brain – perhaps repeatedly) may be need further investigation, however.  
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Table1. 4 Example therapeutic agents that have been delivered across the BBB or BTB 
Therapeutic Agent Size Use Delivered to 
Temozolomide 194 Da Chemotherapy Glioma model (9L)¹  [194]  
1,3-bis(2-choroethyl-1-
nitrosourea (BCNU)² 
214 Da Chemotherapy Glioma model (C6)¹  [180,195]  
Cytarabine 243 Da Chemotherapy Normal brain  [168]  
Boronophenylalanine 330 Da Agent for boron neutron 
capture therapy 
Glioma models (GBM 8401  [177]; 
9L  [178]) 
Doxorubicin 540 Da Chemotherapy Normal brain  [118]  
Methotrexate 545 Da Chemotherapy Normal brain  [167]  
siRNA ~13 kDa Huntington's disease therapy Normal brain  [157]  
Glial cell line-derived 
neurotropic factor 
(GDNF)²  
24 kDa Neuroprotective agent Normal brain  [181]  
Brain-derived neurotropic 
factor (BDNF) 
27 kDa Neuroprotective agent Normal brain³  [183]  
Herceptin (Trastuzumab) 148 kDa Anti-cancer antibody Normal brain  [175]; Breast cancer 
brain met. model (BT474)¹  [190]  
BAM-10 Aβ targeted 
antibodies 
~150 kDa Therapeutic antibody for 
Alzheimer's Disease 
TgCcrND8 Alzheimer's model 
mice¹  [184]  
BCNU-VEGF²  ~150 kDa Antiangiogenic-targeted 
chemotherapy 
Glioma model (C6)¹  [182]  
Plasmid DNA (pBDNF-
EGFP)² 
~3600 kDa4 Gene therapy Normal brain  [163]  
Epirubicin in Magnetic 
nanoparticles 
~12 nm Magnetic targeted 
chemotherapy 
Glioma model (C6)¹  [196]  
Doxorubicin in magnetic 
nanoparticles² 
~6-10 nm Magnetic targeted 
chemotherapy 
Glioma model (C6)  [174]  
BCNU in magnetic 
nanoparticles 
~10-20 nm Magnetic targeted 
chemotherapy 
Glioma model (C6)¹  [173]  
Adeno-associated Virus 
(AAV) 
~25 nm Gene therapy vector Normal brain  [186–188]  
Liposomal doxorubicin 
(Lipo-DOX) 
90 nm Chemotherapy Normal brain  [115]; Glioma model 
(9L)¹  [170,191]  
Interleukin-4 receptor 
targeted Lipo-DOX 
100-120 nm Chemotherapy Glioma model (8401)  [171]  
Neural progenitor cells 7-10 µm Stem cell Normal brain  [185]  
Natural killer cells (NK-
92) 
~10 µm Cell therapy for brain tumor Breast cancer brain met. model 
(MDA-MB-231-HER2)  [179]  
¹ Also showed improved outcomes with FUS-induced BBB disruption;  
² Used drug-loaded microbubbles;  
³ Also showed drug activity after delivery;  
4 Assumed 660 Da per base pair (bp), 760 bp for BDNF, and 4700 bp for pEGFP-N1 
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1.8.7 Treatment Planning, Monitoring and Evaluation 
As described above, FUS-induced BBB disruption utilizes the mechanical 
interactions between microbubbles oscillating in the ultrasound field and the 
vasculature. These interactions critically depend on the exposure parameters as well 
as the vascular density and perhaps other properties of the vascular bed. The latter, 
can affect the local concentration of microbubbles, how they interact with the 
ultrasound field  [133], and, more importantly, how much drug will be delivered to 
the brain  [91]. Unfortunately, many of these parameters are difficult to predict and 
are expected to vary significantly across different patients and diseases. Thus, 
methods are needed to (i) determine what parameters to use (treatment planning), (ii) 
refine them during sonication to ensure BBB disruption without overexposure 
(treatment monitoring), and (iii) evaluate the treatment effects (treatment evaluation). 
1.8.7.1 Treatment Planning 
In most cases, experiments evaluating FUS-induced BBB disruption in animal 
models have used a fixed set of acoustic parameters determined from prior experience 
and simple, geometrically-focused transducers. In general, accurate targeting can be 
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achieved with such systems using stereotactic frames  [197] if image-guidance is not 
available, and fairly repeatable results can be obtained with sonication through the 
thin skull in mice and rats, or in larger animals through a craniotomy. Methods to 
avoid standing waves  [93] that take into account variations in skull thickness  [198] 
can improve repeatability in small animal studies where transcranial sonication is 
used. Such approaches may be challenging to translate to human subjects, where the 
thicker skull is complex (a layer of trabecular bone surrounded by layers of cortical 
bone) and can vary substantially between individuals (3.5-9.5 mm)  [199]. The skull, 
which has a substantially higher acoustic impedance than soft tissue, will reflect most 
of the ultrasound beam, and the amount transmitted will depend strongly on the angle 
between the bone and the face of the transducer  [200]. Its irregular shape can also 
deflect and distort the beam, and reflections within the skull cavity need to be taken 
into account. To correct for beam-aberrations introduced by thick skulls, phased 
arrays composed of more than 1000 elements combined with skull aberration 
correction algorithms that utilize CT data are employed  [78,79]. These arrays can 
also be programmed to rapidly steer the beam electronically to multiple targets 
enabling coverage of tissue volumes  [91], and different portions of the array can be 
disabled to reduce internal reflections or exclude certain structures. 
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While these approaches that use acoustic simulations and CT scans are 
effective in restoring the focusing of the array after transmission through the skull, 
clinical experience with them for thermal ablation have shown that one still needs to 
correct for small errors (~1-2 mm) in targeting  [81,82]. To achieve this correction, 
one needs to be able to visualize the focal region at exposure levels that do not induce 
damage or other unwanted effects. Currently, this can be achieved using MRI-based 
methods that can visualize low-level (1-2°C) focal heating  [80,201] or map small 
tissue displacements of a few microns induced by radiation force  [202]. Ensuring 
accurate targeting will be most important if one aims to precisely disrupt the BBB at 
discrete locations. In addition, since the strength of the total microbubble activity, as 
well as magnitude of the disruption will depend on the vascularity of the targeted 
tissue (gray vs. white matter, for example  [91], it will be important to know exactly 
where the target is located. It might also be desirable to avoid direct sonication on 
large blood vessels. If one is uncertain about the targeting of the focal region, it may 
be challenging to understand whether a poor or unexpected result is due to an 
incorrect exposure level or to mistargeting. Pre-treatment imaging delineating 
vascularity, perfusion, or other vascular properties may prove useful for planning the 
treatment. It may also be useful to combine these measurements with models of the 
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microbubble oscillations within the microvasculature  [133,203]. 
Accurate control of the focal pressure is critical to ensure BBB disruption is 
produced while preventing inertial cavitation. The thick and complex human skull 
makes accurate focal pressure estimations extremely challenging. While the acoustic 
modeling methods developed for aberration correction may provide estimates of the 
focal pressure amplitude, it has not been validated to my knowledge. It may be 
possible to use the MRI-based methods mentioned above that can visualize focal 
displacements or heating to ensure a predictable focal pressure amplitude. Marty et al., 
for example, used MRI acoustic radiation force imaging to ensure a consistent 
exposure level between subjects in BBB disruption experiments in rats  [134]. 
However, one needs to take the underlying tissue properties (which may be unknown 
for tumors or other abnormalities) into account or test it in proximal normal brain 
locations. 
1.8.7.2 Treatment Monitoring and Control  
Given the challenges in predicting the focal pressure amplitude when 
sonicating transcranially, it is anticipated that effective monitoring of the procedure 
will be important if this technology is to be translated to clinical use. At minimum, 
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such monitoring should provide an indication that the exposure level is sufficient to 
induce BBB disruption and alert the user if inertial cavitation is occurring. One could 
use MRI methods for this purpose. Contrast-enhanced imaging can be used to 
visualize when the disruption occurs, and T2*-weighted or susceptibility-weighted 
MRI can be used to detect petechiae produced by inertial cavitation  [114,138]. These 
methods could be used now for control over the procedure in initial clinical tests of 
FUS-induced BBB disruption with experienced users. However, performing multiple 
MRI acquisitions would be time-consuming and may require to use excessive 
amounts of both US and MRI contrast agents, thus real-time and, perhaps, more direct 
methods are desirable for the prospect of widespread clinical implementation. 
1.8.7.2.1 Acoustic Emission  
Acoustic cavitation describes the oscillatons of either vapour or gas filled 
cavities within a liquid. Acoustic emissions from the oscillating microbubbles offer a 
potential way to guide and monitor bubble activities during ultrasound exposure in 
biological tissue. Harmonic (nf0, n = 1, 2, 3.., f0 = fundamental frequency) signal 
components can arise from different sources such as tissue, coupling media and 
microbubbles. Conversely, subharmonic (f0/2) and ultraharmonic (3f0/2, 5f0/2..) 
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emissions can arise only from bubble emissions and are indicators of stable 
cavitation  [204]. Acoustic cavitation can be detected both actively and passively. 
Active techniques use a pulse echo transducer to monitor the region where cavitation 
is expected. If transient cavitation occurs the diagnostic pulse will reflect off of the 
generated bubble cloud and a change in the backscattered signal will be detected. The 
same technique can be used to detect changes in backscattered signal following the 
injection of microbubbles. Alternatively, a passive transducer can be used to monitor 
the field and record the signal following sonications from the active transducer  [125].  
The spectral content and strength of the recorded emissions is sufficient to 
characterize and subsequently control the microbubble oscillations. Inertial cavitation 
is manifested in the frequency domain of the acoustic emission as a broadband 
signal  [74], and has generally been associated with the production of vascular 
damage during BBB disruption  [123,125], although other studies have suggested that 
it can occur without damage  [124]. Harmonic and/or sub- and ultra-harmonic 
acoustic emissions in the absence of broadband signal are indicative of stable 
volumetric oscillations, which consistently have been associated with safe BBB 
disruption  [123–125]. Arvanitis et.al have explored the strength of the harmonic 
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emissions as a basis for such a controller, as they have found that one can reliably 
detect it before inertial cavitation occurs and that it is correlated with the magnitude of 
the BBB disruption measured via MRI contrast enhancement  [123,125]. If one can 
integrate a large number of receivers into the FUS system, one can use passive 
reconstruction methods  [205,206]  to create two- or even three-dimensional maps of 
the microbubble activity to ensure that it is occurring at the expected location.  
1.8.7.3 Treatment Evaluation 
As described above, contrast-enhanced imaging and T2*- or susceptibility-
weighted imaging can be used to verify that BBB disruption has occurred and whether 
significant vascular damage has occurred, respectively. For tumors, it may be 
necessary to compare the signal enhancement after contrast injection to measurements 
obtained before FUS. However, as I show in section 6.1.2, the permeability changes 
to a small molecule MRI contrast agent may be minimal for late stage tumors. Other 
imaging modalities may also be useful  [207]. If the contrast-enhanced imaging is 
obtained before the therapeutic agent is injected, one can confirm that the BBB 
disruption is only occurring at the targeted locations before administering the drug, 
providing another level of control to ensure that drugs are delivered only to desired 
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regions. 
Post-treatment imaging could be more useful if one could use it to estimate 
drug uptake and penetration in the brain tissue. This can be achieved directly by 
labeling the drug with a contrast agent for MRI or other modality  [174]. It might also 
be possible to use a standard contrast agent as a surrogate measurement. A number of 
studies have related signal intensity changes of contrast-enhanced MRI at the end of 
the sonication with tissue drug concentrations  [95,175,208]. More quantitative and 
repeatable techniques, such as estimating contrast agent concentrations via T1-
mapping  [134,209] or vascular transfer coefficients via analysis of dynamic contrast-
enhanced MRI (DCE-MRI)  [99] have been used to perform spatial and temporal 
characterization of BBB permeability. DCE-MRI can also predict the resulting 
payload of drugs  [118] and in some cases in tumors  [209]. I explored this method 
with a liposomal agent in section 1.9. If one understands the relationship between the 
concentrations of the therapeutic and the imaging contrast agent, which can perhaps 
be established in animals, one might be able to titrate the drug administration to 
achieve a desired level in the brain. However, this may be challenging in tumors, 
where the vascular permeability can change over time  [209]. 
1.9 Dynamic Contrast Enhanced Magnetic Resonance Imaging
  
The technique of dynamic contrast enhanced magnetic resonance imaging 
(DCE-MRI), in which multiphase MRI scans are taken following the intravenous 
injection of a contrast agent. It has broadly been used in past studies to compute the 
permeability in applications such as embolic stroke, various types of cancer and 
injuries, both in humans  [210–212] and animals  [209,213–215].  
1.9.1 Pharmacokinetic Analysis of DCE-MRI 
There are many kinetic models; however, the Toft and Kermode (TK) model 
is usually used in clinical studies  [216–218]. This model provides information about 
the influx forward volume transfer constant from plasma into the extravascular 
extracellular space (EES) and fractional volume of EES per unit volume of tissue.  
1.9.1.1 Tofts and Kermode (TK) Model 
The TK model is one of the popular compartment models, which assumes the 
equilibrium of contrast media between the plasma and the EES and the isodirectional 
permeability therefore, the equilibrium is described by 
 )/(/ etptranst CCKdtdC     1. 17 
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where t is the time, Ct is the concentration of contrast media (CM) in tissue, Cp 
is the concentration of CM in plasma, Ktrans is the influx forward volume transfer 
constant (into EES from plasma), and ve is the fractional volume of EES per unit 
volume of tissue.  
The original TK model (one-compartment, two parameter model) assumes the 
concentration of the CM is derived from the EES components and the plasma 
component is negligible: 
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The modified TK model (two-compartment, three parameter model) assumes 
the concentration of the CM is derived from the EES and plasma 
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where υe is the fractional volume of plasma per unit volume of tissue. 
Substituting Ct and Cp in equation (1.19) variables (Ktrans, vp, ve) can be esitimated. 
Patlak analysis was used to estimate Ktrans and vp which assumed the value of the 
exponential term is unity because either the back diffusion rate Ktrans/ve is small, t-t’ 
is small or both. Under this condtion equation (1.19) becomes  
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Dividing entire equation by Cp(t) gives a linear equation and it’s slope and 
intercept gives the value of Ktrans and vp, respectively. For this analysis the required 
value of Ct can be obtained from DCE-MRI. However, the relationship between the 
signal intensity (SI) and the concentration of the CM is not linear, so the conversion 
of the SI into the concentration of CM is needed. In our case, the agent Gd-DTPA 
(Magnevist, Gd-DTPA; Bayer Healthcare; 0.25 ml/kg) as a CM was used.  
The Gd-DTPA concentration was estimated as a function of time at each 
image voxel with the following equation: 
     1. 21  CRTT 1101 /1/1 
where T10 is T1 relaxation time before injection of Gd-DTPA, T1 is T1 
relaxation times during the dynamic sequence (during and after injection of Gd-
DTPA), R1 is a constant (relaxation rate) of Gd-DTPA, which is 4.39 s−1 mM−1  [219] 
and C is the concentration of Gd-DTPA during the dynamic sequence. Maps of T10 
were generated by fitting the signal intensity of an spoiled gradient echo (SPGR) 
sequence acquired at multiple flip angles as described elsewhere  [220]. T1(t) was 
estimated using a SPGR sequence with the following expression:  
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where   and TR are the flip angle and repetition time of the SPGR sequence, 
respectively (more detail in chapter 1.13). S(t) is the signal intensity of the sequence 
as a function of time, and S(0) indicating the signal intesnsity before the contrast 
injection. 
The concentration of Gd-DTPA in plasma Cp(t) can be written as Cp(t) = Cb 
(t)/ (1-Hematocrit) where Cb(t) could be obtained by chosing   a region of interest in a 
vascular unit (ophthalmic artery ortransverse sinus) and value of hematocrit in rat was 
adjusted for a 45% capillary hematocrit level  [220]. 
1.10 Magnetic Resonance Imaging 
1.10.1 Basic Principles of MRI 
In the presence of external magnetic field B0 along z axis, a spin 1/2 nucleus 
can have one of two energy states Figure1. 3 with corresponding energies  [221] 
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where mI = ±1/2 are the values of z-component of angular moment of the 
nucleus,       is gyromagnetic ratio with a typical value for hydrogen nucleus is 2.675 
X 108 s-1 tesla-l, and   = 1.05× 10-34 J s is the Dirac constant. 
 
Figure1. 3 Energy level splitting of a nucleus of spin I = 1/2 in a static magnetic field B0 
The two energy leveles of the spin 1/2 nucleus depend on the relative 
orientation of spin with respect to applied magnetic field. The nuceli with parallel and 
anti-parallel spin orentations have low and high enerigies, respectively. The energy 
difference (E) between two levels depend on the applied magnetic field as  
0γBE        1. 24 
The corresponing electromagentic frequency 0γB  is called Larmor 
frequency (42.6 MHz/Tesla) and at this frequency atomic nuclus precess in the 
magnetic field. The value of magnetization in the direction of the applied field 
(longitudinal magnetization) is the sum of z-component of the nuculear magnet within 
unit volume and at thermal equilibrium this can be obtained by using Boltzman statics 
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 is spin density. Fo RI p , the most used spin 1/2 nuclus is 
hydrogen nucleus due to its abundance in animals. The magnetization due to the 
hydrogen nuclues is the source of signal in a MRI. For the detection of the 
magnetization, its direction is tilted away from B by applying radio frequency signals 
with frequency equals to Larmor frequency. When RF pulses are applied, the nuclear 
magnets start to distribute equally over the two energy states and gain the phase 
coherence.The magnetization can be tilted completely in transverse direction 
(perpendicular to B ) when the RF pulse is applied for long time. Immediately after 
RF pulse application, the spins start to return to thermal equilibrium and lose phase 
coherence. As a result the transverse magnetization (M ) begins to decay 
exponentially as  
where N r M urpose
0 
0

  20)(M T
t
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. In case of the inhomogeneous 
applied magnetic field, an additional decay in magnetization happened with time 
constant T2. In this case overall time constant is called T2* relaxation which can be 
written as  
  
where T2 is called the spin-spin relaxation time
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e value of lon a ation (Mz) start to 
increase as  
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lled spin-lattice rela ation. 1 and T2 relaxation times 
depend on the medium and are responsible for much of the tissue contrast exploited in 
standard MRI imaging sequences.  
roperties of MRI is to visualize the specific structure 
of biological tissue. The signal intensity depends on many parameters, including 
proton density, T1 and T2 relaxation times. Different pulse sequence parameters such 
as repetition time (TR) and echo time (TE) can vary with different bilogical tissues. 
TR is the time between two consecutive RF pulses measured in milliseconds. For a 
given type of nucleus in a given environment, TR determines the contributions to 
image contrast arising from the spin-lattice relaxation time T1. The longer the TR, the 
more the longitudinal magnetisation is recovered. Tissues with short T1 have greater 
signal intensity than tissues with a longer T1 at a given TR. A long TR allows more 
where T1 is ca x The T
1.10.2 MRI Sequences 
One of the most useful p
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magnetization to recover and thus reduces differences in the contribution of T1 to the 
image contrast. Signals with differing T1 values will therefore not be reduced in 
intensity to differing extents, giving rise to little or no T1-weighted contrast. TE is the 
time from the application of an RF pulse to the measurement of the MRI signal. TE 
determines how much decay of the transverse magnetisation is allowed to occur 
before the signal is read. It therefore controls the spin-spin relaxation time T2 and 
signal intensities in images will be weighted according to T2 values. The application 
of RF pulses at different TRs and the receiving of signals at different TEs produces 
variation in contrast in MRI images. A number of pulse sequences have been (and 
continue to be) developed. Here, we briefly discuss two basic sequences that illustrate 
the generation of T1-, T2- and T2*-weighted images. (1) The spin echo (SE) sequence 
is the most commonly used pulse sequence to create T1-and T2-weighted images. The 
sequence comprises two radiofrequency pulses - the 90 degree pulse that creates the 
detectable magnetisation and the 180 degree pulse that refocuses it at TE. The 
selection of TE and TR determines resulting image contrast. (2) Gradient echo (GRE) 
sequences can be generated by means of reversal of a pulsed field gradient, rather 
than by the introduction of a 180 degree pulse. Gradient echoes are commonly used in 
rapid imaging sequences; they generate T2*-weighted images.  
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 weight: 580Da) is a commonly-used anticancer drug 
for treatment of a wide range of cancers. Also known as Adriamycin, it is an 
anthracycline antibiotic derived from daunorubicin, which was isolated from the 
pigment producing bacteria Streptomyces peucitis  [222]. Doxorubicin is active 
against leukemias and many solid tumours, including breast, endometrial, ovarian and 
bladder cancers, as well as adult and pediatric sarcomas, either alone or more 
commonly in combination with other drugs  [223]. Typically administered as 
infusions of 50 mg/m2 repeated every four weeks, the dose and frequency of 
administration are limited by acute myelosuppression, the occurrence of which is 
correlated with the integral of the plasma doxorubicin concentrations over time  [224]. 
Figure1. 4 shows that intratumoral Doxorubicin concentration is strongly correlated 
(R2 = 0.90) with patient response rate, irrespective of the type of cancer  [225]. 
However, it has not typically used for brain related diseases because it can not pass 
through the BBB. Walter et.al  [226], showed that direct intratumoral infusion of 
Doxorubicin prolonged the survival time in glioma patients. It is believed that 
doxorubicin’s antitumour effect is due to its localization in the nucleus of tumour cells 
where it binds to topoisomerase II and prevents resealing of the double helix during 
1.11 Doxorubicin  
Doxorubicin (molecular
DNA synthesis, leading to growth arrest and apoptotic cell death. This process also 
causes the unwanted death of normal cells.  
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In order to reduce the toxic effect, encapsulation of Doxorubicin within 
microsc
    
opic (~100 nm) phospholipids vesicles, known as liposomes, has been used. 
Liposomally encapsulated doxorubicin (Lipo-DOX) also prolongs the circulation 
time  [227] in the vasculature. Due to these benefits, Lipo-DOX is commonly used in 
clinics instead of free doxorubicin.  
 
Figure1. 4 Fluorescence spectra for doxorubicin in aqueous solution. A, Absorption spectrum shows 
maximum absorption at 480 nm (curve B, pH 2-7)  [228]. B, Emission spectrum with excitation at 479 
For quantification of Doxorubicin one can use optical spectroscopy since it 
has em
nm shows maximum emission near 595 nm  [229]. 
 
ission peaks at 554 nm and 585 nm when excited at wavelengths of 470-490 
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 of t is Thesis 
Prior research work demonstrated that FUS can enhance the delivery of Lipo-
DOX i
The first set of experiments were focused on the study of the distribution and 
quantif
nm  [228,229].   
1.12 Scope h
n normal brain through the BBB using high frequency (1.6 MHz) ultrasound 
with a long exposure time  [95]. In addition, a single treatment with FUS and Lipo-
doxorubicin in glioma tumor model showed an improvement ~24% compared to 
untreated controls  [115]. However, detailed quantification of the drug delivery 
though BBB and therapeutic efficacy of multiple treatments have not been studied. 
The overall objective of this thesis work was to investigate effect of low frequency 
(0.69 MHz) transcranial FUS (similar to that used clinically) on the permeability of 
the BBB/BTB, the pharmacokinetics of Lipo-DOX, and the therapeutic efficacy and 
safety profile of multiple treatments with FUS+Lipo-DOX in an animal model. 
ication of Lipo-DOX and the released free doxorubicin, both on a macroscopic 
and a microscopic level. Here the doxorubicin concentrations after BBBD were 
compared for cases when the agent was administered before and after ultrasound. The 
findings of this study helped to establish the drug injection protocol to increase the 
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In the second set of experiments using the developed protocol for drug 
injectio
Using the parameters established in the above safety study, the therapeutic 
efficacy
The usefulness of MRI as a monitoring and feedback tool for the delivery of 
Lipo-D
local penetration of Lipo-DOX across the BBB to achieve a high concentration of 
doxorubicin for subsequent drug delivery experiments. 
n, the effect of multiple sessions of FUS-induced BBB disruption with and 
without Lipo-DOX were compared in the normal rat. Variations in the acoustic power 
required to to disrupt the BBB were established over three weeks to take into account 
the thickening of the skull as the rats grew. This safety study showed that FUS-BBBD 
can be used for treatment at multiple times based on histological evaluation, and it 
identified potential risks related to inertial cavitation. 
 of multiple treatment sessions with FUS-BBBD and Lipo-DOX was explored 
in the 9L rat glioma model. These treatments were compared to control animals and to 
animals who received treatments with FUS-BBBD or Lipo-DOX only. The impact of 
multiple treatments on tumor growth rates, survival times and histology were 
compared among these four groups.  
OX was explored by comparing the transfer coefficient Ktrans for the MRI 
65 
 
Overall, these results provide evidence that the multiple treatments with this 
ultrasou
 
contrast agent Gd-DTPA, which was measured using DCE-MRI, to the resulting 
doxorubicin concentration in the tumor. Moreover, acoustic monitoring of bubble 
activity during sonication was correlated with signal intensity of Gd-DTPA after 
sonication.  
nd-enhanced drug delivery technique has a good potential to enable the 
effective use of Lipo-DOX for the treatment of brain tumor. 
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Chapter 2: Methods and Materials 
2.1. Animals  
The experiments performed in our laboratory were approved by our 
institutional animal committee. The test subjects used were male Sprague-Dawley rats 
(200-400 g) acquired from Charles River Laboratories (Boston, Massachusetts). In 
preparation for imaging, surgery or sonication, the rats were anesthetized by i.p. 
administration of ketamine (90 mg/kg) and xylazine (10 mg/kg) per hour, or as 
needed. The hair covering the dorsal surface of the skull was removed with depilatory 
lotion. For experiments requiring i.v. administration of contrast agents or 
chemotherapy, a 24-gauge catheter was inserted into the tail vein.  
All animals were cared for in accordance with our institutional animal care 
policy. For animals in experiments of ultrasound-mediated drug delivery, animals 
were euthanized by transcardiac methods with normal saline 1-4 h after the last 
sonication. For animals which were implanted with glioma for the survival study, 
euthanasia of those exhibiting severely impaired activity or weight loss exceeding 
20% within one week, tumor dimensions exceeding 10–11 mm, or if treatment-related 
severe adverse events occurred that caused pain or distress and that could not be 
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ameliorated. Euthanasia in these animals was conducted by transcardial perfusion 
with saline followed by 10% phosphate-buffered formalin while under deep 
anesthesia. The animals employed in the safety study that did not exhibit such poor 
outcomes were euthanized approximately seven weeks after the last treatment by 
transcardial perfusion with saline followed by 10% phosphate-buffered formalin 
while under deep anesthesia. 
2.2 Ultrasound Transducer 
For all experiments, the ultrasonic fields were generated by a single-element, 
spherically curved, air-backed piezoelectric (PZT-Lead zirconium titanate) transducer 
(manufactured in-house) with a diameter of 100 mm, radius of curvature of 80 mm, 
and resonant frequency of 0.690 MHz (Figure 2. 1). The electrical impedance of the 
transducer was matched to the output impedance of the amplifier by means of an 
inductor-capacitor circuit contained within an external matching box. The function 
generator, amplifier, power meter, and matching circuit were part of the MRI-
compatible FUS system described below in section 2.1.3 
 
 Figure 2. 1 A single-element, spherically curved, air-backed piezoelectric transducer with a diameter of 
100 mm, radius of curvature of 80 mm, and resonant frequency of 0.690 MHz. 
2.1.2.2 Transducer Characterization  
Figure 2. 2 shows the characteristic beam plots of the 0.690 MHz transducer, 
which produced a ellipsoid focal spot with diameter and length of 2.3 mm and 12 mm, 
respectively, at half-maximum pressure amplitude. The plots were created by 
scanning a needle hydrophone (ONDA, Sunnyvale,CA) in a raster pattern 
perpendicular (top) and parallel (bottom) to the direction of the ultrasound beam.  
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Figure 2. 2 Characteristic beam plots of the intensity for the 0.69 MHz transducer 
2.1.2.3 Transducer Calibration  
The transducer efficiency was measured using an acoustic radiation force 
balance system  [51]. The system is based on the principle that an acoustic wave 
exerts a force F on an absorbing target that is proportional to the total ultrasonic 
power (P) intercepted by the target surface. The radiation force (F) is  
v
DPF    2. 1 
where v is the propagation velocity of the wave in water and D is a constant 
that depends on the type of interaction between the target and beam. For a perfect 
absorber D = 1. If R is the radius of curvature of the transducer, L is the focal length, 
and the angle of incidence is zero degrees, then the force measured along the beam 
axis is  
])[()2)(( 2
1
222 LLR
R
L
v
PF     2. 2  
The transducer was immersed in degassed, deionized water (pO
2 
<1 ppm) and 
driven at peak-to-peak voltages ranging from 0.01-0.09 V in 10 mV steps. A densely 
bristled brush was used as the absorbing target to encompass the complete acoustic 
beam emitted by the transducer. The brush was suspended in the water by a thin wires 
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attached to an electronic scale so that its face lay directly opposite the transducer. For 
each voltage, the acoustic power output of the transducer was calculated from the 
force exerted on the brush, which was measured by the change in weight of the 
absorbing brush. The output acoustic power was averaged over three measurements 
was divided by the input electrical power to compute the efficiency of the transducer 
(Table 2.1). Measurements made at the lowest applied voltage were disregarded. 
 
 
Table 2. 1 Acoustic efficiency of air-backed single-element transducer. Frequency: 0.69 MHz; Radius 
of curvature: 80 mm; Diameter: 100 mm; F number: 0.8. 
 
Applied Voltage (V) Electrical Power (W) Acoustic Power (W) Efficiency (%) 
0.01 0.025 0.0059 23 
0.02 0.112 0.089 80 
0.03 0.25 0.19 76.5 
0.039 0.42 0.39 76.9 
0.04 0.44 0.41 78 
0.041 0.46 0.42 77 
0.042 0.48 0.44 78.5 
0.043 0.5 0.47 78 
0.044 0.53 0.48 77.7 
0.045 0.56 50 76 
0.05 0.68 0.53 77.6 
0.06 0.99 0.76 77.5 
0.07 1.36 1.05 76.9 
0.08 1.77 1.35 76 
0.09 2.25 1.56 70.6 
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2.1.2.4 Estimated Pressure Amplitude in the Brain 
Throughout this thesis, the reported exposure levels are absolute peak negative 
pressure amplitudes measured in water with a membrane hydrophone (Marconi; 0.5 
mm diameter). Attenuation by the brain and rat skull is expected to reduce the 
pressure amplitude by ~30% at this frequency  [198] with additional uncertainty 
arising from standing waves within the skull and increases in skull thickness as the 
animal ages  [230].  
2.3 Experimental Set-up 
The sonication system was operated within a clinical 3T MRI scanner (Signa; 
GE Healthcare). The transducer was immersed in a small tank of degassed, deionized 
water and attached to an MRI-compatible, manually-operated positioning system 
(Figure 2. 3). The animal was laid supine on a tray above this tank, with a water bag 
providing an acoustic path to the dorsal surface of the head. The animal's body 
temperature was maintained with a heated water pad. Before treatment, the heating in 
a silicone phantom was visualized using temperature-sensitive MRI to localize the 
acoustic focal point in the MRI coordinate space. 
 
 Figure 2. 3 Schematic of the MRI-guided FUS system. Inside the MRI magnet room, the transducer 
was mounted on a manual MRI-compatible 3-D positioning system and immersed in a water tank 
integrated into the MRI table. Outside the magnet room, a network consisting of a function generator, 
power amplifier, power meter, and dual directional coupler served to control the transducer. The animal 
was laid supine on a tray above this tank, with a water bag providing an acoustic path to the dorsal 
surface of the head.  
 
2.4 Magnetic Resonance Imaging  
The experimental set-up shown in Figure 2-3 was integrated into the table of a 
3-Tesla clinical MRI scanner (Signa; General Electric Healthcare) for image guidance 
and evaluation. Each animal was placed on the table in the supine position with the 
dorsal surface of the head centered on a 7.5-cm-diameter transmit/receive surface coil 
(constructed in-house). 
For all BBB disruption experiments, two-dimensional T2-weighted fast spin-
echo (FSE) images were acquired in three orthogonal planes to plan the sonications 
(parameters: repetition time (TR): 2000 ms; echo time (TE): 79.7 ms; echo train 
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length (ETL): 8; matrix size: 256×256; slice thickness/spacing: 1 mm/interleaved; 
field of view (FOV): 8 cm; number of excitations/averages (NEX): 2; bandwidth: 
15.63 kHz). The target site for BBB disruption was identified on the MR images and 
the transducer repositioned accordingly. Sonications were performed through the 
opening of the surface coil, which was filled with a plastic bag [poly(vinyl chloride), 
thickness ~75 μm] containing degassed water. After ultrasound-mediated BBB 
disruption was completed, a bolus of gadopentatate dimeglumine (Gd-DTPA) MRI 
contrast agent (Magnevist; Berlex Laboratories, Wayne, NJ; 0.125 mmol/kg; 0.25 
mL/kg; molecular weight: 938 Da) was injected into the tail vein and T1-weighted 
fast spin-echo (FSE) images (repetition/echo time (TR/TE): 500/17 ms; echo train 
length (ETL): 4; matrix size: 256 x 256; slice thickness: 1 mm; field of view (FOV): 8 
cm; number of excitations (NEX): 2; flip angle (FA): 90 degrees) brain were acquired 
in three orthogonal planes to confirm BBB permeabilization. Axial three-dimensional 
T2*-weighted fast spoiled gradient echo images were also acquired (TR/TE: 33.3/19 
ms; matrix size: 256×256×28; slice thickness: 0.8 mm; FOV: 8 cm; NEX: 1; flip 
angle: 15°; bandwidth: 15.63 kHz). These images are sensitive to small susceptibility 
changes and were used for detecting iron-containing petechaie caused by excessive 
FUS  [114] and hemorrhagic regions within the tumor and additional images were 
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acquired as needed. 
2.5 Fluorometry 
A benchtop cuvette fluorometer (VersaFluor; Bio-Rad Laboratories, Hercules, 
California) with changeable filters was used to quantify doxorubicin accumulation in 
brain tissue. Because doxorubicin absorbs the most light between approximately 473 
nm and 494 nm and emits maximal fluorescent light at about 590 nm  [229,231], 
fluorescence measurements were performed using filters with excitation and emission 
wavelengths of 480 ± 10 nm and 590 ± 5 nm, respectively. 
To calibrate the fluorometer for doxorubicin quantification, a serial dilution of 
doxorubicin in acidified alcohol was used to measure the fluorescent signal of the 
extracted supernatant. The gain of the VersaFluor fluorometer was set to medium for 
doxorubicin concentrations of 100-1000 ng/mL. For lower doxorubicin concentrations 
of 10-100 ng/mL, the fluorometer was not sensitive enough to differentiate small 
differences in concentration using medium gain, so the gain was set to high. For each 
experiment, a freshly prepared solution of acidified alcohol was used as a "blank" to 
zero the fluorometer. Figure 2. 4 shows the calibration curves used to convert the 
fluorometric readings to doxorubicin concentration. 
  
 
Figure 2. 4 Calibration curves for fluorometric measurements of doxorubicin concentration showing a 
strong linear correlation between the arbitrary fluorometric units and the doxorubicin concentration for 
medium gain (R2 = 0.99) in A and high gain (R2 = 0.99) in B. The calibration coefficients were 
obtained after forcing each linear fit through zero.  
 
2.6 Targeted Doxorubicin Delivery through Blood Brain and 
Blood Tumor Barrier using Transcranial MRI-guided 
Focused Ultrasound 
The first step towards developing a protocol for targeted drug delivery across 
the BBB/BTB in a standard pre-clinical rodent model was the modification of the 
ultrasound parameters needed to achieve reproducible, localized BBB/BTB disruption 
in rats. Although ultrasound is strongly attenuated in bone, past studies had shown 
that the skull of the rat is thin enough to permit the focusing of the ultrasound beam 
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sufficient to induce localized BBB opening [Refs].  
2.6.1 Sonications  
Energy was delivered in pulsed sonications with burst length of 10 ms and 
pulse repetition frequency of 1 Hz (i.e., 10 ms ON followed by 990 ms OFF; duty 
cycle: 1%) for 60 s. Each sonication was accompanied by a bolus of a microbubble-
based ultrasonic contrast agent (Definity, Lantheus Medical Imaging; N. Billerica, 
MA) 0.01 mL/kg) into the tail vein catheter. Each mL of Definity contains a 
maximum of 1.2 × 1010 microbubbles, which are composed of octafluoropropane gas-
filled lipid shells with a mean diameter of 1.1-3.3 × 10-6 m. The administration of 0.01 
mL/kg Definity was as a bolus approximately 9 s before sonication, followed by a 0.2 
mL saline flush. To facilitate the injections of such a small volume, the Definity was 
diluted to 0.1× normal concentration in phosphate buffered saline (PBS). Multiple 
sonications in an individual rat were spaced 3-5 min apart to allow time for vascular 
clearance of most of the Definity, which has a pulmonary elimination half-life of 1.9 
min in humans. 
The pressure amplitude 0.4 MPa was initially set based on a prior study in rats 
with this device  [232] for BBB disruption. The range from 0.55 to 0.81 MPa based 
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on empirical observations on the exposure level needed to achieve a consistent level 
of BBB disruption as the age and weight of the animals increased. This observation 
was made in our initial treatments and is similar to previous reports that demonstrated 
that the skull becomes thicker as the animal ages  [198].  
Once the parameters for consistent BBB disruption by transcranial sonication 
were modified as needed, the technique to aid in the targeted delivery of Lipo-DOX in 
the rat brain was adapted. In the first set of experiment, the central aim was to develop 
a drug injection protocol for ultrasound-mediated BBB disruption which would allow 
Lipo-DOX to accumulate at sufficient levels in the normal in rat brain to have a 
therapeutic effect and in the second set, to visualize and quantify the resulting 
doxorubicin distribution at the focal plane. 
2.6.2 Chemotherapy  
In our experiments, a chemotherapy agent was administered intravenously. 
Doxorubicin hydrochloride encapsulated in long-circulating pegylated liposomes 
(Dox-NP; Avanti POLAR LIPIDS, INC., Alabaster, AL; 5.67 mg/kg, Half life in 
plasma: 2-3 days) was selected for targeted delivery through the blood-brain barrier. 
In this form, greater than 90% of the drug is encapsulated within the liposomes. Once 
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the liposomes pass from the vascular compartment to the parenchyma, the liposome is 
degraded by endogenous enzymatic processes, and the encapsulated doxorubicin is 
released in the tissue. In the first set of experiments, a drug injection protocol which 
would deliver a therapeutic level of Lipo-DOX through the BBB was sought to be 
identified.    
2.6.3 Effect of Drug Injection Protocol on Doxorubicin Delivery to the 
Brain 
The experimental set-up of the first study was used. A peak negative pressure 
amplitude of 0.55 MPa was used to provide BBB disruption to deliver Lipo-DOX to 
the brain. The sonications were delivered at 3-5 min intervals in a grid pattern 
(spacing: 1-1.5 mm) to 9 targets.  
In the first set, the rats were assigned in two groups: (A) Lipo-DOX injection 
before FUS (N = 5), (B) Lipo-DOX injection after FUS (N = 4). For the animals in 
group A, both hemispheres were sonicated. A full dose of Lipo-DOX (5.67 mg/kg) 
was divided into a 9 fractions in the first sonicated hemisphere; one fraction was 
administered before each sonication in this hemisphere. Since Lipo-DOX has such a 
long circulation time, we assumed that a full dose was already in the circulatory 
79 
 
system of the subject, so we did not administer any additional drug before sonication 
in the contralateral hemisphere. For the animals in group B, only one hemisphere was 
sonicated and the other hemisphere served as a control. A full dose of Lipo-DOX was 
administered 10 minute after the sonications.  
2.6.3.1 Fluorometric Assay  
Trypan blue (Aldrich Chemical Company, Inc. Milwaukee, WI, USA; 
2.5ml/kg) was administered through the tail vein after the completion of the 
sonications and imaging to further confirm successful BBB disruption and to mark the 
target site of sonication for tissue harvesting. Each animal was put into a state of deep 
anesthesia with an overdose of ketamine and xylazine. To flush unabsorbed Lipo-
DOX from the cerebral vasculature, the brain was perfused by transcardiac methods 
with normal saline 4 h after the last sonication. The site of BBB disruption, 
identifiable by its trypan blue stain, was harvested along with nonsonicated control 
tissue. The concentration of Lipo-DOX of each tissue sample was determined by 
taking the average of at least three fluorometric readings on a benchtop fluorometer.  
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2.6.3.2 Extraction and Quantification of Doxorubicin  
A preparation of acidified alcohol (0.3 N HCl in 50% EtOH) was used to 
extract doxorubicin from harvested tissue samples for fluorometric 
quantification  [233]. For these minute samples, the tissue density was assumed to be 
approximately 1 g/cm3. Thus, the mass of each sample was equal to its volume. The 
mass of each sample was measured and cut down until was approximately 30 mg. 
Each sample was put into a 1.5-mL centrifuge tube with 20 volumes (400-500 μL) of 
acidified alcohol, then homogenized with a tissue blender (Next Advance, Averill 
Park, NY), refrigerated for 24 hours at 4ºC. Samples were then centrifuged at 16,000× 
g for 25 min. at 4ºC. The supernatant was extracted for immediate fluorometric 
reading using a benchtop fluorometer (VersaFluor; Bio-Rad Laboratories, Hercules, 
CA; Ex/Em: 480/590 nm) or stored at -80ºC.  
2.6.3.3 Statistical Analysis  
Sonicated and contralateral control paired samples were compared using a 
two-tailed paired student’s t-test. Values of p < 0.05 were considered statistically 
significant. Additional analyses included least-squares linear regression and 
calculation of correlation coefficients.  
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2.6.4  Fluorescence Imaging  
In the second set of experiments, a fluorescent microscope was used to 
visualize the distribution of doxorubicin in the brain after treatment with ultrasound-
induced focal BBB/BTB disruption and intravenous Lipo-DOX administration. 
Doxorubicin has excitation maximum of 480 nm and emission maximum at 590 nm 
respectively. Fluorescence images were acquired using a fluorescent microscope 
Observer.Z1 with the X-Cite 120Q series light source and a AxioCam MRm mounted 
camera (Zeiss, Germany) with 10× objective, 1.6x optovar, and a 500 ms exposure 
time. High resolution images of different tissue sections were obtained in tiles using a 
motorized stage so that the distribution of doxorubicin was obtained for the entire 
tissue section. 
2.6.4.1 Tissue Preparation 
The rat brain was flash frozen in dry ice with 2-methylbutane (Fisher, 
Pittsburgh PA). For tissue sectioning, the frozen rat brain was mounted with a 
minimal amount of optimal cutting medium (OCT) compound (the owner of the 
cryostat did not want OCT to come into contact with the cryotome blade), and 
sectioned at a 20µm thickness using a Microm HM550 cryostat (Mikron Instruments 
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Inc, Vista, CA). The specimen temperature was set at -19ºC and the chamber 
temperature at -20ºC. Tissue sections were thaw-mounted on microscope glass slides 
(Fisher, Pittsburgh PA) for fluorescence imaging.  
2.7 Multiple Sessions of Liposomal Doxorubicin and Ultrasound-
Mediated Blood-Brain Barrier Disruption: A Safety Study in 
the Rat Brain 
After the identification of the Lipo-DOX injection protocol that could deliver 
a therapeutic level of Lipo-DOX through the BBB and showed the doxorubicin 
distribution in the sonicated area with fluorescence microscope, the safety profile of 
this delivery was investigated in normal rat brain.  
2.7.1 Study Design 
Lipo-DOX (5.67mg/kg) was administered intravenously. That dosage was 
selected on the basis of prior work testing this agent in rats  [234]. Nine rats were 
assigned to one of two groups: (1) three weekly treatments with FUS and concurrent 
chemotherapy (FUS+Lipo-DOX) (N=5), (2) three weekly treatments with FUS only 
(N=4). After determining the coordinates of the focal point within the MRI space, 
treatment planning MRI was acquired, and the focal region was positioned so its 
center was 2 mm lateral to the midline and 4 mm deep from the dorsal brain surface. 
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They were centered 2.5 mm anterior to the bregma in the striatum. The striatum was 
of interest because that was the place where 9L-rat glioma tumors were grown and 
treated  [170]. Sonications (0.69 MHz; 0.55-0.81 MPa; 10 ms bursts; 1 Hz PRF; 60s 
duration) were performed in a grid pattern at 5, 9, and 12 targets, respectively. Before 
each sonication, ultrasonic contrast agent (Definity, Lantheus Medical Imaging; 0.01 
mL/kg) was administered intravenously. To facilitate the injections of such a small 
volume, the agent was diluted to 0.1× normal concentration in PBS. It was injected as 
a bolus approximately 9 s before each sonication, followed by a 0.2 mL saline flush. 
Lipo-DOX was administered intravenously over multiple slow injections just before 
each sonication. 
2.7.2 Magnetic Resonance Imaging 
MRI was used to evaluate and monitor treatment effects. T2-weighted imaging 
was used to plan the treatments. BBB disruption was evaluated using T1-weighted 
imaging acquired before and after administration of the MRI contrast agent 
gadopentatate dimeglumine (Magnevist Gd-DTPA; Bayer Healthcare; 0.25 mL/kg). 
T2*-weighted imaging was used to confirm that petechaie, which are produced by 
excessive FUS exposures, did not occur  [114] .  
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2.7.3 Histology 
All of the animals from FUS-Only and FUS+Lipo-DOX were sacrificed 
seventy days from the first treatment to evaluate the histological effects. The animal 
was deeply anesthetized with ketamine/xylazine, sacrificed, and the brain fixed via 
transcardial perfusion (0.9% NaCl, 100 mL; 10% buffered formalin phosphate, 250 
mL). The brain was then removed, embedded in paraffin, and serially sectioned at 5 
μm sections in the axial plane (perpendicular to the direction of ultrasound beam 
propagation). Every 50th section (250 μm apart) was stained with hematoxylin and 
eosin (H&E). The author who evaluated the histology was blind to the FUS exposure 
parameters. 
2.8 Multiple Treatments with Liposomal Doxorubicin and 
Ultrasound-Induced Disruption of Blood-Tumor and Blood-
Brain Barriers Improve Outcomes in a Rat Glioma Model 
The therapeutic efficacy of the technique was investigated in rats with 
implanted aggressive glioma using the same paramaters used in the experiments 
where the safety profile for multiple treatments with FUS only and FUS + 
doxorubicin were investigated. The following steps were involved in this work.  
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2.8.1 Cell Culture 
9L rat gliosarcoma cells (passage number 3, obtained from the Neurosurgery 
Tissue Bank at University of California-San Francisco) were grown in Minimum 
Essential Medium (1×) with Earle's salts, supplemented with 10% fetal bovine serum, 
1% L-glutamine, 1% MEM nonessential amino acids, and 0.1% gentamicin in a 5% 
CO2 chamber held at 37°C.  
2.8.2 Tumor Implantation 
In the anesthetized rat, the dorsal surface of the skull was sterilized with an iodine 
swab. A 5-mm skin incision was made and a 1-mm burr hole was drilled into the skull 
approximately 1 mm anterior to the bregma and 2 mm lateral to the midline. A 4 μl 
volume of cell suspension (1 × 105 cells) was injected into the right caudate putamen 
at a depth of 3.5 mm relative to the dural surface using a 10 μl gas-tight syringe 
(Hamilton). The cells were injected over a period of 5 min. Two min later, the needle 
was retracted slowly over another 5 min, and the skin was closed with 5-0 silk sutures 
(Ethicon, Somerville, New Jersey). The rat recovered from anesthesia under 
observation. Each animal was given a one-time dose of antibiotic (Baytril, 2.5 mg/kg; 
Bayer HealthCare, Wayne, New Jersey) and analgesic (Buprenex, 0.05 mg/kg; Reckitt 
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Benckiser Healthcare, Hull, England, UK) every 12 h for 24 h following surgery by 
i.p. administration. The sutures were removed 5 days later, and treatment began on 
day 7 or 8, at which point the tumor had an MRI-evident diameter between 1 and 3 
mm.  
2.8.3 Study Design 
The rats were randomly assigned to one of four groups: (1) no treatment 
(Control) (N=7), (2) three weekly treatments with FUS-induced BBB/BTB 
permeabilization (FUS-Only) (N=8), (3) three weekly treatments with liposomal 
doxorubicin (Lipo-DOX-Only) (N=6), and (4) three weekly treatments with FUS and 
concurrent chemotherapy (FUS+Lipo-DOX) (N=8). The animals were monitored 
regularly to evaluate the treatment effects on survival and tumor growth. Animals 
surviving 6 weeks after treatment were considered long-term survivors. However, 
some were followed for longer periods for later histological examination, as they 
appeared healthy. The animals were euthanized if they exhibited severely impaired 
activity, weight loss exceeding 20% within one week, tumor dimensions exceeding 
10–11 mm, or if treatment-related severe adverse events occurred that caused pain or 
distress and that could not be ameliorated. The animals were euthanized via 
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transcardial perfusion with saline followed by 10% phosphate-buffered formalin 
while under deep anesthesia. The brain was removed and immersed in 10% 
phosphate-buffered formalin for histological preparation. To avoid skin infections that 
were observed in two animals (Table 5. 1), animals receiving FUS and chemotherapy 
were treated with an antibiotic Baytril (Bayer; 2.5 mg/kg). 
2.8.4 Sonication 
Animals in group 2 (FUS only) and 4 (FUS+Lipo-DOX) were provided 
treatment with microbubble-enhanced MRI-guided FUS. After determining the 
coordinates of the focal point within the MRI space, treatment planning MRI was 
acquired, and the focal region was positioned within the tumor. Sonication parameters 
were the same as in the safety study and consisited of multiple points in and around 
the tumor combined with microbubbles. The sonications were delivered at 5 min 
intervals in a grid pattern (spacing: 1 or 1.5 mm, depending on tumor volume) to 5-20 
targets, with the number of locations increasing over the three weeks as the tumor 
volume increased. The central aim was to permeabilize the BTB in the entire tumor 
and the BBB in a surrounding rim of at least 1 mm.  
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2.8.5 Chemotherapy 
Animals in group 3 (Lipo-DOX Only) and 4 (FUS+Lipo-DOX) were 
administered chemotherapy. For chemotherapy, 5.67 mg/kg of Lipo-DOX was 
administered intravenously. In initial experiments (5 rats in Lipo-DOX Only group; 5 
in FUS + Lipo-DOX group), DOXIL (Centocor Ortho-Biotech) was used. Due to a 
current national shortage of this agent that occurred during these experiments, Lipo-
Dox (TTY Biopharm) was used for the remaining animals (1 rat in the Dox-Only 
group; 3 in the FUS+Lipo-DOX group). For the FUS+Lipo-DOX group, 
chemotherapy was administered over multiple slow injections administered just 
before each sonication. For the Lipo-DOX Only group, the agent was administered 
over 5 slow injections at 5 min intervals. This scheme was adopted from chapter 2.6.3. 
Each injection was followed by a 0.2 mL saline flush.  
2.8.6 Magnetic Resonance Imaging 
T2-Weighted imaging was used to plan the treatments and measure tumor 
volumes. BBB/BTB disruption was evaluated using T1-weighted imaging acquired 
before and after administration of the MRI contrast agent gadopentatate dimeglumine 
(Magnevist Gd-DTPA; Bayer Healthcare; 0.25 mL/kg). T2*-Weighted imaging was 
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used to investigate whether petechiae, which are produced by excessive FUS 
exposures, did not occur  [114] and to evaluate hemorrhagic regions in the tumors. 
2.8.7 Image Analysis 
Non-contrast MRI imaging was performed weekly (±1–3 days depending on 
MRI availability). Tumor boundaries were manually segmented in axial T2-weighted 
images using ImageJ; the volume was calculated by the sum of the areas multiplied by 
the image thickness. In weeks 1–2, the tumors appeared as clearly circumscribed 
volumes, which were sometimes surrounded by hyperintense regions (presumably 
edema). These boundaries were sometimes not evident at later times in the 
FUS+Lipo-DOX group, and it was not clear whether MRI abnormalities were 
residual/recurring tumor or treatment-related effects. To be conservative, such cases 
were included in the volume calculations. 
2.8.8 Histology 
Representative examples from the Control (4/7 animals) and FUS-Only (5/8 
animals) groups were selected for histological examination. The treatment response 
varied for animals in the Lipo-DOX Only and FUS+Lipo-DOX groups (see Table 5. 
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1) and all brains from these animals were examined. Tissue blocks containing the 
tumor were embedded in paraffin and cut into 4–6 μm serial sections perpendicular to 
the direction of ultrasound propagation. Sections with the largest evident tumor were 
stained with H&E for examination in light microscopy. 
2.8.9 Statistical Analysis 
Tumor volumes for the four groups were compared using one-way ANOVA. 
The Kaplan–Meier method was used to compare survival of animals in each group. 
Significance was calculated by using log-rank test with Yates' correction. These 
analyses were performed using Matlab (MathWorks) and Microsoft Excel. The 
Bonferroni method was used to compare multiple pairs of groups  [235]. With four 
treatment groups (including controls) and with six possible paired comparisons, pair-
wise P values less than the Bonferroni-corrected threshold of 0.05/6 = 0.0083 were 
considered statistically significant. 
2.9 Enhancement in Blood-Tumor Barrier Permeability and 
Delivery of Liposomal Doxorubicin using Focused 
Ultrasound and Microbubbles: Evaluation during Tumor 
Progression in a Rat Glioma Model 
After the therapeutic efficacy of the technique was investigated in a rat glioma 
91 
 
model, DCE-MRI was used to characterize the FUS-induced permeability changes of 
the BBB/BTB at different times after implantation, and these changes were related to 
the doxorubicin concentrations.  
2.9.1 Bilateral Tumor Implantation 
The previously described techniques for tumor cell implantation were adopted 
for a bilateral tumor model where 9L rat gliosarcoma cells were injected into both the 
right and left caudate putamen at a depth of 3.5 mm relative to the dural surface. 
Tumors on both hemispheres were observed in MRI on day 7 or 8. Animals were 
included in the study if the tumors on both hemispheres were approximately the same 
size: a diameter between 1-3 mm on day 7 or 8. The animals were euthanized if they 
exhibited severely impaired activity, weight loss exceeding 20% within one week, or 
tumor dimensions exceeding 10-11 mm. 
2.9.2 Study Design 
The rats were randomly assigned to one of three groups where FUS was 
applied on day 9, day 14, or day 17 after implantation (N=5 for each group). After 
determining the coordinates of the focal point within the MRI space, the focal region 
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was positioned in the tumor in the right hemisphere. The nonsonicated left tumors 
served as controls. Ultrasound bursts were then applied at multiple points in and 
around the tumor at pressures amplitudes ranging from 0.55-0.81 MPa (burst length: 
10 ms, pulse repetition frequency: 1 Hz, duration: 60 s). Before each sonication, 
ultrasonic contrast agent (Definity, Lantheus Medical Imaging; 0.01 mL/kg) was 
administered intravenously. To facilitate the injections of such a small volume, the 
agent was diluted to 0.1× normal concentration in PBS. It was injected as a bolus 
approximately 9 s before each sonication, followed by a 0.2 mL saline flush. The 
sonications were delivered at 5 min intervals in a grid pattern (spacing: 1.5 mm) to 5-
20 targets, depending on the tumor volume. The goal was to permeabilize the BTB in 
the entire tumor and the BBB in a surrounding rim of at least 1 mm. For drug delivery, 
5.67 mg/kg of Lipo-DOX was administered in fractions over multiple slow injections 
intravenously just before each sonication Each injection was followed by a 0.2 mL 
saline flush. 
2.9.3 Magnetic Resonance Imaging  
T2, T1-contrast and T2* weighted images were obtained as described above. In 
addition, DCE-MRI was performed before and after the sonications. For T1-mapping, 
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a spoiled gradient echo (SPGR) sequence (TR/TE: 9.9/4.8 ms; matrix size: 256×256; 
slice thickness: 2 mm; FOV: 8 cm; Scan time for each flip angle: 15.3s; bandwidth: 
31.25 kHz) acquired at multiple flip angles (30/20/15/10/2°). For the DCE imaging, 
eight pre-contrast sets of SPGR images (TR/TE: 9.9/4.8 ms; matrix size: 256×256; 
slice thickness: 2 mm; FOV: 8 cm; Scan time: 534.6s flip angle: 35°; bandwidth: 
31.25 kHz) were acquired. Then, a bolus of Gd-DTPA (2x 0.25 mL/kg) was 
administered I.V. and an additional 62 sets of SPGR images were acquired with a 
temporal resolution of 7.6 s for 8 min. A double dose of Gd-DTPA was used in order 
to secure the presence of a bolus peak in the vascular system to determine the arterial 
input function (AIF) and to obtain accurate tissue concentrations  [236]. Identical slice 
locations were used for T1 mapping and DCE-MRI. These measurements were made 
before and after FUS-BBBD in the right tumor. The time interval between 
measurements was at least an hour to avoid excessive Gd-DTPA accumulation. 
2.9.4 Fluorometric Assay and Doxorubicin Extraction  
After the completion of the sonication and imaging session, Trypan Blue was 
administered through the tail vein to mark the regions where the BBB was disrupted 
and to improve visualization of the tumors. Animals were deeply anaesthetized with 
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ketamine/xylazine and euthanized about two hours after the last sonication. After 
transcardial perfusion with normal saline (0.9% NaCl, 250 mL) to flush unabsorbed 
doxorubicin from the cerebral vasculature, the brain was removed. Small tissue 
volumes (approximately 30 mg) from both tumor sites which were identified by its 
trypan blue stain were harvested. Samples were homogenized in a tissue blender with 
acidified ethanol (50% ethanol in 0.3 N HCl), refrigerated for 24 hours at 4°C, and 
centrifuged at 16,000×g for 25 min. at 4°C. The concentration in each tissue sample 
was determined by taking the average of at least of three readings. 
2.9.5 Data Analysis  
Tumor boundaries were manually segmented in axial T2-weighted images 
using ImageJ; the volume was calculated by the sum of the areas multiplied by the 
image thickness. On day 9, 14 and 17, the tumors appeared as clearly circumscribed 
volumes, which were sometimes surrounded by hyperintense regions (presumably 
edema). The TOPPCAT software package  [220] was used to calculate maps of the 
coefficient Ktrans that describes transport of Gd-DTPA across the BBB/BTB, and the 
vascular volume fraction, fv. The entire tumor was manually segmented in these maps 
in Matlab (MathWorks), and the mean value was calculated. Rats that had regions 
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within either tumor with little or no signal enhancement after Gd-DTPA 
administration were excluded, as these regions were assumed to be necrotic.  
2.9.6 Statistical Analysis 
Tumor volumes, measurements of Ktrans and fv, and doxorubicin 
concentrations for the sonicated and non-sonicated tumors were compared using 
unpaired, two-tailed t-tests. Comparisons of Ktrans and fv before and after sonication 
were made using a paired t-test. Other analysis included linear least-squares 
regression and calculation of correlation coefficients. Data analysis was performed 
using Matlab and Microsoft Excel. 
2.9.7 Histology   
Two additional animals, one animal with tumors at day 9 and one at day 14, 
were sacrificed 4 hours after the last sonication via transcardial perfusion with 0.9% 
NaCl solution followed by 10% phosphate-buffered formalin while under deep 
anesthesia with ketamine and xylazine. Brains were harvested and fixed in formalin. 
Tissue blocks containing the tumor were embedded in paraffin and cut into 4-6 μm 
serial axial sections. The section with biggest tumor was stained with hemotoxylin 
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and eosin (H&E) for examination of light microscopy. Lipo-DOX and trypan blue 
were not administered in the animals used for the histology study. 
2.9.5 Acoustic Emission  
The acoustic emissions were recorded using a piezoelectric passive cavitation 
detector (center frequency: 3.5 MHz, bandwidth: ±30%, diameter: 8 mm, Smart 
Materials, Sarasota, FL) ransducer for every 10 ms burst. The procedure for 
measurement and analysis of the emissions are described in detail elsewhere  [125]. 
Briefly, the passive cavitation detector was mounted next the the transducer and 
aimed at the focal region to monitor the acoustic emission produced during sonication. 
The signals from the detector was amplified, filtered, and recorded to a computer 
using a high-speed digitizing card (PXI-5124; National Instruments). The time signal, 
frequency spectra, and magnitude of the emission at different harmonics were 
displayed in real-time during each sonication using software developed in-house in 
Matlab and stored for later analysis.  
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Chapter 3: Targeted Lipo-DOX Delivery through Blood-Brain and 
Blood-Tumor Barriers using Transcranial MRI-Guided 
Focused Ultrasound 
3.1 Results 
3.1.1 Permeabilization of BBB/BTB 
BBB permeabilization and the presence or lack of petechiae were confirmed 
using contrast-enhanced and T2*-weighted MRI, respectively.. All animals 
demonstrated hyperintense regions in contrast enhanced T1-weighted images after 
FUS, confirming BBB permeabilization. In several cases, one or more hypointense 
spots were observed in T2*-weighted MRI at the brain surface in the cortex, 
demonstrating the presence of petechiae. Such spots were observed in both 
hemispheres near the brain surface in 4 of the 5 animals in the animals where 
doxorubicin concentrations were measured and that received Lipo-DOX before or 
during after sonication. They were not observed in animals who received Lipo-DOX 
after sonication.  
 
 
Figure 3. 1 Visualization of BBB/BTB permeabilization. (A) Axial images acquired before (left) and 
after (right) the FUS-BBBD showing the signal enhancement in T1-weighted MRI after Gd-DTPA 
injection. Before FUS, the tumor was a small enhancing area (red circle). The magnitude and extent of 
this enhancement were increased after FUS. (B) Signal enhancement in this example as a function of 
time.  
3.1.2 Effect of Lipo-DOX Injection Protocol on doxorubicin Delivery to 
the Brain 
Doxorubicin concentrations were compared for cases when the Lipo-DOX 
was injected before or after sonication Figure 3. 2. In group A, both hemispheres were 
sonicated. In the right hemisphere, Lipo-DOX was administered in 9 fractions, one 
before each sonication whereas in the left, sonications were performed without 
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additional Lipo-DOX administration. In group B, the sonications were performed only 
in one hemisphere, and the total dose of Lipo-DOX was injected in bolus 10 min later. 
The sonication time was approximately 30 min for the 9 targets.  
In group A, the mean doxorubicin concentrations in the right and left 
hemispheres were 4.7 ± 0.5 and 4.8 ± 0.5 µg/g, respectively; they were not 
significantly different (p > 0.05). In group B, the doxorubicin concentration was 
significantly less (p < 0.001) than in both hemispheres in group A. The mean 
concentration in these animals was 3.2 ± 0.3 µg/g, 32% less compared to the volumes 
in group A. The doxorubicin concentrations were significantly enhanced in all cases 
(p < 0.001) compared to the control tissue. In addition, in every case the doxorubicin 
concentrations in the sonicated areas exceeded our goal of 0.819±0.482 µg/g, a value 
reported to correlate with a clinical response for human tumors  [237].  
 
 
Figure 3. 2  Doxorubicin concentrations corresponding to different Lipo-DOX injection protocols. The 
doxorubicin concentration was 4.7±0.5 and 4.8±0.5 µg/g, when the agent was administered in fractions 
during the sonications and when it was injected before sonication, respectively; these values were not 
significantly different from each other (p>0.05). This concentration was reduced by 32% to a value of 
3.2±0.3 µg/g when Lipo-DOX was administered 10 min after the last sonication. This reduction was 
significant (p<0.001). In all groups, the doxorubicin concentration was significantly larger than in 
control tissue that did not receive FUS-BBBD. The concentrations in all sonicated volumes were above 
our goal of 0.819±0.482 µg/g, a value reported to correlate with a 39% clinical response rate in human 
tumors (Cummings and McArdle 1986).   
3.1.3 Fluorescence Imaging 
100 
 
Fluorescence microscopy was used to investigate the distribution of 
doxorubicin in the normal brain and in a tumor. Example results from animals 
euthanized xxx-xxx h after Lipo-DOX administration and FUS-BBBD are shown in 
Figures (3.3) and (3.4) respectively.  In the normal brain, the pattern of extravasation 
of the fluorescent drug matched well with the focal contrast enhancement on T1- 
weighted MRI and focal trypan blue staining evident on tissue blocks. High 
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concentrations were observed around a site of capillary damage. Otherwise, drug was 
observed in a relatively homogeneous region. In the tumor, it appeared that the 
sonications enhanced the delivery more at the edge of the tumor than in the center. 
This may reflect the high cell density and increased interstitial pressure that makes 
drug delivery in tumors challenging  [238]. Overall, using fluorescence in this way is 
promising for evaluating drug distributions and penetration. The development of this 
protocol can be utilized in the future by our laboratory to characterize and optimize 
the procedure. 
 Figure 3.3 Left: Contrast-Enhanced T1-weighted imaging (CE-T1WI); Middle: Photograph of post 
mortem brain tissue stained with Trypan blue; Right: image showing doxorubicin fluorescence. CE-
T1WI verified the BBB permeabilization immediately after the sonications (0.69 MHz; 0.55-0.81 MPa; 
10 ms bursts; 1 Hz PRF; 60s duration, 10 µl/kg Definity microbubbles), which were performed in a 
grid pattern at 5 targets with intravenous injection of Lipo-DOX (5.67mg/kg). The animal was 
euthanized 2 h later. The areas where the MRI contrast agent, Trypan blue, and doxorubicin were 
observed agreed well, with the greatest levels near a small area with capillary damage. 
 
 
 
Figure 3.4 Contrast-Enhanced T1-weighted imaging (CE-T1WI); Middle: Photograph of post mortem 
brain tissue stained with Trypan blue; Right: image showing doxorubicin fluorescence. Sonications 
(0.69 MHz; 0.55-0.81 MPa; 10 ms bursts; 1 Hz PRF; 60s duration, definity) were performed in a grid 
pattern at 5 targets with intravenous injection of Lipo-DOX (5.67mg/kg) on the tumor on the left side 
of the images. The animal was euthanized 2 h later. The three methods agreed well in visualizing the 
areas with the greatest delivery. The highest doxorubicin levels were observed in the sonicated tumor at 
the margins. 
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3.2 Discussion  
It has been demonstrated that ultrasound and microbubbles can enhance the 
delivery of Lipo-DOX into the healthy rat brain parenchyma and the 9L glioblastoma 
rat tumor model. If this result can be translated, it would have some advantages over 
other drug delivery methods. For example, being able to use the currently approved 
drug removes the need and expense of developing and testing new drug formulations. 
The method is noninvasive and restricts the drug delivery only to desired brain 
regions.  
While a high doxorubicin concentration was achieved in each group, higher 
concentrations were achieved when we injected Lipo-DOX before sonication (group 
A) rather than afterwards (group B). This finding may have been due to partial BBB 
restoration in group B. With the acoustic parameters used in this study, Park et al. 
reported an exponential decay in permeability to Gd-DTPA (molecular weight: 938 
Da) after FUS-BBBD with half-life of 2.2 hours  [118]. With this time, the barrier 
permeability would be reduced by approximately 20% for the first target that was 
sonicated 40 min before Lipo-DOX administration. Others have shown that this 
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restoration is faster for larger agents and suggested that an agent the size of Lipo-
DOX (100 nm) would have a half-life of only a few minutes  [134]. 
This finding might also reflect transient effects occurring during sonication 
that actively transported Lipo-DOX out of the blood vessels. A number of studies on 
“sonoporation” have shown that sonication with microbubbles can drive drugs across 
cell membranes through the creation of pores that are present for a short time  [239]. 
It may also be possible that the microbubble-enhanced sonications lysed the ~100 nm 
liposomes, releasing free doxorubicin which was readily transported through the BBB 
disruption. Others have shown that microbubble collapse can cause such a release 
when the liposomes are attached to the microbubbles  [240], and perhaps something 
similar happened here. Additional experiments would be necessary however to 
determine whether the exposure levels used here could release doxorubicin.  
Another unexpected finding was that surface damage was observed in the 
animals in group A in the doxorubicin concentration study, but not in group B. This 
finding could suggest that the presence of Lipo-DOX, which was in circulation during 
the sonications in group A, somehow reduced the inertial cavitation threshold. The 
mechanism by which this lowering could have been produced is unknown. This 
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finding needs to be verified. 
My investigation into using fluorescence to map the released doxorubicin into 
the rat brain and into a tumor was promising for future work. It would also be 
interesting to fluorescently tag Lipo-DOX and examine in microscopy how far the 
intact liposomes, and at a later time the released doxorubicin, penetrates into the brain 
after FUS-BBBD. In addition, it would be interesting to repeat these experiments 
using a smaller drug or a drug with a short plasma half-life. The dependence on the 
order of the sonication and the drug administration on the delivered drug 
concentrations may be different in such cases.  
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Chapter 4: Multiple Sessions of Focused Ultrasound Blood-Brain 
Barrier Disruption to Enhance Delivery of Liposomal 
Doxorubicin: A Safety Study 
An effective drug treatment for an invasive brain tumor such as glioma will require 
chemotherapy delivery to the normal tissues at the tumor margin, where the BBB 
protects infiltrating tumor cells, in addition to the semipermeable solid tumor. In a 
patient with a glioma, this infiltrative margin can extend  several centimeters  [241]. 
While an earlier study of FUS-BBBD and Lipo-DOX found that a single drug 
delivery session did not result in the normal brain tissue damage in rats  [191] , it is 
possible that multiple treatments could produce side effects such as those observed in 
our survival study tumor-bearing rats (see section 5.1.3 below). Furthermore, early 
studies with mannitol BBB disruption and free doxorubicin suggested that this drug is 
significantly neurotoxic, even at small concentrations   [242,243]. Others have 
observed concentration-dependent neurotoxicity when free doxorubicin or Lipo-DOX 
was infused into the brain via convection-enhanced delivery  [244]. 
For these reasons, we tested whether multiple sessions of Lipo-DOX 
administration and FUS-mediated BBB disruption (FUS-BBBD) can induce severe 
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adverse events in the normal brain tissue. Sonicating multiple targets in the normal 
brain over three weeks, we evaluated whether multiple sessions of FUS-BBBD and 
Lipo-DOX produced significant brain tissue damage. For these experiments, we 
aimed to use sonications similar to our tumor survival study described in section 2.8.4. 
We sonicated multiple overlapping brain targets to induce BBB disruption in regions 
that increased in volume over the three weeks. The tissue effects were compared in 
histology to animals who received FUS-BBBD or Lipo-DOX alone.  
In the previous chapter, the results showed that FUS-BBBD and Lipo-DOX 
can deliver clinically-relevant concentrations of doxorubicin, and we found that 
injecting the agent before or during sonication was more effective than administering 
it afterwards. Thus, we used these parameters in this chapter and throughout the rest 
of the work described in this thesis. 
4.1 Results 
4.1.1 BBB Permeabilization 
BBB permeabilization and the presence or lack of petechiae were confirmed 
using contrast-enhanced and T2*-weighted MRI, respectively (Fig 4.1). A higher 
pressure amplitude (0.81 vs. 0.55 MPa) was needed for the third session to induce 
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consistent BBB permeabilization, presumably because of an increase in skull or dura 
thickness as the rats grew  [198]. All animals demonstrated hyperintense regions in 
contrast enhanced T1-weighted images after each session, confirming BBB 
permeabilization. In several cases, one or more hypointense spots were observed in 
T2*–weighted MRI in the focal plane or at the brain surface in the cortex, 
demonstrating the presence of petechiae. Such spots were observed after the second or 
third session in 4 of the 5 animals who received both FUS-BBBD and Lipo-DOX and 
in 3 of the 4 animals who received FUS-BBBD alone. They were not seen in animals 
who received MRI at day 53 or 67. In addition to these hypointense spots in the focal 
plane, hypointense spots were also observed in the cortex at the brain surface in every 
animal except one who received FUS-BBBD alone.  
 
Figure 4. 1 MRI-images acquired during three weekly treatments: T2-weighted imaging (T2WI) used 
for treatment planning; Contrast-Enhanced T1-weighted imaging (CE-T1WI) verified the BBB 
permeabilization; T2*-weighted imaging (T2*WI) detected tissue damage. The targeted spots are 
indicated in dots; the yellow curves outlined extent of MRI contrast enhancement due to BBB 
permeabilization. Sonications (0.69 MHz; 0.55-0.81 MPa; 10 ms bursts; 1 Hz PRF; 60s duration) were 
performed in a grid pattern at 5, 9, and 12 targets, respectively, mimicking the three weekly treatments, 
which were administered in the tumor treatment study described in section 2.8.4. (bars: 5mm) 
4.1.2 Histological Findings 
All animals that received FUS-BBBD alone were found to be unaffected in the 
targeted plane in the striatum (Figure 4.2). However, four of the five rats who 
received FUS-BBBD and Lipo-DOX had small regions with evidence of prior 
damage in the focal plane (Figure 4.3). In three of these animals, this was evidenced 
by the presence of small scars with largest dimensions of 0.5-2.0 mm. These scars 
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consisted of infiltrating macrophages and activated astroglial cells. In the fourth 
animal, a small (1.0×2.0 mm) cyst formation was observed. No changes were 
observed in the control hemisphere that received Lipo-DOX only (black boxes in 
Figure 4.3). 
Evidence of more severe prior damage was observed in the cortex near the 
brain surface in four of the five animals who received FUS-BBBD and Lipo-DOX 
and in one of the four animals who received FUS-BBBD alone. The effects were 
similar in appearance to those in the striatum, but the dimensions of the affected areas, 
which ranged from 0.5-2.5 mm, were larger. Examples of these effects are shown in 
Figure 4.4.  
  
Figure 4. 2 T2*-weighted MRI and corresponding histological appearance of a brain after three weekly 
sessions with FUS-BBBD alone. The samples for histology (H&E stained sections) were obtained 70 
days after the first FUS-BBBD session. T2*-weighted imaging (A) appeared normal in this example. 
Some signal enhancement was observed in the T2*-weighted imaging after the three treatments. This 
enhancement was due to MRI contrast, which was administered earlier. The histological appearance of 
the sonicated regions (C) was indistinguishable from the corresponding non-sonicated regions in the 
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other hemisphere (D). The regions shown in C and D are indicated in B by the red and black squares, 
respectively. (bars: 5 mm in A-B; 200 µm in C-D). 
 
Figure 4. 3 Representative examples of T2*- weighted images and histology (H&E stained sections) in 
the focal plane for rats who received three weekly sessions of FUS-BBBD and Lipo-DOX. Histology 
was obtained 70 days after the first FUS-BBBD session. (A-D) Example where the treated regions 
appeared unaffected in both T2*-weighted MRI (A) and histology (B-D). The histological appearance 
of the sonicated regions (C) was indistinguishable from the corresponding non-sonicated regions in the 
other hemisphere (D). The regions shown in C and D are indicated in B by the red and black squares, 
respectively. (E-H) Example where hypointense areas (arrows) were evident in T2*-weighted MRI 
after session 2 and a scar was observed in histology (G). Note that the location of the scar was evident 
in the area that was hypointense in T2*weighted imaging. A small cluster of hemosiderin (inset) was 
observed, likely remnants from earlier petechiae. No changes were observed in the control location in 
the other hemisphere (H). The regions shown in C and D are indicated in B by the red and black 
squares, respectively. Some signal enhancement was observed in the T2*-weighted imaging (A,E) after 
the three treatments. This enhancement was due to MRI contrast, which was administered earlier. . 
(bars: 5 mm in A,B, E,F; 200 µm in C-D, G-H). 
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Figure 4. 4 An example of adverse effects in the cortex near the brain surface in an animal that received 
three sessions of FUS-BBBD and Lipo-DOX. A: Hypointense spots (arrows) were detected in T2*-
weighted imaging after the second treatment. Tissue necrosis (C) is evident in the area that appeared 
hypointense in T2*weighted imaging. Hemosiderin (yellowish brown granular pigments formed by 
breakdown of hemoglobin) was observed in macrophages within the necrotic area (inset in C). No 
changes were found in the contralateral hemisphere that did not receive FUS-BBBD. These adverse 
effects, which were evident in four of the five animals who received FUS-BBBD and Lipo-DOX and in 
one of the four animals who received FUS-BBBD alone, were probably due to the long focal length of 
the transducer (full-width, half maximum of the pressure field: 12 mm) compared to thickness of the rat 
brain (10-12 mm) and reflections within the skull.  (bars: 5 mm in A-B; 200 µm in C-D). 
4.2 Discussion 
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Regardless of the order of the sonication, it is clear that the sonication 
parameters used here effectively resulted in a clinically-relevant doxorubicin 
concentration in the normal brain. However, the severe neurotoxicity that was 
observed in earlier studies was not observed here. Early work on the toxicity of 
intracarotid administration of free doxorubicin in rats and dogs following osmotic 
BBB modification revealed that this agent can be significantly neurotoxic, even at 
small concentrations  [242,243]. In that study, the animals developed neurological 
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deficits including seizures, with corresponding necrosis and hemorrhagic infarcts 
observed in histopathology. Other experiments using convection-enhanced delivery 
have also observed extensive necrosis when high concentrations of doxorubicin or 
Lipo-DOX were infused into the brain  [244]. These studies, along with effects we 
observed previously at the tumor margins  [170], prompted the current study to 
investigate whether FUS-BBBD and Lipo-DOX can induce such extensive damage. 
Such effects were not observed. 
Evidence for small regions of minor prior tissue damage, however, was 
detected in this work. We suspect these regions were due capillary damage induced 
during the sonications. The exposure levels used were the same as in our prior study 
in tumors and were somewhat aggressive, as evidenced by the presence of 
hypointense spots in T2*-weighted imaging in most animals. Prior work suggests that 
these dark spots are caused by the presence of iron-laden particles from 
petechiae  [245] presumably caused by capillary damage caused by inertial 
cavitation  [123]. Based on other studies examining long-term effects of FUS-BBBD, 
such minor capillary damage is not expected to result in significant long-term 
effects  [94,137], and indeed this was the case here for the animals who did not receive 
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Lipo-DOX. In contrast, evidence of small areas of prior tissue damage was observed 
in most of the animals who received FUS-BBBD and Lipo-DOX. The cause of this 
difference is not known, but it is possible that excessive doxorubicin concentrations 
resulted around capillaries damaged by inertial cavitation. It may also be possible that 
doxorubicin impaired repair or otherwise exacerbated such capillary damage that 
could have resolved over time without the drug. Based on these results we anticipate 
that while sonication with low-level inertial cavitation may be acceptable – or even 
desirable – when the focal region is inside a solid tumor, such aggressive exposure 
levels may not be appropriate for delivering Lipo-DOX to the surrounding normal 
brain tissue. 
An unexpected finding of this work was that more severe damage was evident 
in both MRI and histology near the brain surface in the cortex. This damage could 
have been the result of the low frequency and a long focal region – longer than the 
thickness of the rat brain – that was used in this study. This frequency was chosen to 
be similar to the transcranial FUS system that is currently being used in clinical 
trials  [246] and it is known that such a frequency can result in reflections and standing 
waves when sonicating transcranially in a rat  [93]. However, the lack of tissue 
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damage in the far-field close to the skull base, where one might expect the pressure 
amplitude to be highest due to reflection, suggests that perhaps something else caused 
these surface effects. Perhaps the microbubble concentration was sufficiently large in 
the highly vascular cortex to produce shielding, resulting in a lower pressure 
amplitude at the focal point. While future work is needed to verify this speculation, if 
it were correct, it may be possible that under some circumstances elevating the 
exposure level of the sonications can lead to diminishing returns in FUS-BBBD at the 
focal plane. 
Another unexpected finding was that surface damage was observed in the 
animals in group A in the doxorubicin concentration study, but not in group B. This 
finding could suggest that the presence of Lipo-DOX, which was in circulation during 
the sonications in group A, somehow reduced the inertial cavitation threshold. The 
mechanism by which this lowering could have been produced is unknown. This 
finding needs to be verified. 
 This study had some limitations. The sample size was relatively small, 
and more work is needed to verify the link between the capillary damage produced 
during some of the sonications and the small areas of downstream tissue damage that 
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were evident here with the delivery of Lipo-DOX. We also only considered a single 
dose of Lipo-DOX and a single set of sonication parameters, and we examined the 
tissue effects only at a single time point using standard light microscopy and H&E 
stained sections. A larger study using more sensitive methods may find minor tissue 
effects that were missed here. However, the relevance of such potential minor effects 
is questionable in the context of a glioma treatment. 
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Chapter 5:  Multiple Treatments with Liposomal Doxorubicin and 
Ultrasound-Induced Disruption of Blood–Tumor and 
Blood–Brain Barriers Improve Outcomes in a Rat 
Glioma Model 
The purpose of this work was to evaluate whether multiple treatment sessions can 
effectively improve the therapeutic effect of Lipo-DOX in a rat glioma model. 
Previous work has shown that a single treatment with FUS-enhanced delivery of this 
agent to orthotopically-implanted 9L rat gliosarcoma model had a modest 
improvement in survival and tumor growth  [191]. Here we examined whether three 
weekly sessions can provide a more pronounced treatment effect in this tumor model. 
We also utilized low-frequency FUS to better match an existing clinical FUS 
device  [81]. 
5.1 Results 
5.1.1 BBB/BTB Permeabilization 
BBB/BTB permeabilization and a lack of significant FUS-induced tissue damage 
were confirmed using contrast-enhanced and T2*-weighted MRI, respectively. A 
higher pressure amplitude (0.81 vs. 0.55 MPa) was needed for the third treatment to 
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induce consistent BBB/BTB permeabilization, presumably because of an increase in 
skull or dura thickness as the rats grew  [198]. To confirm that the sonications 
increased the vascular permeability in the tumor, contrast-enhanced imaging before 
and after the sonications in several animals was performed (Figure 5. 1 A-B). 
Sonication targets were applied in a grid to cover the tumor evident in T2-weighted 
imaging plus a surrounding margin (C). Weekly MRI examination was used to 
monitor the tumor progression. Representative examples from each experimental 
group over the first three weeks and the tumor volume measurements are shown in 
Figure 5.2. 
  
Figure 5. 1 Treatment overview. (A) Axial images acquired before (left) and after (right) the first FUS 
+ Lipo-DOX treatment showing the signal enhancement in T1-weighted MRI after Gd-DTPA injection. 
Before FUS, the tumor was a small enhancing area (arrow). The magnitude and extent of this 
enhancement were increased after FUS. (B) Signal enhancement in this example as a function of time. 
(C) T2-weighted imaging (T2WI) used for treatment planning, contrast-enhanced T1-weighted imaging 
(CE-T1WI) used to verify the BBB/BTB permeabilization, and post-FUS T2*-weighted imaging 
(T2*WI) acquired during three weekly FUS+Lipo-DOXtreatments. The location of the tumor in 
treatment planning is indicated by the solid line, and the extent of MRI contrast enhancement is 
indicated by the dotted line. The coordinates of the sonication targets are also noted (white circles). 
Two hypointense spots (arrows) were evident after the third treatment in T2*-weighted imaging. The 
enhancing area evident in the other hemisphere in (A) and (C) (asterisk) was a location in the brain that 
was sonicated before the first Gd-DTPA injection to confirm the accurate targeting of the FUS beam. 
Bars: 5 mm. 
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5.1.2 Tumor progression 
In most animals in the three control groups, the tumor grew rapidly over this 
time Figure 5.2 (A) resulting in significant midline shift and compression of the 
lateral ventricles. Hypointense regions were often evident within the tumor in T2*-
weighted imaging in all groups. Eleven of fifteen rats (73%) in these groups either 
died or were euthanized before the third treatment due either to tumor dimensions 
exceeding 10–11 mm or poor health conditions (weight loss exceeding 20% or 
severely impaired activity). The rest died or were euthanized for these reasons before 
week 4. One rat in the Lipo-DOX Only group was euthanized before the third 
treatment; the rest were euthanized shortly after week 3. 
All animals in the FUS + Lipo-DOX group received all three treatments, and 
no rat in this group was euthanized before week 4 Figure 5.2 (B–C). The tumor 
volume reached a maximum at weeks 3 or 4, after which they began to shrink. The 
outcomes for the eight animals in this group varied and are summarized in Table 5. 1 . 
The maximum tumor volume varied substantially, with some tumors reaching 
volumes similar to the control group, and others never reaching 100 mm³. The mean 
tumor volume in the FUS + Lipo-DOX group was less than in the three control groups 
121 
 
at weeks 2–3 Figure 5.2 (C). These differences were not found to be significant. 
The first two rats treated in the FUS + Lipo-DOX group (Rats 1 and 2 in Table 
5. 1) exhibited local skin toxicity (inflammation, peeling; minor bleeding) on the scalp 
and the front and hind paws beginning on or after week two. These two animals 
developed a skin infection and were euthanized at days 34 and 35. In their last 
imaging session, one of these animals had no tumor evident in MRI, and the other had 
a small tumor that appeared to be responding to the treatment. Subsequent animals 
were treated prophylactically with antibiotics. While skin irritation or mild 
inflammation was observed, they did not develop infections. 
Three animals (Rats 3, 4 and 8 in Table 5. 1) did not exhibit any evident 
morbidity. They gained weight and behaved normally. These animals were followed 
for 9 or more weeks, at which time they were euthanized for histological examination. 
One of these long-term survivors was euthanized at day 66; the other two were 
observed for longer periods (136 and 142 days). Tumors in these animals grew to a 
substantial volume (greater than 300 mm3) before they began to resolve. MRI from 
one of these animals is shown in (Figure 5.2B). After the tumors disappeared, brain 
tissue loss at the former tumor site was evident in MRI, along with damage in 
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adjacent tissues and enlarged ventricles. Tissue damage appeared as highly 
hyperintense regions in T2-weighted imaging. In some regions, within this damaged 
area, discrete hyperintense zones in both T2* and T2-weighted imaging were seen. 
Two animals in the FUS + Lipo-DOX group (Rats 5 and 7 in Table 5. 1) were 
euthanized due to poor health at days 32 and 36, respectively. At the time of sacrifice, 
one of these animals exhibited only a small hyperintense region in T2-weighted 
imaging, and no tumor was evident in histology (see below). The other had an 
extensive hyperintense area in T2-weighted imaging, but only a small cluster 
containing a few tumor cells was found in histology. Finally, in one animal (Rat 6 in 
Table 5. 1), a large hypointense region was observed in T2*-weighted imaging at 
week 4 that was assumed to be intratumoral hemorrhage. This animal also exhibited 
impaired activity and was euthanized at this time. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 2 MRI appearance of the tumors and their growth over time. (A) MRI for the three control gr
oups for weeks 1–3. The rapid growth that was observed in most of the rats in these groups is evident i
n T2-weighted imaging (T2WI). Hypointense areas were often observed within the tumor in T2*-weigh
ted MRI (T2*WI). (B) Serial MRI for a long-term survivor in the FUS + Lipo-DOX group (Rat 4 in Ta
ble 5. 1) showing rapid tumor growth and subsequent resolution. The volume was maximum at week fo
ur, at which time it covered a significant portion of one hemisphere. It then began to shrink, and from 
week 8 onwards it was no longer evident. Brain tissue loss at the former site was evident, and the latera
l ventricle was enlarged and filled much of this space. Tissue adjacent to the former tumor mass was hi
ghly hyperintense in T2-weighted imaging, and presumably damaged. A hypointense region was obser
ved at the former tumor site in T2*-weighted imaging starting at weeks 6–7, which slowly shrunk over 
time. Imaging between weeks 8 and 20 was mostly similar. Note that the T2*-weighted imaging in the 
FUS-Only and FUS + Lipo-DOX animals was acquired after Gd-DTPA in weeks 1–3; contrast enhance
ment was observed in the tumor and surrounding brain. Bar: 5 mm. (C) MRI-measured tumor volumes 
as a function of time for each experimental group. Tumors were implanted at week 0. The number of su
rviving animals at each week is noted below the plot (MRI from two animals in the FUS-Only group w
as not included in this analysis due to poor image quality). Mean ± S.E. is shown. 
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Table 5. 1 Outcomes in FUS+Lipo-DOX group 
Rat Survival (days) 
Maximum vol. in 
MRI (mm³) 
Vol. in MRI at 
euthanasia (mm³)
Tumor found 
in histology Outcome 
1 34 244 63 Yes Skin infection, euthanized 
2 35 52 0 No Skin infection, euthanized 
3 66 358 0 No Long-term survivor 
4 142 365 0 No Long-term survivor 
5 32 424² 424² Yes¹ Poor health, euthanized 
6 31 312 312 Yes Intratumoral hemorrhage, euthanized 
7 36 96 40 No Poor health, euthanized 
8 136 312 0 Yes¹ Long-term survivor 
¹Only an small cluster containing a few tumor cells was found 
²A well-defined tumor margin was not evident in T2-weighted MRI at week 3-4 in this animal; only a 
large hyperintense region was observed (see Figure 4F). The volume of this hyperintense region was 
included in the volume measurements, as if this region was with tumor or edema could not be 
determined. 
5.1.3 Histological Findings 
Tumors in the Control and FUS-Only groups appeared at days 15–23 as solid 
masses that replaced large amounts of brain tissue (Figure 5. 3A). The tumor bulk 
consisted of viable and rapidly dividing spindle-shaped cells interspersed with 
multiple small necrotic sites. Microvessels that were necrotic, dilated, and congested 
with erythrocytes were observed throughout and were surrounded by necrotic zones 
(Figure 5. 3B). Small hemorrhagic regions were also found. Blood cells in these 
regions and in congested blood vessels were consistent with the hypointense regions 
observed in T2*-weighted imaging. In the largest tumors, numerous necrotic and 
hemorrhagic areas accompanied by cell necrosis and apoptosis were found scattered 
throughout the tumor mass. Rapid tumor growth and invasion displaced and 
125 
 
compressed the surrounding brain tissue, resulting in ischemia and cell death 
(infarction) in some adjacent brain regions (Figure 5. 3C). A narrow (0.5–1 mm) band 
of invading/infiltrating cells was evident at the tumor margin (Figure 5. 3D).  
The tumor appearance in the Lipo-DOX Only group varied. Although viable 
and dividing cells were generally present, a reduced cellularity compared to the other 
control groups, along with unhealthy-appearing tumor cells and an intensely 
vacuolated matrix was evident in this group (Figure 5. 3E). Large regions of necrosis 
were observed in some cases, but some viable tumor cells were always found within 
these necrotic areas. Substantial hemorrhage was evident at the periphery of some 
tumors, accompanied by infarction in the surrounding brain. Tumor cell invasion 
along perivascular tracts and tumor cell clusters were observed at sites as far as 1–2 
mm from the edge of the solid tumor mass (Figure 5. 3F). In one animal (euthanized 
at day 26 due to impaired activity), no tumor cells were found in histology. 
In contrast to the controls, all but one of the animals in the FUS + Lipo-DOX 
group exhibited a strong treatment response, with no tumor mass detected in 6/8 
animals. However, in two of these animals a few residual or recurrent tumor cells 
were found in the former tumor site. In one rat, which was euthanized due to skin 
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infection at day 34, a tumor was found to be shrunken compared to its maximum size 
in MRI and partly destroyed. The central area contained a viable tumor mass, and a 
surrounding rim of tissue appeared to be damaged. Only one animal (Rat 6 in Table 5. 
1) had a large tumor like most rats in the control groups. This animal, in which 
intratumoral bleeding was suspected in MRI, was euthanized at week 4. Histological 
examination confirmed hemorrhagic infarction in a region of tumor necrosis. This 
region was restricted to the tumor mass; no blood was found inside the adjacent 
ventricular space. 
Example histological findings from the FUS + Lipo-DOX group are shown in 
Figure 5. 4. In the three long-term survivors, where the tumors grew to a substantial 
volume before beginning to resolve, brain tissue loss was evident at the former tumor 
site (Figure 5. 4A). The adjacent lateral ventricle was significantly enlarged and filled 
this missing area. A region in the adjacent brain was necrotic, with an appearance 
consistent with infarct (Figure 5. 4B). A small cyst was observed within this necrotic 
zone. The hypointense regions evident in MRI contained hemosiderin — either in 
clusters or taken up by macrophages (inset in Figure 5. 4B). In one long-term survivor, 
a small cluster of recurring or residual tumor cells was found. 
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Findings from two animals from the FUS + Lipo-DOX group that were 
euthanized for impaired activity are shown in (Figure 5. 4C–H). In one case 
(euthanized at day 36) only a small necrotic area with macrophage infiltration was 
found at the former tumor site (Figure 5. 4C–E). In the second animal (euthanized at 
day 32), a larger necrotic area was found at the former tumor site, and affected or 
damaged tissue was observed in the surrounding brain that was hyperintense in T2-
weighted MRI (Figure 5. 4F–H). A tiny cluster of tumor cells was found in this 
example (inset in Figure 5. 4G). 
  
Figure 5. 3 Appearance of 9L gliosarcoma in the three control groups in histology. Animals receiving 
no treatment or FUS-Only (A–D) all had a similar appearance. The tumor appeared as a solid mass that 
replaced large volumes of brain tissue (A). The bulk of the tumors consisted of viable and rapidly 
dividing spindle-shaped cells (inset in A). Congested blood vessels were observed throughout, 
surrounded by necrotic tissue (B). Some regions of adjacent brain tissue were severely damaged, 
presumably from ischemia (C). There was a rim of infiltrating cells at the margin (D). Most tumors in 
the Lipo-DOX Only group (E–F) were also large masses of tumor cells with an infiltrating margin (E). 
However, unlike the other two control groups, they had a lower cellularity, unhealthy tumor cells, and 
intensely vacuolated matrix (inset in E). Tumor cell invasions along perivascular tracts and tumor cell 
clusters were observed at distant sites up to 2 mm from the edge of the solid tumor. The vacuolation 
evident in the tumor mass was often not observed in the infiltrating margin (* in F). 
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Figure 5. 4 Histological appearance of the brain in three of the animals from the FUS + Lipo-DOX 
group. (A–B) Long-term survivor (see xxxB for MRI). No tumor cells were found. Brain tissue loss at 
the former tumor site was evident, and the lateral ventricle was enlarged and filled this space. Tissue 
necrosis (infarct) was observed in the adjacent tissue, presumably from ischemia. Hemosiderin, either 
in clusters or inside macrophages was observed within the necrotic area. A small cyst (*) was also 
observed. (C–E) Example frogman animal, whose tumor was resolved, but the animal was euthanized 
at day 36 due to poor health. (C) T2-weighted MRI showing tumor growth and shrinkage. At week 4, 
only a small hyperintense region was visible. (D–E) A small necrotic area with macrophage infiltration 
was found at the former tumor site. (F–H) Another animal with a strong treatment response, but that 
was euthanized due to poor health at day 32. In this animal, the tumor grew to a relatively large size 
over weeks 1–2. At week 4, an extensive hyperintense area was observed in T2-weighted imaging (F). 
A necrotic area with micro-hemorrhages was found in histology at the former tumor site (G–H). 
Damaged or necrotic brain tissue was evident in the area that was hyperintense in T2-weighted imaging. 
A small cluster of tumor cells remained (inset in G). 
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5.1.4 Survival Analysis 
Kaplan–Meier survival analysis is shown in Figure 5. 5; the corresponding 
statistical data are summarized in Table 5. 1. The median survival time for the animals 
in both the Control and FUS-Only groups was about 18 days. For animals in the Lipo-
DOX Only group, it was 20.3 days - a 16% improvement over the animals in the 
Control group. However, this difference was not significant (P = 0.16). In contrast, 
the animals in the FUS + Lipo-DOX group showed a significant survival benefit (P < 
0.001) compared to the other three groups. The median survival time was 35 days, a 
100% and 72% improvement over the Control and Lipo-DOX Only groups, 
respectively. Note that this analysis did not censor the two animals euthanized early 
due to skin infection. If one assumes those animals did not die from their tumor and 
censors them, the estimated median survival of the FUS + Lipo-DOX group would be 
longer than 142 days, as more than 50% of the remaining animals survived until this 
time. 
 Figure 5. 5 Kaplan–Meier survival curves for the four experimental groups. Three long-term survivors, 
who did not exhibit impaired activity, were euthanized at different times (tick marks). Afterwards they 
were censored. 
 
Table 5. 2 Survival analysis 
Treatment 
Group 
N 
rats 
Max. 
survival 
(days) 
Median 
survival 
(days) 
ISTmedian 
(%) 
Mean survival 
± S.D. (days) 
P-value, 
Hazard ratio 
Control 7 23 17.5 ..... 18.6 ± 3 ..... 
FUS-Only 8 21 18.0 2.9 18.9 ± 1 0.85, 1.16 
Lipo-DOX 
Only 6 27 20.3 16.2 22.5 ± 3 0.16, 1.18 
FUS+Lipo
-DOX 8 >142 35.0 100.0 64.0 ± 48 0.00031, 5.36 
Note - Increase in Survival Time [ISTmedian (%)], P-value, and Hazard ratio are relative to the Control 
group. P-value and Hazard ratio from Log-Rank test between FUS+Lipo-DOX and Dox-Only group 
are 0.00057, 4.52 respectively.  
 
5.2 Discussion  
Doxorubicin is a commonly-used anticancer drug for treatment of a wide 
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range of cancers. While its effectiveness against glioma has been shown in 
vitro  [247] and in vivo when injected directly into the tumor  [226,248], systemic 
administration has not been effective clinically  [249], presumably reflecting 
insufficient delivery  [250]. A number of drug formulations have been developed to 
enhance the delivery of doxorubicin in animal glioma models  [251–255] and at least 
one clinical trial is ongoing with such an agent  [256]. Here, ultrasound and 
microbubbles can effectively improve outcomes in a rat glioma model using an 
existing liposomal agent, removing the need to develop and test new drug formulation 
was demonstrated. The method is noninvasive and restricts the drug delivery only to 
desired brain regions. While more work is needed to optimize the treatment and to 
better understand its safety profile, these results are promising for the development of 
new treatment options for glioma patients. They join several other studies that showed 
this FUS method can enhance drug delivery and improve outcomes in brain tumor 
models  [166,167,172,173,190,191,257]. 
This study also demonstrates the importance of multiple treatments. 
Previously, a modest survival improvement (24%) compared to untreated controls 
was observed with a single treatment in this tumor model  [191]. With three weekly 
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treatments, median survival was increased by 100% compared to the controls, and it 
was observed that 72% survival improvement compared to treatment with 
chemotherapy only. While the drug alone produced some treatment effects, it did not 
significantly improve survival or stop tumor proliferation in most cases. Histological 
examination of the tumors in this group showed a heterogeneous response to the 
treatment, with necrotic areas interspersed with viable tumor cells — perhaps 
consistent with heterogeneous vascular permeability and insufficient drug delivery to 
some regions. It also appeared that perhaps the drug did not reach the infiltrating 
tumor cells, as the matrix vacuolation evident in the tumor mass was not seen around 
the tumor cells at the tumor margin. In contrast, all but one of the tumors in the FUS + 
Lipo-DOX group exhibited a strong treatment effect 
Several adverse events were observed. Three rats with little or no tumor 
evident in histology – one in the Lipo-DOX Only group and two in the FUS + Lipo-
DOX group were euthanized due to impaired activity after three treatments. This 
finding may suggest that we used an aggressive treatment schedule that may not be 
tolerated by all subjects. Doxorubicin, even when encapsulated, has multiple known 
side effects, some of them severe. Use of medications to reduce the symptoms of 
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these side effects may help to avoid the impairment we observed. In one animal 
(shown in Figure 5. 4F–H), damaged brain tissue was evident over a large portion of 
the treated hemisphere. Brain tissue loss and necrosis in the surrounding brain in the 
three long-term survivors in the FUS + Lipo-DOX group was observed. It was not 
known whether these effects were due to the FUS + Lipo-DOX treatment or to the 
extensive tumor burden that could have damaged the surrounding brain due to mass 
effects. The results in Chapter 4 suggest that the amount of doxorubicin delivered 
across the BBB in the normal brain with these sonication parameters would not result 
in such severe neurotoxicity.  
A potentially significant adverse event was the extensive intratumoral 
hemorrhagic area that occurred in one animal one week after the last FUS + Lipo-
DOX treatment. While frank bleeding (such as into the ventricles) was not observed, 
vascular risks associated the treatment should be examined in more detail. This 
hemorrhage may have resulted from necrosis of the vessel wall in a large tumor vessel. 
Others have reported hemorrhages in this tumor model with different doxorubicin 
formulations  [255,258]. Skin toxicity was observed, a finding that may not be 
surprising since such toxicity, particularly in the hands and feet, is a known side effect 
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of doxorubicin  [259]. However, it might be prudent to confirm that the sonications do 
not increase drug delivery into the scalp. The focal region of our transducer 
overlapped the small rat skull, and the intensity on the scalp may have been relatively 
high. While the intensity on the scalp is expected to be less in humans, this issue 
might still be important, as large tumors may require sonication at hundreds of 
individual targets, and any low-level effects may accumulate. Reflections from the 
skull bone can exacerbate this effect.  
This study had several limitations. One limitation was our tumor model. While 
the 9L rat gliosarcoma model is highly aggressive and the robust survival 
improvement observed here is certainly encouraging, future work is needed with 
models that are genetically similar to human GBM and that have similar growth 
patterns. The 9L glioma model is not considered to be highly infiltrating  [260] and 
only a relatively narrow infiltrating zone was observed. The disruption of the BBB in 
the surrounding brain tissue may not have played as large a role in our outcomes as 
might be anticipated clinically. Targeting infiltration is anticipated to be critically 
important with human GBM, and based on clinical patterns of recurrence  [5,6,261], a 
margin extending several centimeters into the “normal” brain may require BBB 
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disruption for effective therapy. Additional work in a more infiltrating tumor model is 
needed to ensure that such regions can safely and effectively to be targeted. Finally, 
this model has been reported to be immunogenic  [260], which may have led to more 
improved outcomes than would be achieved in non-immunogenic tumor model. 
Another limitation was to use two different drug formulations in some animals 
due to a national shortage of doxorubicinIL. While they had similar liposome 
properties, there may have been differences unknown to us that may have impacted 
our results. The sample size was also relatively small, and more work is needed to 
better characterize the effectiveness of the treatment and the rate of adverse events. 
More consistent results may be obtained using online methods to optimize the 
exposure levels. While the exposure levels based on the animal age and weight were 
modified, retreatment of regions where MRI contrast enhancement was poor to 
attempt to achieve a uniform level of enhancement was performed. The monitoring 
the microbubble dynamics in real-time using online acoustic emission 
monitoring  [139,204] and re-treating areas with poor contrast enhancement can 
improve the local delivery and perhaps allow for a reduced systemic dose was being 
anticipated. Here, only one dose of liposomal doxorubicin was evaluated. By utilizing 
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post-treatment MRI contrast imaging, which can be correlated to drug 
concentrations  [95,118], along with online methods to control the exposures was 
expected, the optimization of the drug dose delivered to the tumor and the 
surrounding brain tissue. If one understands the relationship between the 
concentrations of the therapeutic and the imaging contrast agent, which can perhaps 
be established in animals, one might be able to titrate the drug administration to 
achieve a desired level in the brain. However, this may be challenging in tumors, 
where the vascular permeability can change over time. This relationship was explored 
in work described in the next Chapter. 
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Chapter 6:  Enhancement in Blood-Tumor Barrier Permeability 
and Delivery of Liposomal Doxorubicin using Focused 
Ultrasound and Microbubbles: Evaluation during 
Tumor Progression in a Rat Glioma Model 
It would be desirable to demonstrate that the amount of drug delivered and its 
penetration into the brain parenchyma is sufficient to produce a therapeutic response. 
Ideally, this would be performed for each patient. Post-treatment imaging could 
provide this assurance by labeling the drug with a contrast agent for MRI or other 
imaging modality  [174]. It might also be possible to use a standard contrast agent as a 
surrogate measurement, which would be advantageous since it could be used with 
existing drugs. A number of studies have related signal intensity changes in contrast-
enhanced MRI after BBB disruption with tissue drug concentrations  [95,175,208]. 
More quantitative and repeatable techniques, such as estimating contrast agent 
concentrations via T1-mapping  [134,209] or vascular transfer coefficients via 
analysis of dynamic contrast-enhanced MRI (DCE-MRI)  [99] have been used to 
perform spatial and temporal characterization of BBB permeability after FUS. DCE-
MRI can also been investigated to predict the resulting payload of drugs to the 
139 
 
brain  [118] and in tumors  [262].  
Despite these promising findings, one needs to be careful when expanding to 
different patient populations or if different drugs are used. The relationship between 
the delivery of a contrast agent and a therapeutic can be complicated. For example, a 
relationship found in the normal brain may not translate to patients with CNS 
disorders. This challenge could be particularly difficult in tumors where the vascular 
properties can change over time  [238]. Further complications may arise when the 
therapeutic has a different size or other chemical property than the contrast agent.  
Here, the usefulness of MRI as a monitoring and feedback tool for the drug 
delivery procedure was explored. I measured the transfer coefficient Ktrans of the MRI 
contrast agent Gd-DTPA with DCE-MRI for cases with and without sonication and 
Lipo-DOX administration. I then compared Ktrans to the resulting doxorubicin 
concentrations in tumors. Morever, I performed this characterization at three time 
points to investigate if this relationship changes over time as the tumor blood vessels 
become more degenerate. Finally, a feasibility study was performed where acoustical 
monitoring of bubble activity during sonication was correlated with signal intensity 
changes in contrast-enhanced MRI was investigated.  
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6.1 Results 
6.1.1 Bilateral Tumor Progression and BBB/BTB Disruption 
The MRI appearance of the bilateral tumors on day 9, 14, and 17 were monitored in 
MRI where they grew rapidly over time (Figure 6. 1A), resulting in significant 
midline shift and compression of the lateral ventricles. The tumor volumes in the right 
hemisphere were 14.5, 113.8 and 151.4 mm³ at days 9, 14, and 17 respectively. The 
corresponding volumes of the left tumors were 16.0, 110.8, and 143.8 mm³, and were 
not significantly different (P=0.9) from those on the right (Figure 6. 1B). A higher 
pressure amplitude (0.81 vs 0.55 MPa) was needed at day 17 to induce consistent 
BBB/BTB permeabilization, presumably because of an increase in skull or dura 
thickness as the rats grew  [198]. The sonication pattern was similar to the studies in 
earlier chapters, where 5-20 targets were applied in a grid (spacing: 1.5 mm) to cover 
the entire tumor and a rim of surrounding brain tissue. Post–FUS T2*-weighted 
images were used to detect small petechaie which would appear in this imaging as 
hypointense spots. 
 
Figure 6. 1 MRI appearance of bilateral 9L gliosarcoma, their growth curves, and doxorubicin 
concentrations measured approximately 2 hours after the ultrasound experiments as a function of tumor 
volume. (A) Axial views of MRI at day 9, 14, and 17 after implantation. The rapid growth of tumor 
was evident in T2-weighted MRI (T2WI), changes of BBB/BTB permeabilization were observed in 
contrast-enhanced T1-weighted images (CE-T1WI) after gadolinium injection, and FUS-induced tissue 
damage was evaluated in T2*-weighted images (T2*WI) which would appear as hypointense spots in 
images. (B) The growth curves shows no significant difference between the volumes of the sonicated 
and non-sonicated tumors (P=0.9). (C) Doxorubicin concentrations measured in the tumors post 
mortem in tumor tissue were correlated to tumor volume (R²=0.58, 0.51 for the sonicated and non-
sonicated tumors, respectively). Doxorubicin concentration in the sonicated tumor was generally larger 
than the non-sonicated tumor. 
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6.1.2 Doxorubicin Concentration and Kinetics of BBB/BTB 
Permeability Changes  
Lipo-DOX was administered in fractions immediately before each sonication, and its 
concentration in the tumors was measured about two hours later. The doxorubicin 
concentration measured post mortem via fluorometry increased monotonically as a 
function of tumor volume in both the left (non-sonicated) and right (sonicated) tumors 
(Figure 6. 1C). A good correlation (R² = 0.58 and 0.51 for the left and right tumors, 
respectively) was observed between doxorubicin concentration and tumor volume 
(Fig.2C). The concentration in the sonicated tumor (2222±784, 3687±796 and 
5658±821ng/g) was generally greater than in the non-sonicated tumor (823±600, 
1817±732 and 2432±448ng/g).  
In most animals, DCE-MRI was obtained before and after FUS-induced 
BBB/BTB to calculate the transfer coefficient Ktrans for Gd-DTPA. Example maps of 
Ktrans and changes of signal intensity before and after sonication are shown in (Figure 
6. 2). After FUS, the signal intensity on sonicated tumor was increased significantly 
(P < 0.05), at day 9 but not at day 14 or 17 compared with before FUS (Figure 6. 2A-
C). Before FUS, the Ktrans values for the both tumors appeared similar on days 9, 14 
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and 17. They increased, particularly at day 9, for the sonicated tumors (shown by the 
arrow in Figure 6. 2D). Comparisons of mean Ktrans before and after sonication are 
shown in Figure 6. 3. In the non-sonicated tumor, the mean Ktrans values (±S.D) before 
FUS were 0.0068±0.0027, 0.0088±0.0026 and 0.012 ± 0.0086 min-1 at day 9, 14 and 
17, respectively; after the sonications these values were 0.0044±0.0018, 
0.0103±0.0047 and 0.0115±0.0015 min-1 (Figure 6. 3A). In the sonicated tumors, the 
mean Ktrans values before FUS were 0.0077±0.0053, 0.0082±0.0025, and 
0.01006±0.0019 at day 9, 14, and 17, respectively. After FUS they were 
0.0129±0.0064, 0.0128±0.0062 and 0.0116±0.0018 (Figure 6. 3B). No significant 
difference (P>0.05) was observed in the mean Ktrans between the two DCE-MRI 
acquisition for the non-sonicated tumor at any day. However, for the sonicated tumor, 
Ktrans was significantly increased (P < 0.05) at day 9 but not at day 14 or 17. 
 Figure 6. 2 Example of signal intensity changes in sonicated tumor and permeability maps in the 
bilateral tumors at different stages of tumor growth before and after FUS. (A-C) Change of signal 
intensity of Gd-DTPA on sonicated tumor was measured (before and after FUS) at three different days 
(9, 14 and 17 days after implantation) during DCE-MRI. After FUS, the signal intensity of Gd-DTPA 
on sonicated tumor was increased significantly (P < 0.05), at day 9 but not at day 14 or 17 compared 
with before FUS. (D) Maps of Ktrans for Gd-DTPA obtained after two separate injections (before and 
after FUS) on three different days (9, 14 and 17 days after implantation). Before FUS, the Ktrans 
values for the both tumors appeared similar on days 9, 14 and 17. They increased, particularly at day 9, 
for the sonicated tumors (shown by arrow in Fig. 3D). Ktrans values are indicated in the color bar.  
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Figure 6. 3 Mean Ktrans estimates (±S.D.) before and after FUS for the sonicated and control (non-
Figure 6. 4 shows the comparison of Ktrans and doxorubicin concentration 
between the sonicated and non-sonicated tumors obtained DCE-MRI after sonication 
of one of the tumors. Similar to the results shown in Figure 6. 3, Ktrans was 
significantly greater (P<0.05) at day 9, but not at days 14 or 17. The mean ratio of 
sonicated) tumors at different stages of tumor growth. (A) The Ktrans measurements in non-sonicated 
tumors were not significantly enhanced between the two DCE-MRI acquisitions (before and after FUS) 
at any day. (B) For the sonicated tumors, mean Ktrans was significantly increased (P < 0.05) at day 9 but 
not at day 14 or 17. (* P<0.05) 
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Ktrans between the sonicated and non-sonicated tumors was 1.7±1.2, 1.6±2, 1.1±2, and, 
respectively, at days 9, 14, and 17 (Figure 6. 4)A. In contrast, the doxorubicin 
concentration was enhanced significantly at all days (P < 0.05 at day 9, P < 0.01 at 
day 14 and P < 0.0001 at day 17) (Fig. 5B). The ratio of doxorubicin concentration 
between the sonicated and non- sonicated tumors was 2.7±1.3, 2.03±1.08, and 
2.33±1.8 for days 9, 14, and 17 respectively (Figure 6. 4B). Other than a moderate 
correlation (R²=0.44) at day 9, there was no clear relationship between doxorubicin 
concentration and Ktrans after FUS-induced BBB disruption. No significant difference 
(P>0.05) was observed in fv between measurements made before and after FUS or 
between the sonicated and non-sonicated tumors. 
 
 Figure 6. 4 Mean Ktrans estimates and doxorubicin concentrations (±S.D.) at different stages of tumor 
growth for the sonicated and control (non-sonicated) tumors. (A) The Ktrans measurements in the 
sonicated tumors were significantly enhanced compared those in the controls at day 9 but not at day 14 
or 17. (B) Doxorubicin concentration was significantly enhanced at all days. (* P<0.05; ** P<0.01; 
**** P<0.0001) 
6.1.3 Histological findings 
Histological examination was performed on two rats after sonication at day 9 
and 14. Tumors in both groups appeared as solid masses that replaced large amounts 
of brain tissue (Figure 6. 5A-B). The tumor bulk consisted of viable and rapidly 
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dividing spindle-shaped cells. Tiny necrotic sites scattered throughout the tumor were 
observed on day 14 but not on day 9 (yellow square in Figure 6. 5B). Those sites were 
comparatively smaller than the rest of the tumor mass. The sonicated tumors appeared 
unaffected in the H&E stained sections. The only effect of note was a small number of 
tiny clusters of extravasated erythrocytes (petechaie) that were scattered throughout 
the sonicated tumor regions (Figure 6. 5C-D, magnified view of red squares). 
 
Figure 6. 5 Appearance of two 9L gliosarcoma at different days after implantation in histology. (A-B) 
Appearance of the tumors in an H&E stained section at day 9 (5×) and 14 (1.25×). The tumors 
appeared as solid masses that replaced large volumes of brain tissue. The bulk of the tumors consisted 
of rapidly dividing spindle-shaped cells with some small necrotic zones evident on day 14 (yellow 
square in B). (C-D) Magnified views (20x) of the red boxes. Most of the sonicated region appeared 
unaffected, but in a few areas tiny petechiae were observed. 
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6.2 Discussion 
This study investigated the pharmacokinetic characteristics of small and large-
molecule agents at different stages of tumor growth after BBB/BTB permeabilization 
with microbubble-enhanced FUS. Gd-DTPA (938 Da) and DCE-MRI were used to 
noninvasively provide semiquantitative measures of transport across these vascular 
barriers, and the concentration of doxorubicin, which was administered in ~100 nm 
liposomes, was measured in the tumor post mortem. Microbubble-enhanced FUS 
succeeded in increasing doxorubicin concentration by a factor of two or more 
regardless of the stage of tumor growth, but the enhanced delivery of Gd-DTPA, 
reflected in transport coefficient Ktrans measured in DCE-MRI, was significantly 
enhanced only at the early stage of tumor growth. Ktrans was slightly elevated 
compared to the non-sonicated tumors at later time points, but there was substantial 
variation and the increases were not statistically significant. That finding is consistent 
with the results of a study by Chu et al., who also found that microbubble-enhanced 
sonication could increase delivery of Gd-DTPA in early, but not in late-stage 
tumors  [209] 
If this finding that Ktrans for Gd-DTPA of late-stage tumors cannot be 
significantly increased is correct, it suggests that that there could be a size-dependent 
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maximum level enhancement in BTB permeability that can be achieved by FUS and 
microbubbles. In contrast to Gd-DTPA, the sonication-induced enhancement in 
doxorubicin delivery increased at days 14 and 17. However, future work investigating 
agents with a range of different sizes would be necessary to understand whether these 
results are true in general. In addition, the 9L gliosarcoma is a highly aggressive 
tumor model; it would be interesting to investigate less aggressive models to further 
understand how tumor development influences the ability to enhance delivery of 
drugs of different sizes. 
The fact that FUS appeared to be more effective in delivering a drug 
encapsulated in a large carrier regardless of the tumor stage is encouraging, as it 
suggests that even late-stage tumors can benefit from FUS-induced drug enhancement. 
Many promising drug carriers such as liposomes and various other nano-carriers are 
being developed that may be useful for brain tumors if the challenges created by the 
BTB and BBB can be overcome. These agents can be more targeted and have fewer 
side effects compared to the broad-spectrum chemotherapy agent doxorubicin. 
However, more work is needed to confirm that drug penetration away from the blood 
vessels, which can be relatively small for large particles, is sufficient to achieve a 
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therapeutic response. Prior work with liposomal doxorubicin and brain tumor 
models  [170,191], and the development of “brain-penetrating” nano-carriers  [263] 
are encouraging in this regard.  
Unfortunately, a good correlation with doxorubicin delivery and Ktrans 
measurements with the commonly-used MRI contrast agent Gd-DTPA was not seen, 
which would have been useful since it could enable one to noninvasively estimate 
drug concentrations. Several studies have found a good correlation between signal 
intensity changes in contrast enhanced MRI and that of a drug or tracer in the normal 
brain or in tumor models  [208,264,265]. Most relevant to this study, Treat et al. 
compared MRI signal enhancement after Gd-DTPA injection and doxorubicin 
concentration in the normal rat brain after FUS-BBBD  [95]. Unlike in this work 
those experiments, which also used liposomal doxorubicin, a good correlation was 
observed between these two measurements. This discrepancy was likely due to 
differences between normal brain and tumor blood vessels. In contrast to the normal 
brain, where FUS-induced permeability changes to the BBB might be expected to be 
relatively reproducible, the vascular permeability in a tumor can vary widely and can 
change over time, and it is likely that predicting the sonication-induced changes to the 
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BTB is not straightforward. This discrepancy is likely to be particularly stark when 
the drug and contrast agent have a large difference in size or in other chemical 
properties. It would be interesting to repeat this study with liposomal MRI contrast 
agent. 
6.3 Acoustics Emission  
Previous work has demonstrated that the acoustic emissions recorded during 
sonication can be used to characterize the microbubble activity, which can be useful 
for monitoring FUS-BBBD  [124,125,139,204]. This work has shown that signatures 
for robust stable cavitation – strong harmonics, subharmonics, or ultraharmonics – are 
produced when the microbubbles are sonicated at an intensity that results in BBBD. In 
contrast, when wideband emissions are produced, which are a signature for inertial 
cavitation  [74], vascular damage is produced in addition to FUS-BBBD  [139]. As I 
showed in Chapter 4, avoiding this vascular damage in the brain outside the tumor 
margins can be important for avoiding permanent brain damage. To date, nobody has 
investigated this approach in tumors. 
Thus, in addition to above-mentioned DCE-MRI method, we performed a 
feasibility study where analysis of acoustic emission of microbubbles were compared 
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to extravasation of the MRI contrast agent Gd-DTPA. 
6.3.1 Acoustic Emissions vs. MRI 
The acoustic emission and MRI findings of a tumor sonication are as shown in 
figure Figure 6. 6. A total of nine sonications were applied in a rat with an implanted 
9L rat glioma. First, emissions signals were acquired without microbubbles at each 
target. We then acquired data with microbubbles at the same exposure levels. The 
emissions were recorded with a passive cavitation detector (a hydrophone) using a 
high-speed digitizer card. We then examined the spectra (calculated via FFT) of the 
data acquired with microbubbles normalized to baseline data, as described 
earlier  [125]. The spectrum shown in Figure 6. 6 was typical of what was observed. 
After normalizing the microbubble-enhanced data to that acquired without 
microbubbles, all that remained was strong harmonic emissions. The average strength 
of the harmonics was then calculated for each target, using metrics described 
earlier  [125]. 
Contrast enhanced MRI was also acquired before and after the sonications. A 
contrast enhanced image acquired after FUS is shown in Figure 6. 6; the inset shows a 
map of the enhancement after sonication normalized to that obtained before 
sonication. The locations of the sonicated targets is evident in this enhancement map. 
Superimposed on this map is the strength of the harmonic activity measured from the 
acoustic emission. A correlation between the two measurements is evident.  
 
 
Figure 6. 6A Acoustic emissions acquired during sonications in a tumor-bearing rat. This example is a 
typical power spectra showing strong harmonic emissions. No broadband emission was evident. The 
emissions recorded during sonication with microbubbles were normalized to baseline data obtained 
during identical sonications without microbubbles. 
 
 
Figure 6. 6B MRI acquired after sonication of a tumor in a rat 
brain. (A) Contrast-enhanced T1-weighted MRI acquired after 
the sonications. The same imaging was acquired before the 
sonications as well. To examine the changes induced by the 
sonications, we normalized the post-sonication enhancement 
to the pre-sonication values. The changes in enhancement in 
the tumor are shown in (B). The individual sonication 
locations are evident. The superimposed numbers are the 
strength of the harmonic emissions acquired during these 
sonications. A correlation between the amount of enhancement 
induced by the sonications and the harmonic emissions 
recorded during the sonications is clearly evident. 
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6.3.2 Discussion 
While we clearly need to repeat this study in more animals, these results are 
encouraging for the prospect of controlling FUS-BBBD. Our laboratory found 
previously that the strength of the harmonic emsissions is correlated with the strength 
of BBB disruption in nonhuman primates  [125], and using this as a method to control 
FUS-BBBD to ensure that it is safe and effective. The present results suggest that the 
strength of the harmonic emissions, may also be related to the change in vascular 
permeability in a tumor. If these results are verified, it could be an important 
development for the clinical translation of this technology.  
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Chapter 7:Conclusions and Future Work 
7.1 Conclusions 
In this thesis, MRgFUS technology was used to induce BBB/BTB permeabilization 
for the targeted delivery of a chemotherapy agent that normally does not reach the 
brain at all and that normally is not effectively delivered to brain tumors. The 
BBB/BTB and their limitations for brain drug delivery have prompted several 
different techniques to overcome these limitations, including invasive methods, 
biopharmaceutical approaches, and different methods to transiently disrupt the BBB 
distuption. These methods, including FUS, have different advantages and 
disadvantages, as I discussed in Chapter 1. Additionally, the underlying mechanisms 
due to interaction of microbubble with ultrasound were described briefly in that 
chapter. Furthermore, the working principles of MRI and DCE-MRI method used to 
observe the BBB/BTB permeability change due to FUS were outlined.  
An overview of common methods and materials used in this dissertation was 
discussed in Chapter 2. In that chapter I described the animal preparation protocol, my 
experimental set up for MRI-guided FUS, the chemotherapy agent I used, the methods 
I used for transducer calibration, the MRI sequences I used to guide the procedure and 
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evaluate the results, and the fluorometry and fluorescent microscopy techniques I 
employed to visualize and measure drug concentrations.  
Ultrasound-mediated Lipo-DOX delivery through BBB and its concentration 
in the brain were described in Chapter 3. Clinically relevant concentrations of 
doxorubicin (~4.8±0.5 µg/g) were delivered to the brain with the sonication 
parameters (0.69 MHz; 0.55 MPa; 10 ms bursts; 1 Hz PRF; 60s duration), 
microbubble concentration (Definity, 10 µl/kg), and Lipo-DOX dose (5.67 mg/kg) I 
used. I found that I could achieve a clinically-relevant concentration, which I based on 
a study that compared doxorubicin concentrations in human tumors with clinical 
outcomes  [237]. I also found that the resulting concentration was reduced by 32% 
when the agent was injected 10 minute after the last sonication. These results are 
encouraging for the prospect of using this drug delivery technique in an invasive 
glioma, where we will need to deliver drugs across the intact BBB to reach cancer 
cells infiltrating into the normal brain, and for optimizing the procedure. 
The safety of using multiple sessions of FUS-BBBD and Lipo-DOX in the 
normal brain was investigated in Chapter 4. From histological analysis, we found that 
after three weekly treatments, the sonicated brain tissue in the focal plane was 
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unaffected in rats that received FUS-BBBD only, despite MRI evidence that minor 
vascular damage occurred during some of the sonications. In contrast, only one out of 
four rats that received FUS-BBBD and Lipo-DOX appeared completely unaffected at 
focal plane; the other three  evidence of prior tissue damage (small scars and a small 
cyst in one case). The result indicates that while delivery of Lipo-DOX to the rat brain 
can result in minor damage, the severe neurotoxicity seen in earlier works  [266] does 
not appear to occur with delivery via FUS-BBB disruption. While future work is 
needed, the results suggest that Lipo-DOX can exacerbate damage resulting from 
inertial cavitation. I base this speculation on the fact that MRI evidence suggested that 
vascular damage was produced during the sonications in the animals that both did and 
did not receive Lipo-DOX, while evidence of permanent prior damage was only 
observed in the rats who received Lipo-DOX. Based on these findings, I would 
recommend caution when sonicating the margin around a tumor.   
The therapeutic efficacy of three weekly sessions of FUS and Lipo-DOX in 
the 9L rat glioma model has been demonstrated in chapter 5. Animals that received 
FUS and Lipo-DOX (N=8) had a median survival time that was increased 
significantly (P < 0.001) compared to animals who received Lipo-DOX only (N = 6), 
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FUS only (N=8), or no treatment (N=7). The median survival for animals that 
received FUS and Lipo-DOX was increased by 100% relative to untreated controls, 
whereas animals who received Lipo-DOX alone had only a 16% improvement. 
Animals who received only FUS showed no improvement. No tumor cells were found 
in histology in 4/8 animals in the FUS + Lipo-DOX group, and in two animals, only a 
few tumor cells were detected. Overall, this work demonstrates that multiple sessions 
using this FUS technique to enhance the delivery of Lipo-DOX can result in a 
pronounced therapeutic effect, at least in this rat glioma model. I would recommend 
continuing this work in a better tumor model that is genetically similar to a human 
glioma and that is more infiltrative. Methods to minimize the systemic dose and to 
avoid side-effects also should be pursued. 
Changes in vascular permeability in a rat glioma model resulting from FUS 
and microbubbles were investigated as a function of time after tumor implantation 
using dynamic contrast-enhanced MRI (DCE-MRI) in Chapter 6. The transfer 
coefficient (Ktrans) describing the extravasation of the MRI contrast agent Gd-DTPA 
was measured via DCE-MRI before and after sonication. I then euthanized the animal 
and measured doxorubicin concentration in the tumors. Tumor doxorubicin 
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concentrations increased monotonically (823±600, 1817±732 and 2432±448 ng/g) in 
non-sonicated control tumors at 9, 14 and 17 days respectively. With FUS-induced 
BTB permeabilizaiton, the Lipo-DOX concentrations were enhanced significantly 
(P<0.05, P<0.01, and P<0.0001 at days 9, 14, and 17, respectively) and were greater 
than the control tumors by a factor of two or more (2222±784, 3687±796 and 
5658±821 ng/g) regardless of the stage of tumor growth. In contrast, the transfer 
coefficient Ktrans was significantly (p<0.05) enhanced compared to control tumors 
only at day 9 but not at day 14 or 17. These results suggested that FUS-induced 
enhancements in Lipo-DOX delivery are relatively consistent over time, at least in 
this tumor model. These results are also encouraging for the use of large drug carriers, 
as they suggest that even large/late-stage tumors can benefit from FUS-induced drug 
enhancement. The corresponding enhancements in Ktrans, however, were found to be 
variable in large/late-stage tumors and not significantly different than controls. This 
difference perhaps reflects the size mismatch between the liposomal drug (~100 nm) 
and Gd-DTPA (molecular weight: 938 Da) and is unfortunate since it could be helpful 
to be able to use the MRI contrast agent as a drug surrogate to predict drug delivery. It 
may be necessary to use a larger MRI contrast agent to effectively evaluate the 
sonication-induced enhanced permeabilization in large/late-stage tumors when a large 
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drug carrier such as a liposome is used. In addition to DCE-MRI method, I 
investigated  the feasibility of using recordings of the acoustic emissions produced by 
the microbubbles can be related to the extravasation of Gd-DTPA, as has been done 
previously in normal brain tissue  [123,125]. While more work beyond this feasibility 
study is clearly needed, a correlation was evident between these two measurements 
suggesting that such methods can be useful for monitoring the sonications. Such 
methods are important when considering clinical translation. Ultimately we want to 
move this procedure out of the MRI environment. Having a method to reliably control 
the exposure level to ensure an adequate level of BBB/BTB permeabilization can 
enable this translation. 
This work shows that FUS is a unique technology that can induce BBB or 
BTB permeabilization that is targeted, noninvasive and transient. It can enable the 
delivery of therapeutics (even nanocarriers such as a liposome) that normally do not 
reach the brain, enhance their delivery to brain tumors, and improve outcomes in a 
tumor model. When inertial cavitation is avoided, the sonications do not appear to 
have any deleterious effects on the brain, and the method is readily repeatable. I 
demonstrated that multiple treatments with FUS and Lipo-DOX significantly 
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inhibited tumor growth, increased survival, and appeared to completely eradicate the 
tumor in an aggressive rat gliosarcoma model. I also showed how MRI and acoustic 
methods can help to plan, monitor, and evaluate the treatment which offers the 
possibility of having control over the locations where drugs are delivered and 
concentrations of the drugs used. Importantly, my work has demonstrated that such 
methods can become more complicated in tumors and when a chemotherapy drug is 
used. When such methods are being developed, one cannot simply evaluate them in 
normal brain with imaging tracers.  
7.2 Future work 
The ultimate goal of this research is to translate ultrasound-mediated drug 
delivery technology from an animal model to human patients of with disorders of the 
CNS. Further research works need to be done before this technology becomes 
practical for widespread clinical trials. The results of the work in this thesis can help 
guide this future research.  
Preliminary optical imaging results presented in Chapter 3 offer interesting 
findings on the likely cellular colocalization of doxorubicin in the brain after 
ultrasound-enhanced chemotherapy. While these results are not conclusive, it is clear 
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that this method has promise to further improve and optimize the procedure. For 
example, it is known that high interstitial pressures and a dense extracellular matrix 
can impede the delivery of drugs far enough from the vasculature to reach tumor cells, 
which can survive even in a hypoxic state   [238]. By visualizing the drug and by 
staining blood vessels, we can investigate and even quantify this penetration 
depth  [267]. We can then investigate different sonication parameters and other 
factors that we can use to improve drug penetration in addition to simply getting the 
drugs out of the blood vessels.  
The experiments with FUS and Lipo-DOX in Chapters 4 and 5 showed that 
multiple treatments can have significant therapeutic outcomes while avoiding serious 
neurotoxicity. More consistent results may be obtained using online methods to 
optimize the exposure levels. Microbubble dynamics in real-time using online 
acoustic emission can be monitored  [139,204] and re-treating areas with poor 
contrast enhancement can improve the local delivery and perhaps allow for a reduced 
systemic dose. It would also be interesting to investigate whether the sonications can 
release the doxorubicin from the liposomes, and has been observed by others with 
liposome-coated microbubbles  [240] . While the 9L rat gliosarcoma model is highly 
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aggressive and the robust survival improvement observed here is certainly 
encouraging, future work is needed with models that are genetically similar to human 
GBM and that have similar growth patterns. Additional work in a more infiltrating 
tumor model is needed to ensure that we can safely and effectively target such regions. 
Since 9L has been shown to be immunogenic  [260], it would be helpful to show that 
one can reproduce similar outcomes in non-immunogenic model. 
In Chapter 6, if my finding that the transfer coefficient Ktrans for Gd-DTPA 
of late-stage tumors cannot be significantly increased is correct, it suggests that there 
could be a size-dependent maximum level enhancement in BTB permeability that can 
be achieved by FUS and microbubbles. In contrast to Gd-DTPA, the sonication-
induced enhancement in doxorubicin delivery increased at days 14 and 17. However, 
future work investigating agents with a range of different sizes would be necessary to 
understand whether these results are true in general. It would also be interesting to 
repeat this study with liposomal MRI contrast agent with size similar to Lipo-DOX. In 
addition, the 9L gliosarcoma is a highly aggressive tumor model; it would be 
interesting to investigate less aggressive models to further understand how tumor 
development influences the ability to enhance delivery of drugs of different sizes.  
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Finally, beyond its ability to enhance drug delivery for brain tumors, FUS can 
induce a number of different effects through mechanical, thermal, and vascular 
interactions. I am fascinated by the wide array of transient and irreversible bioeffects 
that we can induce using FUS in the brain. These bioeffects can be employed to 
develop new therapies and to probe brain function. I am particularly interested in 
studying the physiological response of the brain to ultrasound exposure in more detail. 
For example, it would be interesting to investigate the effects of ultrasound on the 
local concentrations of neurotransmitters/neuroinhibitors in different brain structures. 
If we can use FUS to modulate these substances in a controllable and predictable way, 
we will have a valuable tool that can open up entirely new directions for neuroscience. 
Targeted drug delivery is just the beginning. 
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The physiology of the vasculature in the central nervous system (CNS), which includes the blood–brain barrier
(BBB) and other factors, complicates the delivery of most drugs to the brain. Different methods have been
used to bypass the BBB, but they have limitations such as being invasive, non-targeted or requiring the formula-
tion of new drugs. Focused ultrasound (FUS), when combined with circulating microbubbles, is a noninvasive
method to locally and transiently disrupt the BBB at discrete targets. This review provides insight on the current
status of this unique drug delivery technique, experience in preclinical models, and potential for clinical transla-
tion. If translated to humans, this methodwould offer a ﬂexiblemeans to target therapeutics to desired points or
volumes in the brain, and enable the whole arsenal of drugs in the CNS that are currently prevented by the BBB.
© 2014 Elsevier B.V. All rights reserved.
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1. Introduction
Theblood–brain barrier (BBB) is a specialized non-permeable barrier
in cerebral microvessels consisting of endothelial cells connected
together by tight junctions, a thick basement membrane, and astrocytic
endfeet. The tight junctions between the endothelial cells, together with
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an ensemble of enzymes, receptors, transporters, and efﬂux pumps of
the multidrug resistance (MDR) pathways, control and limit access of
molecules in the vascular compartment to the brain by paracellular or
transcellular pathways [1]. The BBB normally protects the brain from
toxins, and helps maintain the delicate homeostasis of the neuronal
microenvironment. However, it also excludes 98% of small-molecule
drugs and approximately 100% of large-molecule neurotherapeutics
from the brain parenchyma [2,3]. Only small-molecule drugs with high
lipid solubility and a molecular mass under 400–500 Da can cross the
BBB in pharmacologically signiﬁcant amounts, resulting in effective
treatments for only a few diseases such as depression, affective disor-
ders, chronic pain, and epilepsy. Given the paucity of small-molecule
drugs effective for CNS disorders, it is clear that the BBB is a primary
limitation for the development and use of drugs in the brain. Overcoming
this hindrance could mean potential therapies for a wide range of
disorders, including Alzheimer's andHuntington's diseases, amyotrophic
lateral sclerosis (ALS), neuro-AIDS, stroke, brain or spinal cord trauma,
autism, lysosomal storage disorders, fragile X syndrome, inherited
ataxias, and blindness.
Tumors, particularly those in the brain also face challenges for
effective drug delivery. While the blood vessels in most primary and
metastatic brain tumors are often somewhat permeable from the lack
of a fully formed BBB, inﬁltrating cancer cells at the tumor margins
and small metastatic seedsmay be protected by the BBB of surrounding
normal tissue [4]. Glioblastomas in particular are highly inﬁltrative, and
commonly recur after localized treatments such as conformal radiother-
apy or surgery. Relapse usually occurs within a few centimeters of the
treatment site [5–7]. Furthermore, their vascular permeability is hetero-
geneous, and additional barriers to drug delivery include increased
interstitial pressures [8] and drug efﬂux pumps that contribute to
their multidrug resistance phenotype [9]. As for metastatic tumors,
work in mice suggests that the blood–tumor barrier (BTB) is only
partially compromised in breast adenocarcinoma brain metastases,
and that toxic concentrations of chemotherapy are only achieved in a
small subset of tumors that are highly permeable [10]. Also, systemic
drug accumulation in brain metastases can be substantially less than
in extracranial metastases [10]. Thus, the BTB is a hindrance to effective
drug delivery similarly to the BBB.
2. Methods for drug delivery in the brain
In order to overcome these limitations, it is necessary to either bypass
these vascular barriers altogether, or to facilitate passage across it via
controlled exploitation of endogenous transport mechanisms. Different
methods have been explored to bypass the BBB (or the BTB) (Table 1)
[11–13]. While these methods are promising, they also have limitations.
2.1. Invasive approaches to brain drug delivery
High local drug concentrations can be achieved by inserting a needle
or catheter into the brain and directly injecting or infusing drugs or by
implanting drug-exuding devices. With such techniques, therapeutic
beneﬁts have been shown for brain tumors and other disorders
[14–17]. However, because of their invasiveness, there are some risks
of infection or brain trauma, and theymay not be amenable for repeated
treatments or for drug delivery to large areas of the brain. It can also be a
challenge to control the drug distribution, as drug concentrations
decrease exponentially from the injection or implantation site [18].
When convection-enhanced diffusion is used, the infused agents are
delivered preferentially along white matter tracts [19], which may not
be desirable.
Another approach for bypassing the BBB is to introduce drugs into
the cerebrospinal ﬂuid (CSF) via intrathecal or intraventricular routes.
It then follows the ﬂow patterns of the CSF and enters the brain paren-
chyma via diffusion. This approach has been successful in cases where
the target is in the subarachnoid space [20], but drug diffusion drops
off exponentially from the brain surface and penetration into the brain
parenchyma can be limited [11]. It is also possible to deliver drugs
transnasally from the submucus space into the olfactory CSF [21–24].
This approach has advantages of being noninvasive and being relatively
easy to administer. However, only small drug volumes can be delivered
and interindividual variability and other factors may pose challenges to
this procedure [24]. Nevertheless, the technique is a promising route to
bypass the BBB and is currently being investigated by numerous
researchers.
2.2. Transvascular brain drug therapy: Biopharmaceutical approaches
Anumber of approaches have been investigated to develop ormodify
drugs that can cross the BBB. While these methods are highly promising
and offer the ability to easily administer drugs to the CNS as in other
organs, they do require the expense and time of developing new agents,
and they result in drugs being delivered to the entire brain, which may
not always be desirable.
Converting water-soluble molecules that would not ordinarily cross
the BBB into lipid-soluble ones is one approach to brain drug therapy.
This can be achieved by the addition of lipid groups, or functional groups
such as acetate to block hydrogen bonding. The molecule would then
undergo passive diffusion across the BBB. An example of this is the con-
version of morphine to heroine by the acetylation of two hydroxyl
groups, which results in the removal of the molecule from hydrogen
bonding with its aqueous environment [25]. Although utilized by the
pharmaceutical industry, this approach has limited applicability to
drugs greater than 400–450 Da [12,26].
Another approach involves utilizing the large variety of solute carrier
proteins (SLC) on the endothelial surface that speciﬁcally transport
many essential polar and charged nutrients such as glucose, amino
acids, vitamins, small peptides, and hormones transcellularly across
the BBB [27]. These transporters move the solute into the cytoplasm
where they await another SLC at the opposite cell membrane to exocy-
tose them into the brain parenchyma. An example of SLC used for brain
drug therapy is the large neutral amino acid transporter type 1 (LAT1),
Table 1
Different methods investigated to get around the BBB to deliver drugs to the brain.
Method Advantages Disadvantages
Direct injection, convection-enhanced
delivery, implantable devices
High local drug concentrations can be achieved; systemic
administration avoided.
Invasive; side effects; challenging to control; not readily
repeatable.
Intrathecal, intraventricular injection Effectively delivers drugs to subarachnoid space, brain surface. Little drug penetration beyond brain surface; invasive.
Trans-nasal delivery Noninvasive; easy to administer; repeatable. Small volume of drug delivered; interindividual variability.
BBB disruption via arterial injection of
osmotic solution or other agents
Effectively delivers drugs to large brain regions; large clinical
experience.
Invasive; requires general anesthesia; side effects; not readily
repeatable.
Modiﬁcation of drugs to cross barrier
through endogenous transport
mechanisms
Easily administered; delivered to whole brain. Requires systemic administration; expensive; each drug requires
new development; clinical data lacking.
BBB disruption via FUS and
microbubbles
Noninvasive; readily repeatable; can target drug delivery to desired
volumes; can control “magnitude” of disruption; can be combined with
drug-loadedmicrobubbles ormagnetic particles for additional targeting.
Requires systemic administration; currently technically
challenging; large volume/whole brain disruption unproven; no
clinical data.
2 M. Aryal et al. / Advanced Drug Delivery Reviews xxx (2014) xxx–xxx
Please cite this article as: M. Aryal, et al., Ultrasound-mediated blood–brain barrier disruption for targeted drug delivery in the central nervous
system, Adv. Drug Deliv. Rev. (2014), http://dx.doi.org/10.1016/j.addr.2014.01.008
which transports the amino acid Parkinson's drug L-dopa across the
BBB. Once across, it is converted to dopamine by aromatic amino acid
decarboxylase, and can then bind to its target receptor. Dopamine
being water-soluble cannot cross the BBB [26,28].
Finally, the molecular targeting of endothelial-surface receptors,
colloquially termed the “TrojanHorse” approach, is yet another paradigm
in drug transport across the BBB. This involves using a targeting ligand
such as a serum protein, monoclonal antibody, or other high afﬁnity
targeting molecule that binds to its receptor and activates endocytosis
of the complex into a vesicle that is transported across to, and released
from the opposite pole (i.e., transcytosis). In theory, if the ligand is chem-
ically linked to a drug or drug carrier, it too is transported across the BBB.
Over the last twodecades, a number of animal studies have suggested the
transport of antineoplastic drugs, fusion proteins, genetic therapies (plas-
mid vectors, siRNA), liposomes, and nanoparticles by this mechanism
[29–32]. For transcytosis to occur, it requires that the endosome not
fuse with lysosomes while in the cytoplasm, which would degrade the
internalized macromolecules. Unlike other tissues, endothelial cells in
brain capillaries appear to have low levels of endosome fusion with
lysosomes, facilitating transport of necessary substances through the
transcellular route [33–35].
2.3. Transvascular brain drug therapy: BBB disruption
Others have investigatedmethods to temporarily disrupt the BBB to
enable CNS delivery of circulating agents. One such technique investi-
gated intensively for several decades is the intraarterial injection of
hyperosmotic solutions such asmannitol. This procedure causes shrink-
age of endothelial cells and consequent stretching of tight junctions
[36–39] through which drugs may pass. This method has been shown
repeatedly to enhance delivery of therapeutic agents to brain tumors,
and several promising clinical trials have been performed [40–45].
Other agents such as bradykinin have also been investigated [46–49].
While such methods can be an effective means to deliver drugs to
large brain regions, they are invasive procedures that require general
anesthesia, and can have side effects. For example, one study reported
focal seizures in 5% of patients who received osmotic BBB disruption
[40], and others have noted vasovagal response with bradycardia and
hypotension [39]. Having a less-invasive way to achieve this disruption
would be desirable.
The use of ultrasound,when combinedwith circulatingmicrobubbles,
offers a potential way to disrupt the BBB in a targeted, noninvasive, and
repeatable manner to deliver a wide range of drugs to the brain and to
brain tumors. Below, we review the literature on this technique,
(i) describing how it is performed, (ii) how different parameters effect
the BBB disruption, (iii) what has been delivered in preclinical studies,
and (iv) methods that can be used to guide the procedure. While to
date the technique has only been performed in animals, it is clear that
it holds great promise for the treatment of a wide range of CNS disor-
ders. If successfully translated to the clinic, it offers a means to target
drugs, biomolecular therapies, and perhaps cellular therapies to desired
brain regions while sparing the rest of the brain from unnecessary
uptake. The technique also offers the potential to control the “magni-
tude” of BBB disruption at each focal target through modiﬁcation
of the ultrasound parameters, enabling a level of control over drug
delivery that is not available with other technologies. This ﬂexibility,
along with its noninvasiveness, lack of need for general anesthesia,
and amenability to be readily repeatedmake FUS a potentially transfor-
mative technology.
3. Focused ultrasound
An ultrasound ﬁeld can be noninvasively focused deep into the body
and used to induce a broad range of bioeffects through thermal or
mechanical mechanisms. FUS has been investigated since the 1940's
for noninvasive ablation in thebrain, as a potential alternative to surgical
resection and radiosurgery [50–53]. Until recently, clinical testing
required a craniotomy to allow for ultrasound propagation into the
brain [54,55] because of ultrasonic heating of the skull, and beam aberra-
tion caused by the skull's irregular shape and large acoustic impedance.
In the past decade, FUS thermal ablation systems have been devel-
oped that overcome these obstacles produced by the skull [56]. They
reduce skull heating through active cooling of the scalp and a transducer
design with a large aperture to distribute the ultrasound energy over a
large skull region, and they correct for beam aberrations using a phased
array transducer design.When combinedwithmethods that use acoustic
simulation based on CT scans of the skull bone to determine the phase
and amplitude corrections for the phased array [57,58] andMR temper-
ature imaging (MRTI) to monitor the heating [59], a completely nonin-
vasive alternative to surgical resection in the brain becomes possible.
These systems use very high intensities to enable thermal ablation
through the human skull, and are currently in initial human trials
[60–63].
The effects of FUS can be enhanced by combining the ultrasound
exposures (“sonications”) with preformed microbubbles that are com-
mercially available as ultrasound imaging contrast agents. They consist
of semi-rigid lipid or albumin shells that encapsulate a gas (typically
a perﬂuorocarbon), range in size from about 1–10 μm, and are
constrained to the vasculature. The microbubbles concentrate the
ultrasound effects to the microvasculature, greatly reducing the FUS
exposure levels needed to produce bioeffects. Thus, with microbubbles
one can apply FUS transcranially without signiﬁcant skull heating.
When microbubbles interact with an ultrasound ﬁeld, a range of
biological effects have been observed [64]. Depending on their size,
the bubbles can oscillate within the ultrasound ﬁeld, and they can
grow in size via rectiﬁed diffusion. They can interact with the vessel
wall through oscillatory and radiation forces [65,66]. They also can
exert indirect shear forces induced by micro-streaming in the ﬂuid
that surrounds them [67]. At higher acoustic pressures, they can
collapse during the positive pressure cycle, a phenomenon known as
inertial cavitation, producing shock waves and high-velocity jets [65],
free radicals [68], and high local temperatures [69,70]. Themicrobubbles
used in ultrasound contrast agents can presumably exhibit these behav-
iors, either with their shells intact or after being broken apart by the
ultrasound beam and their gas contents released.
4. Ultrasound-induced BBB disruption
Since the early years of investigation into ultrasound bioeffects on
the brain, several studies have noted localized BBB disruption, either
accompanied with tissue necrosis or without evident tissue damage
[52,71–76]. None of these early studies however, elucidated sonication
parameters that could repeatedly and reliably produce BBB disruption
without occasionally producing lesions or necrosis.
In 2000 our laboratory found that if short ultrasound bursts are pre-
ceded by an intravenous injection of microbubble contrast agent, the
BBB can be consistently opened without the production of lesions or
apparent neuronal damage [77]. The circulating microbubbles appear
to concentrate the ultrasound effects to the blood vessel walls, causing
BBB disruption through widening of tight junctions and activation of
transcellular mechanisms, with little effect on the surrounding paren-
chyma [78]. Furthermore, the opening occurs at acoustic power level
orders of magnitude lower than was previously used, making this
method substantially easier to apply through the intact skull. For BBB
disruption, the sonications have been typically applied as short (~1–
20 ms) bursts applied at a low duty cycle (1–5%) for 0.5–1 min. With
a few simple modiﬁcations to enable low-intensity bursts, existing
clinical brain FUS systems can be used for BBB disruption [79]. Clinical
translation may also be possible using simpler FUS systems [80].
Fig. 1 shows examples of targeted BBB disruption in amacaque from
our institution using a clinical transcranial MRI-guided FUS system
(ExAblate, InSightec, Haifa, Israel) [79]. The device uses a hemispherical
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1024-element phased array operating at 220 kHz, and is integrated
with a 3T MRI scanner. The focal region can be electronically steered
to different locations using this array without physically moving the
transducer. Volumes can be targeted by systematically steering the
focal point to different targets, enabling one to deliver drugs to desired
brain regions. Fig. 2 shows an example of such “volumetric” FUS-
induced BBB disruption. BBB disruption was evaluated using two MRI
contrast agents and with the vital dye trypan blue. Note the lack of con-
trast enhancement in white matter despite evident staining with the
dye. This difference is presumably due to the lower vascular density in
white matter compared to gray matter.
4.1. Effect of ultrasound parameters and other factors on BBB disruption
A number of sonication parameters can be varied in ultrasonic BBB
disruption. Each parameter variationmay impact the threshold pressure
amplitude needed to disrupt the BBB, the magnitude of its disruption,
and the resultant drug quantity delivered to the brain parenchyma. As
determined from a number of studies, parameter variations and their
effects are listed in Table 2. These studies used an MRI contrast agent,
ﬂuorescent probe, or drug to evaluate the BBB disruption. Given the
large parameter space, and different techniques and criteria used to
evaluate the disruption (each with different sensitivities), it can be
challenging to compare results from different laboratories. Such com-
parisons are additionally confounded by uncertain accuracies in esti-
mates of acoustic pressure amplitude when sonicating through the
skull [81]. However, general trends can be observed.
For a ﬁxed set of parameters, as one increases the pressure ampli-
tude, the magnitude of the BBB disruption increases, and at some level
it appears to saturate [82–84]. Below some value, no disruption is
detected, and at some higher pressure threshold, vascular damage is
produced along with the disruption (see below). Such studies repeated
while varying a different parameter have shown that the threshold for
BBB disruption depends strongly on the ultrasound frequency [85] and
burst length [86]. Most experiments have been done with commercially-
available ultrasound contrast agents that consist of microbubbles with
a wide range of diameters. Experiments with microbubbles with
narrow size distributions suggest that the BBB disruption threshold
can also be reduced by using larger microbubbles [87–89].
By ﬁxing the pressure amplitude and varying each parameter, one
can evaluate their effects on the magnitude of the disruption. The mag-
nitude has been found to increasewith the burst length up to a duration
of approximately 10 ms, with further increases in burst length having
little or no effect [77,81,86,90,90–92]. Several groups have shown that
the disruption magnitude may be increased by using a larger dose of
ultrasound contrast agent [83,93–95] (although other works have
shown little or no effect [86,90]) or by using larger microbubbles
[87–89]. Pulse repetition frequency can also inﬂuence the magnitude
of disruption up to a point [90,91], but other studies have seen no
dependence [86]. Finally, the magnitude of the disruption can be
increased by increasing the sonication duration [84] or by repeating the
sonication after some delay [96,97], but excessive durations may result
in tissue damage [84,97]. Factors such as using an infusion instead of a
bolus injection of microbubbles [98] and choice of anesthesia protocol
[99] may also inﬂuence the resulting disruption. Other factors such as
the delay between the microbubble injection and the start of sonication,
andwhether the drug or tracer is administered before or after the sonica-
tion may also be expected to have an effect. Additive effects have been
observed when FUS-induced BBB disruption is combined with agents
that affect vascular permeability [100–102].
These trends observed in parametric studies are difﬁcult to interpret
with conﬁdence since the exact mechanism by which microbubble-
enhanced FUS induces BBB disruption is currently unknown (see
below). They are perhaps consistent with the following notions. First,
for BBB disruption to occur, the microbubbles oscillations may need to
reach a certain minimal radius, which can be achieved by increasing
the pressure amplitude or by using larger microbubbles, and assuming
the bubbles grow during each burst via rectiﬁed diffusion, by decreasing
the ultrasound frequency or increasing the burst length. Next, in addi-
tion to depending on the bubble size during its oscillation, the magni-
tude of the disruption depends on the number of sites on which the
microbubbles interact with the vasculature. The number of these sites
can be increased by increasing the microbubble dose, or by increasing
the sonication duration and/or number of bursts. Data showing a strong
dependence on burst length may also suggest that the threshold and
magnitude of the disruption depend on the amount of time the
microbubbles interact with the blood vessels during each burst. Pulse
repetition frequency may have an inﬂuence if the microbubbles are
being fragmented or destroyed — time may be needed to replenish
them if that is the case [103]. Finally, it appears that the magnitude of
the disruption can saturate at some level, and increasing the different
parameters has no additional effect.
4.2. Optimal parameters?
Overall, these studies have made it clear that BBB disruption is
possible over a wide range of exposure parameters. Disruption has
been demonstrated at frequencies between 28 kHz [104] and 8 MHz
[92], burst lengths as low as a few ultrasound cycles [90,91,98] up
to 100 ms [77], and over a range of pulse repetition frequencies,
Fig. 1. Contrast-enhanced T1-weighted MRI of the brain of a rhesus macaque showing enhancement at four focal targets in the cingulate cortex after injection of Gd-DTPA. (Left image:
Axial; middle: Sagittal; right: Coronal). Enhancement of this MRI contrast agent, which normally does not extravasate into the brain, indicates areas with BBB disruption. Four targets
were sonicated using a 220 kHz clinical MRI-guided FUS system along with an infusion of Deﬁnity microbubbles. The dimensions of the disrupted spots were approximately 3 mm
wide and4 mm long. Note the leakage of contrast agent into the cingulate sulcus evident in the sagittal image (arrow). These imageswere obtained in a study evaluating passive cavitation
mapping during microbubble-enhanced FUS [176] (bar: 1 cm).
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microbubble doses, and sonication times. It is not clear what the “opti-
mal” parameters are, or what criteria to use to establish them. In our
view, the primary consideration could be to ﬁnd parameters that
maximize the window in acoustic pressure amplitude where robust
BBB disruption is possible without producing vascular damage. It will
be challenging to precisely estimate the pressure amplitude in the
human brain after transcranial sonication, and having the widest safety
margin possible will be desirable for clinical translation. How close the
FUS frequency is to the “resonant size” of the microbubbles may have
an impact on the width of this safety window. Additional important
criteria would be to optimize the frequency and transducer geometry
to produce the desired focal spot size, to effectively focus through the
skull with minimal distortion, and if a phased array transducer is used,
to be able to steer the focal region throughout the brain. It may also be
desirable to ﬁnd parameters that enable BBB disruption in the shortest
possible sonication time so that multiple targets can be targeted in a
reasonable amount of time, and tomaintain a safe dose ofmicrobubbles.
4.3. Potential mechanisms
Even though FUS exposures combinedwithmicrobubbles have been
investigated to disrupt the BBB in numerous studies, the exact mecha-
nism to open BBB still remains unknown. It does appear that two
known effects that can be induced by FUS, bulk heating and inertial
cavitation, are not responsible. Initial studies on the method utilized
MRI-based temperature imaging [77] during the sonications, and no
measureable heating was observed. Studies that recorded the acoustic
emissions during the sonications [105–107] have found that BBB
disruption can be achieved without wideband acoustic emission,
which is a signature for inertial cavitation [53]. It also may not be the
same mechanism utilized for so-called “sonoporation”, where transient
pores in cell membranes created by sonication with microbubbles
enable drugs to enter [108]. Those pores are rapidly resolved, while
FUS-induced BBB disruption lasts for several hours.
Fundamentally, we do not know if the FUS/microbubble interactions
physically modify the vessel walls, or if they are triggering a physiolog-
ical response that includes temporary BBB breakdown. As described
below, electron microscopy studies have shown delivery of tracers
through widened tight junctions [78,109], which could be consistent
with a direct physical force pulling themapart, aswell as active transport
[78,110]. Other work has shown the sonications can induce vascular
spasm [111,112]. While the role of this spasm is not clear, it does make
clear that the sonications can trigger a physiological response.
In the absence of bulk heating and inertial cavitation,we are leftwith
mechanical effects induced during the microbubble oscillations in the
ultrasound ﬁeld. A number of effects are produced with potential to
induce the observed BBB disruption. Microbubbles tend to move in
the direction of the wave propagation via acoustic radiation force [66],
which will bring them in contact with vessel endothelium. During
oscillation, the shell of the microbubble can break, the bubbles can be
fragmented into smaller bubbles, and they can grow via rectiﬁed
diffusion. Microstreaming due to microbubble oscillations can induce
biologically-signiﬁcant shear stresses on the neighboring endothelium,
and the oscillations produce inward forces that in extreme cases can
Fig. 2. Demonstration of FUS-induced BBB disruption using contrast enhanced MRI and
trypan blue. (A–C) Contrast-enhanced T1-weighted MRI after BBB disruption at six
volumes in the cingulate cortex. At each volume, the focal regionwas steered electronically
in sequence to nine targets in a 3 × 3 grid using a phased array. (A) Low-level enhance-
ment observed with gadofosveset trisodium, an MR contrast agent that binds to albumin
in the blood (MW of albumin: ~67 kDa); it was administered before sonication.
(B) Enhancement after injection of Gd-DTPA (MW: 938 Da). The inset in (B) shows the
same view in T2-weighted imaging. The enhancement patterns correspond to regions of
cortical gray matter visible in T2-weighted imaging. (C) Sagittal view of Gd-DTPA
enhancement, which included leakage of agent into a sulcus (arrow). (D–E) Volumetric
BBB disruption at three targets centered on the boundary between the cingulate cortex
and white matter; from another experimental session in this animal. (D) T1-weighted
MRI showing Gd-DTPA extravasation in the cingulate cortex, but not in the white matter.
(E) Photograph of formalin-ﬁxed brain showing trypan blue extravasation into both the
cingulate cortex and white matter. This differential enhancement between gray and
white matter presumably reﬂects differences in vascular density. The white matter com-
ponent of two of these targets is shownwith increased image contrast in the inset to better
visualize low-level trypan blue extravasation. (Scale bars: 1 cm). Reprinted from Cancer
Research 2012; 72:3652–3663; © 2012 American Association for Cancer Research. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the
web version of this article.)
Table 2
Reported effects of different parameters on BBB disruption via FUS and microbubbles.
Parameter Effect on BBB disruption
Pressure amplitude Increase in BBB disruption magnitude as pressure amplitude increases; saturation at some point [82–84]; vascular damage produced at high
pressure amplitudes.
Ultrasound frequency Decrease in BBB disruption threshold as frequency decreases; some evidence of improved safety for lower frequencies [85].
Burst length For burst lengths less than 10 ms, BBB disruption threshold increases and BBB disruption magnitude decreases as burst length is reduced
[86,90–92]; little or no increase in disruption magnitude for longer bursts [77,81,90].
Pulse repetition frequency BBB disruptionmagnitude increases as repetition frequency increases up to a point [90]. Otherworks have observed no effect onBBB disruption
magnitude [86].
Ultrasound contrast agent dose Magnitude of BBB disruption increases with dose [83,90,94,188]; other experiments have reported no effect [86].
Sonication duration Longer durations [84] or repeated sonication [96,97] increasemagnitude of BBB disruption; damage reportedwith excessive sonication [84,97].
Microbubble diameter Threshold for BBB disruption lower for larger microbubbles; disruption magnitude increased with larger microbubbles [87–89].
Ultrasound contrast agent Similar outcomes reported forOptison® andDeﬁnity®microbubbles [189]. Sonovue®microbubbles and research agents are also commonly used.
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pull the vessel wall inward [113]. Clearly, the behavior of a microbubble
in an acoustic ﬁeld is complex, and it can be different in free ﬂuid than
when constrained within a capillary [114].
4.4. Bioeffects induced by FUS and microbubbles
The BBB disruption can occur almost immediately with sonication
[112] and appears to decay exponentially over several hours thereafter
[77,82,96,115]. The amount of agent delivered across the barrier
appears to bemuch larger in graymatter than in whitematter, presum-
ably due to differences in vascular density [79]. Several studies have
found that the barrier appears to be largely restored in approximately
4–6 h [77,82,96,109,115,116]; other experiments have observed low-
level disruption at 24 h after sonication or longer [89]. The source of
this discrepancy is not clear, but it could be simply that more sensitive
detection methods such as high-ﬁeld MRI combined with large doses
of MRI contrast agent are capable of detecting low-level disruption
missed in other works. The duration of the opening to different tracers
appears to be reduced for larger tracers [115].
This window in timewhere the barrier is open is thought to be good
for the prospect of delivering even long-circulating drugs, but not so
long as to produce concern of toxicity arising from chronic BBB break-
down. Indeed, the appearance of the brain after BBB disruption in light
microscopy appears to be normal [117], even after repeated weekly
sessions [79]. Example histology obtained after BBB disruption is
shown in Fig. 3. The only major feature that has been observed in
many studies is the presence of tiny clusters of extravasated red blood
cells (petechiae) [118,119]. It is thought that these petechiae are formed
during inertial cavitation, andexperimentswherenowidebandemissions
(a signature for inertial cavitation)were observed, no such extravasations
were observed [105]. Some have suggested that wideband emissions
can be observed without producing such petechiae [106]. While the
presence of these petechiae is undesirable, their impact on the brain
may be minimal. Investigations looking for apoptosis or ischemia,
which may be expected if serious vascular damage were occurring,
failed to observe anythingmore thana few individual damagedneurons,
and long-term effects have not found evidence of neuronal damagewith
such sonications [118,120]. At excessive exposure levels, more severe
vascular damage, parenchymal damage, and neuronal loss can occur
[77,121].
Transmission electron microscopy (TEM) investigations have
demonstrated an increase of cytoplasmic vesicles in endothelium and
pericytes (suggestive of transcytosis), formation of trans-endothelial
fenestrae, widened tight junctions, and transport of serum components
across the BBB [78]. The use of a 44 kDa tracer molecule helped eluci-
date arterioles as the major sight of trans-endothelial vesicle transport
(followed by capillaries then venules), and showed extensive tracer
deposition in the endothelial paracellular space, basement membrane,
and surrounding brain parenchyma [110]. Finally, using immunogold
labeling, the disappearance of tight junction (TJ) proteins occludin,
claudin-5, and ZO-1 were shown, along with opened endothelial junc-
tions and tracer leakage at 1–4 h post-sonication [109]. The TJ proteins
reappeared at 6 and 24 h. Examples showing tracer penetration across
the BBB through widened tight junctions and vesicular transport are
shown in Fig. 4. Other work has shown down-regulation of the same
TJ proteins along with their mRNA, and recovery to normal levels at
12 h post-sonication [122]. Reorganization of connexin gap junction
proteins have also been reported [123]. An increase of endothelial
vesicles in normal [124] and tumor microvessels [125] have also been
observed on TEM with an up-regulation of caveolin proteins/mRNA,
suggesting that caveolae-mediated transcytosis (CMT) as a contributing
mechanism for permeability. These researchers also found increased
phosphorylation of Src and caveolin-1/2, noting that Src-induced phos-
phorylation of caveolins is a trigger for CMT [126].
Intracellular signaling cascades in response to mechanical stimula-
tion by FUS-induced BBB disruption is likely, but has only recently
been addressed. Increased phosphorylation of Akt and its downstream
molecule GSK3β has been shown in neurons ﬂanking the BBB disrup-
tion at 24 h, well after tight junction reassembly [127]. Akt phosphory-
lation has been implicated in neuroprotection after stroke [128], while
Fig. 3. Normal-appearing histology after FUS-induced BBB disruption. This example was obtained after volumetric sonication to induce BBB disruption in the hippocampus and lateral
geniculate nucleus (LGN) in macaque. This target was sonicated approximately 2 h before the animal was sacriﬁced and in seven prior sessions over several months. (A) Axial contrast-
enhanced T1-weighted MRI showing BBB disruption induced by sonicating nine targets in a 3 × 3 grid. Inset: Low-magniﬁcation microphotograph showing histology in the hippocam-
pus/LGN. (B–C) High-magniﬁcation view showing normal-appearing layers in the LGN. (D–E) High-magniﬁcation views of hippocampus showing the granular cell layer (D) and the pyr-
amid layers (E). (F) Blood vessels in the LGN with a few extravasated red blood cells, presumably from the last sonication session. Only a very small number of such extravasations were
found. (B, F: H&E; C: H&E-Luxol fast blue; D–E: Nissl; scale bars: A: 1 cm, B, D: 1 mm, C, E–F: 200 μm). Reprinted from Cancer Research 2012; 72:3652–3663; © 2012 American Association
for Cancer Research.
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activation of the p38 JNK MAP kinases promotes neuronal apoptosis
[129,130]. Alonso et al. showed increased protein ubiquitination in
neurons not glia post sonication, no increase in heat shock proteins,
and limited neuronal apoptosis at 24 h in areas staining positive for
extravasated albumin [131]. Ca2+ signaling has also been suggested as
being stimulated by FUS-induced BBB disruption. Speciﬁcally, tempo-
rary disruption of the endothelial plasmamembrane (i.e., sonoporation)
can induce immediate transient changes of intracellular Ca2+ concen-
tration in cells with direct contact with microbubbles, and delayed ﬂuc-
tuations in nearby cells [132]. When factoring in ﬂuid shear induced in
an in vitro ﬂow channel (intended tomimic cerebral vessels), themem-
brane disruption and Ca2+ transients were much lower [133].
Multiphoton microscopy (MPM) has provided useful insights into
the bioeffects of FUS-induced BBB disruption. Initial work with this
technique demonstrated arteriolar vasospasm in 14/16 mice lasting up
to 5 min (Fig. 5), and interrupted cerebral blood ﬂow [111]. Although
this could cause ischemic injury, it has been noted that mice have
enhanced vasomotor excitability over other rodents, such as rats [134].
Indeed, a similar study in rats showed vasospasm in only 25% of the
vessels examined [112]. Initial work has also noted two forms of vessel
dye leakage, rapid focal microdisruptions (3–9 s) that were prevalent
at vessel bifurcations and slow disruptions that were observed as a
gradual increase in extravascular signal intensity [111]. Subsequent
work noted three rather than two leakage types: (1) fast, characterized
Fig. 4.BBB permeability for horseradish peroxidase (HRP). (A) Photomicrograph showing part of a cross-sectionedmicrovessel and the surrounding nerve tissue from a nonsonicated area.
No HRP passage to the basement membrane (arrowheads) or the neuropil [NP] can be seen. The lumen [L] appears empty because the tracer was washed out during perfusion ﬁxation.
(B) A portion of a microvessel with adjacent nerve tissue from a sample obtained 1 h after sonication. Passage of HRP (black color) through several interendothelial clefts is indicated by
arrowheads. The tracer has inﬁltrated the basement membrane [B] and the interstitial space (arrows) in the neuropil. (C) A portion of longitudinally sectioned capillary in a sample
obtained 2 h after sonication. The tracer is present in the junctional cleft (arrows), the basement membrane [B] and the interstitial spaces (asterisks) between myelinated axons [Ax].
(D) Full restoration of the tight junctional barrier function 4 h after sonication. Immersion ﬁxation (instead of perfusion ﬁxation) was used in this brain and permits visualization of
the tracer (black) ﬁlling the lumen [L] and being stopped at theﬁrst tight-junction (arrow). No penetration can be seen in the rest of the junctional cleft (arrowheads), nor in the basement
membrane [B] or neuropil [NP]. E: endothelial cell cytoplasm; RBC: red blood cell in the lumen. Scale bars: 200 nm.Modiﬁed fromUltrasound inMed. & Biol., Vol. 34, No. 7, pp. 1093–1104,
2008; Copyright © 2008World Federation for Ultrasound inMedicine & Biology. (E) Electronmicrograph of an arteriole 1 h after sonication at 0.26 MHz. An intense vesicular transport is
demonstrated by the increased number of HRP-positive caveolae (arrows). Signiﬁcantly fewer vesicles were observed in capillaries and venules. L: lumen.
Modiﬁed from Ultrasound in Med. & Biol., Vol. 32, No. 9, pp. 1399–1409, 2006; Copyright © 2006 World Federation for Ultrasound in Medicine & Biology.
Fig. 5. Vascular effects observed in real time during FUS-induced BBB disruption using in vivo multiphoton microscopy. Each frame is a 615 × 615 μm image acquired using a mouse
before, during, and approximately 20 min after sonication. Arterioles and veins (determined by dye transit) are marked ‘a’ and ‘v’ respectively, in the ﬁrst frame. The animal received
0.1 mL (2 mg/mL) 10 kDa, dextran-conjugatedAlexa Fluor 488 intravenously ~5 mins before imaging (green in images). Immediately after theﬁrst framewas taken, a 45-secUSexposure
was initiated and a 0.1 mL bolus (10 mg/mL) of 70 kDa, dextran-conjugated Texas Redwas delivered intravenously (red in images). Almost total occlusion of the large vessel in the center
of the ﬁeld occurred 12 s after the initiation of US (arrow). Beginning at 60 s and by 305 s, leakage in the green channel is apparent in the lower left of the ﬁeld, and around the central
vessel. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Modiﬁed from Journal of Cerebral Blood Flow & Metabolism 2007;27(2):393–403; Copyright © 2006 ISCBFM.
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by rapid increase to peak intensity and rapid decrease, (2) sustained,
described as rapid increase to peak which persisted for up to an hour,
and (3) slow, a gradual increase to peak intensity [112]. The authors
noted that differing vessel calibers have preferences for different leakage
types, and interestingly, that distinct peak negative pressures also show
preference for leakage types. Continuing work suggested correlation
between fast leakage, common with high pressure amplitudes, and
detachment of astrocyte endfeet from the vessel walls [135].
4.5. Delivery of imaging/therapeutic agents and tests in animal disease
models
One advantage of this method for targeted drug delivery in the brain
is that it appears to be “drug neutral” — that is, it appears that many
agents with a wide range of properties can be successfully delivered
across the BBB and/or the BTB. A large number of imaging tracers
(Table 3) and therapeutic agents (Table 4) which normally do not
cross the BBB have been delivered to the brain or to brain tumormodels
with FUS and microbubbles. The amount of substance delivered and
the distance from the blood vessels that it penetrates appears to depend
on its size. This is evident in the examples shown in Fig. 2, where less
delivery of an albumin-bound MRI contrast agent (MW: ~67 kDa) was
evident compared to a standard agent (MW: 928 Da) in a macaque.
This is even more clear in the example shown in Fig. 6, where delivery
of ﬂuorescent dextrans with different molecular weights was examined
after sonication in the mouse hippocampus. For 3000 Da dextrans, a
relatively uniform ﬂuorescence was observed; for the larger 70 kDa trac-
er, itwasmore concentrated near the blood vessels, and a 2000 kDawas
found not to penetrate at all [136]. This result points to a need for close
examination of how the delivery of large agents occurs— it may not be
enough to look for the presence of the agent, but to also investigate
whether it is delivered far enough from the vasculature at a high
enough concentration to reach the desired target at a therapeutic
level. Low-resolution methods such as MRI may not be sufﬁcient for
this purpose. It may be possible, for example, for agents to make it
past the endothelial cells but get trapped at the basement membrane
[137].
4.5.1. Delivery of therapeutics
A large number of therapeutic agents have also been delivered to the
brain and to brain tumor models (Table 4). Many of the studies so far
have investigated the delivery of chemotherapy agents, such as BCNU
[138], doxorubicin [96], methotrexate [139], cytarabine [140], and
temozolomide [141]. Enhanced delivery of chemotherapy packaged in
liposomes [83,142], targeted liposomes [143] and magnetic particles
[144–146], which allow for MRI-based tracking and enhanced delivery
via magnetic targeting, have also been demonstrated (Fig. 7). Other
works have shown Trastuzumab, an antibody-based agent used for
HER2-positive breast cancer [147,148], and boronophenylalanine,
which is used for boron neutron capture therapy, can be delivered to
the brain and to brain tumor models [149,150]. FUS-induced BBB dis-
ruption has also been shown to improve the delivery of natural killer
cells in a brain tumor model [151]. Finally, a number of experiments
have loaded chemotherapy and other agents into the microbubbles
used for the disruption [146,152–155], which offers the possibility of
achieving even higher local payload at the targeted region.
Delivering agents for neurodegenerative diseases, such asAlzheimer's,
Huntington's, and Parkinson's disease, have also been an active area of
research by several groups. A number of therapies for neurodegenera-
tive diseases such as neuroprotective agents [153,156], antibodies
[157,158], plasmidDNA [154], and siRNA [135] have all been successfully
delivered across the BBB using FUS and microbubbles. Other investiga-
tions have shown that circulating neural progenitor cells [159] or viral
vectors for gene therapy [160–162] can be delivered to the sonicated
regions after FUS-induced BBB disruption. An example of delivery of
adeno-associated virus serotype 9 via FUS-induced BBB disruption to
the different cell populations in the mouse brain is shown in Fig. 8.
4.5.2. Disease models
While delivery of these agents is promising, one also needs to dem-
onstrate that the amount of drug delivered – and the drug penetration –
is sufﬁcient to produce a therapeutic response. In some cases it is also
important to demonstrate that the drug reaches the desired target and
is active after it is delivered [156]. Several studies have shown that
FUS enhancement of the BTB can slow tumor growth and/or improve
survival in orthotopic murine models of primary or metastatic brain
tumors [138,141,142,144,145,148,163].While in some cases the response
has beenmodest, several of these studies have seen substantial improve-
ments. Using multiple treatments may be necessary to achieve a pro-
nounced improvement [142]. One factor that has not been investigated
in depth so far is to conﬁrm that drugs can successfully be delivered to
inﬁltrating tumor cells, which are a major feature in glioma and other
primary tumors, and to metastatic “seeds”. Both can be protected by
the normal BBB. The orthotopic models investigated so far do generally
not have large inﬁltrating zones, and the beneﬁt observed in studies so
far may have been primarily due to FUS-enhanced permeability of the
BTB. It may be challenging to get therapeutic levels to distant regions
that are protected by the BBB. Some agents may have neurotoxic effects
on the normal brain that may limit this ability.
Beyond brain tumors, a study by Jordão et al. showed that delivery of
antibodies targeted to amyloid plaques can reduce the plaque burden in
Alzheimer's disease model mice [158]. While the decrease was modest,
with multiple treatment sessions this may be an effective treatment
strategy. In an intriguing follow-up study, the same group recently
Table 3
Example different tracers that have been delivered across the BBB.
Agent Size Use
Lanthanum chloride 139 Da Electron microscopy tracer [109]
99mTc-diethylenetriaminepentaacetic pentaacetate 492 Da SPECT agent [190]
Omniscan® (Gd-DTPA-BMA) 574 Da MRI contrast agent [89]
Magnevist® (Gd-DTPA) 928 Da MRI contrast agent [77]
Trypan blue, Evans blue ~67 kDa Tissue dyes (binds to albumin) [79,191]
Ablavar® (gadofosveset trisodium) ~67 kDa MRI contrast agent (binds to albumin) [79]
Horseradish peroxidase 40 kDa Electron microscopy tracer [78]
Dextran 3–70 kDa Fluorescent tracer [136]
Immunoglobulin G ~150 kDa Endogenous antibodies [157]
pCMV-EGFPa ? Plasmid DNA [192]
MION-47 20 nm MRI contrast agent [120]
Gold nanoparticles 50 nm Carrier for drugs or imaging [193]
Gold nanorods 10 × 40 nm Photoacoustic imaging contrast agent [194]
Dotarem, P846, P792, P904, P03680 1–65 nm MRI contrast agents [115]
a Loaded into a microbubble.
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showed that FUS-induced BBB disruption alone can reduce the size of
the plaques, perhaps through the delivery of endogenous antibodies
[164]. We anticipate that these studies are only the beginning, and
that FUS has a large potential for Alzheimer's disease and other neuro-
degenerative disorders. Issues regarding the feasibility and safety of
disrupting the BBB in large brain regions (or the whole brain— perhaps
repeatedly) may be need further investigation, however.
4.6. Methods to plan, monitor, and evaluate FUS-induced BBB disruption
As described above, FUS-induced BBB disruption utilizes the
mechanical interactions between microbubbles oscillating in the ultra-
sound ﬁeld and the vasculature. These interactions critically depend
on the exposure parameters as well as the vascular density and perhaps
other properties of the vascular bed. The latter, can affect the local
concentration of microbubbles, how they interact with the ultrasound
ﬁeld [114], and, more importantly, how much drug will be delivered
to the brain [79]. Unfortunately, many of these parameters are difﬁcult
to predict and are expected to vary signiﬁcantly across different patients
and diseases. Thus, methods are needed to (i) determine what parame-
ters to use (treatment planning), (ii) reﬁne them during sonication to
ensure BBB disruption without overexposure (treatment monitoring),
and (iii) evaluate the treatment effects (treatment evaluation).
4.6.1. Treatment planning
Inmost cases, experiments evaluating FUS-induced BBBdisruption in
animal models have used a ﬁxed set of acoustic parameters determined
from prior experience and simple, geometrically-focused transducers. In
general, accurate targeting can be achieved with such systems using
stereotactic frames [165] if image-guidance is not available, and fairly
repeatable results can be obtained with sonication through the thin
skull inmice and rats, or in larger animals through a craniotomy.Methods
to avoid standingwaves [81] and that take into account variations in skull
thickness [166] can improve repeatability in small animal studies where
transcranial sonication is used.
Such approaches may be challenging to translate to human subjects,
where the thicker skull is complex (a layer of trabecular bone
surrounded by layers of cortical bone) and can vary substantially
between individuals (3.5–9.5 mm [167]). The skull, which has a sub-
stantially higher acoustic impedance than soft tissue, will reﬂect most
of the ultrasound beam, and the amount transmitted will depend
strongly on the angle between the bone and the face of the transducer
[168]. Its irregular shape can also deﬂect and distort the beam, and
Table 4
Example therapeutic agents that have been delivered across the BBB or BTB.
Therapeutic agent Size Use Delivered to
Temozolomide 194 Da Chemotherapy Glioma model (9L)a [141]
1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)b 214 Da Chemotherapy Glioma model (C6)a [138,152]
Cytarabine 243 Da Chemotherapy Normal brain [140]
Boronophenylalanine 330 Da Agent for boron neutron capture therapy Glioma models (GBM 8401 [149]; 9L [150])
Doxorubicin 540 Da Chemotherapy Normal brain [96]
Methotrexate 545 Da Chemotherapy Normal brain [139]
siRNA ~13 kDa Huntington's disease therapy Normal brain [135]
Glial cell line-derived neurotropic factor (GDNF)b 24 kDa Neuroprotective agent Normal brain [153]
Brain-derived neurotropic factor (BDNF) 27 kDa Neuroprotective agent Normal brainc [156]
Herceptin (trastuzumab) 148 kDa Anti-cancer antibody Normal brain [147]; breast cancer brain met. model (BT474)a [148]
BAM-10 Aβ targeted antibodies ~150 kDa Therapeutic antibody for Alzheimer's disease TgCcrND8 Alzheimer's model micea [158]
BCNU-VEGFb ~150 kDa Antiangiogenic-targeted chemotherapy Glioma model (C6)a [155]
Plasmid DNA (pBDNF-EGFP)b ~3600 kDad Gene therapy Normal brain [154]
Epirubicin in magnetic nanoparticles ~12 nm Magnetic targeted chemotherapy Glioma model (C6)a [144]
Doxorubicin in magnetic nanoparticlesb ~6–10 nm Magnetic targeted chemotherapy Glioma model (C6) [146]
BCNU in magnetic nanoparticles ~10–20 nm Magnetic targeted chemotherapy Glioma model (C6)a [145]
Adeno-associated virus (AAV) ~25 nm Gene therapy vector Normal brain [160–162]
Liposomal doxorubicin (Lipo-DOX) 90 nm Chemotherapy Normal brain [83]; Glioma model (9 L)a [142,163]
Interleukin-4 receptor targeted Lipo-DOX 100–
120 nm
Chemotherapy Glioma model (8401) [143]
Neural progenitor cells 7–10 μm Stem cell Normal brain [159]
Natural killer cells (NK-92) ~10 μm Cell therapy for brain tumor Breast cancer brain met. model (MDA-MB-231-HER2) [151]
a Also showed improved outcomes with FUS-induced BBB disruption.
b Used drug-loaded microbubbles.
c Also showed drug activity after delivery.
d Assumed 660 Da per base pair (bp), 760 bp for BDNF, and 4700 bp for pEGFP-N1.
Fig. 6. Delivery of ﬂuorescent dextrans with different sizes across the BBB in a mouse using FUS and microbubbles (A: 3 kDa; B: 10 kDa; C: 70 kDa; bar: 1 mm). Diffuse ﬂuorescence re-
gions can be observed for all dextrans, whereas spots of high ﬂuorescence are observed only with the 70-kDa dextran.
Modiﬁed from Proc Natl Acad Sci U S A 2011; 108: 16539–16544; © 2011 by The National Academy of Sciences of the USA.
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reﬂections within the skull cavity need to be taken into account. To
correct for beam-aberrations introduced by thick skulls, phased arrays
composed of more than 1000 elements combined with skull aberration
correction algorithms that utilize CT data are employed [57,58]. These
arrays can also be programmed to rapidly steer the beam electronically
tomultiple targets enabling coverage of tissue volumes [79], anddifferent
portions of the array can be disabled to reduce internal reﬂections or
exclude certain structures.
While these approaches that use acoustic simulations and CT scans
are effective in restoring the focusing of the array after transmission
through the skull, clinical experience with them for thermal ablation
have shown that one still needs to correct for small errors (~1–2 mm)
in targeting [60,63]. To achieve this correction, one needs to be able to
visualize the focal region at exposure levels that do not induce damage
or other unwanted effects. Currently, this can be achieved using MRI-
based methods that can visualize low-level (1–2 °C) focal heating
[59,169] or map small tissue displacements of a few microns induced
by radiation force [170].
Ensuring accurate targeting will be most important if one aims to
precisely disrupt the BBB at discrete locations. In addition, since the
strength of the total microbubble activity, as well as magnitude of the
disruption will depend on the vascularity of the targeted tissue (gray
vs. whitematter, for example [79]), it will be important to know exactly
where the target is located. It might also be desirable to avoid direct
sonication on large blood vessels. If one is uncertain about the targeting
of the focal region, it may be challenging to understand whether a poor
or unexpected result is due to an incorrect exposure level or to
mistargeting. Pre-treatment imaging delineating vascularity, perfusion,
or other vascular properties may prove useful for planning the treat-
ment. Itmay also be useful to combine thesemeasurementswithmodels
of the microbubble oscillations within the microvasculature [114,171].
Accurate control of the focal pressure is critical to ensure BBBdisrup-
tion is produced while preventing inertial cavitation. The thick and
complex human skull makes accurate focal pressure estimations
extremely challenging.While the acoustic modelingmethods developed
for aberration correction may provide estimates of the focal pressure
amplitude, it has not been validated to our knowledge. Itmay be possible
to use the MRI-based methods mentioned above that can visualize focal
displacements or heating to ensure a predictable focal pressure ampli-
tude. Marty et al., for example, usedMR acoustic radiation force imaging
to ensure a consistent exposure level between subjects in BBB disruption
experiments in rats [115]. However, one needs to take the underlying
tissue properties (which may be unknown for tumors or other abnor-
malities) into account or test it in proximal normal brain locations.
4.6.2. Treatment monitoring and control
Given the challenges in predicting the focal pressure amplitude
when sonicating transcranially, we anticipate that effective monitoring
of the procedure will be important if this technology is to be translated
to clinical use. Atminimum, suchmonitoring should provide an indication
that the exposure level is sufﬁcient to induce BBB disruption and alert
the user if inertial cavitation is occurring. One could use MRI methods
for this purpose. Contrast-enhanced imaging can be used to visualize
when the disruption occurs, and T2*-weighted or susceptibility-
weighted MRI can be used to detect petechiae produced by inertial
cavitation [77,119]. These methods could be used now for control over
the procedure in initial clinical tests of FUS-induced BBB disruption
with experienced users. However, performing multiple MRI acquisi-
tions would be time-consuming and might require excessive amounts
of both ultrasound and MRI contrast agents. Real-time and, perhaps,
more direct methods are likely necessary for widespread clinical
implementation.
For real-time monitoring and control, a number of studies have
investigated the use of piezoelectric receivers operated in passive
mode (i.e. only listening) to record and analyze the diverging pressure
waves (i.e. acoustic emissions) emitted by oscillating microbubbles
during FUS-induced BBB disruption [105–107,172,173]. The spectral
content and strength of the recorded emissions is sufﬁcient to charac-
terize and subsequently control the microbubble oscillations. Inertial
cavitation is manifested in the frequency domain of the acoustic emis-
sion as a broadband signal [53], and has generally been associated with
the production of vascular damage during BBB disruption [105,107],
although other studies have suggested that it can occur without damage
[106]. Harmonic and/or sub- and ultra-harmonic acoustic emissions in
the absence of broadband signal are indicative of stable volumetric
oscillations, which consistently have been associated with safe BBB dis-
ruption [105–107]. Therefore, depending on the spectral content and
strength of the emissions the output of the device can be increased
until strong harmonic, subharmonic, or ultraharmonic emissions are
observed, and decreased if broadband emissions are detected. O'Reilly
et al. demonstrated a closed-loop controller built around the detection
of ultraharmonic emissions to automatically select an acoustic exposure
that could produce BBB disruption with little or no petechiae [173]. We
have been exploring the strength of the harmonic emissions as a basis
for such a controller, as we have found that we can reliably detect it
before inertial cavitation occurs and that it is correlated with themagni-
tude of the BBB disruption measured via MRI contrast enhancement
[105,107]. An example of this correlation observed during transcranial
BBB disruption in macaques using a clinical brain FUS system is shown
in Fig. 9A.
If one can integrate a large number of receivers into the FUS system,
one can use passive reconstructionmethods [174,175] to create two- or
even three-dimensionalmaps of themicrobubble activity to ensure that
it is occurring at the expected location. Examples from experiments in
Fig. 7. Confocal micrographs of tissue from tumor after FUS-induced BTB permeabilization
followed by magnetic targeting and contralateral brain regions after delivery of magnetic
nanoparticles (MNPs) loaded with epirubicin. Dark structures in the phase micrographs
show MNPs (left); fused ﬂuorescence images (right) indicate the presence of epirubicin
(red) and DAPI-stained nuclei (blue). Arrows indicate the capillaries; epirubicin occurs
in the capillary beds but does not penetrate into the brain parenchyma. (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the web version of
this article.)
Modiﬁed from Proc Natl Acad Sci U S A 2010; 107: 15205–15210; © 2011 by The National
Academy of Sciences of the USA.
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our laboratory in macaques using a linear receiver array integrated into
a clinical brain FUS system are shown in Fig. 9B–C. In these experiments,
we found that the cavitation activity in the passive acoustic maps (red
area in Fig. 9B–C) was co-localized with the resulting BBB disruption
[176].
4.6.3. Treatment evaluation
As described above, contrast-enhanced imaging and T2*- or
susceptibility-weighted imaging can be used to verify that BBB disrup-
tion has occurred and whether signiﬁcant vascular damage has
occurred, respectively. For tumors, it may be necessary to compare the
signal enhancement after contrast injection to measurements obtained
before FUS. Other imaging modalities may also be useful [177]. If the
contrast-enhanced imaging is obtained before the therapeutic agent is
injected, one can conﬁrm that the BBB disruption is only occurring at
the targeted locations before administering the drug, providing another
level of control to ensure that drugs are delivered only to desired
regions.
Post-treatment imaging could be more useful if one could use it to
estimate drug uptake and penetration in the brain. This can be achieved
directly by labeling the drug with a contrast agent for MRI or other
modality [146]. It might also be possible to use a standard contrast
agent as a surrogate measurement. A number of studies have related
signal intensity changes of contrast-enhancedMRI at the end of the son-
ication with tissue drug concentrations [83,147,178]. More quantitative
and repeatable techniques, such as estimating contrast agent concentra-
tions via T1-mapping [115,179] or vascular transfer coefﬁcients via
analysis of dynamic contrast-enhanced MRI (DCE-MRI) [180] have
been used to perform spatial and temporal characterization of BBB per-
meability. DCE-MRI can also predict the resulting payload of drugs to
the brain [96] and in some cases, in tumors [179]. Examples showing
DCE-MRI evaluation of BBB disruption and its subsequent restoration
over time, and its relationship to concentrations of doxorubicin are
shown in Fig. 10. If one understands the relationship between the con-
centrations of the therapeutic and the imaging contrast agent, which
can perhaps be established in animals, one might be able to titrate the
drug administration to achieve a desired level in the brain. However,
this may be challenging in tumors, where the vascular permeability
can change over time [179].
5. Going forward
Based on the extensive preclinical experiencedescribed above, along
with recent studies in non-human primates [79,80] demonstrating that
themethod can be “scaled up”without producing evident tissue damage
or functional deﬁcits even after repeated sessions [79], this method for
targeted drug delivery in the brain is ready in our view for initial safety
tests in humans, where it will hopefully reveal its enormous potential.
Clinical transcranial MRI-guided FUS systems [60,63] and commercially-
available ultrasound contrast agents are available and can be used for
these tests. Given the huge clinical need and the existence of available
approved anticancer agents that are expected to be effective if they
could be adequately delivered, brain tumors may be an appropriate
target for these initial tests.
Given MRI's high cost and complexity, coupled with the need in
many cases to administer therapeutics over multiple sessions, it would
Fig. 8. Gene transfer to neurons, astrocytes, and oligodendrocytes after delivery of adeno-associated virus serotype 9 carrying the green ﬂuorescent protein (GFP) to the mouse brain
via FUS-induced BBB disruption. Immunohistochemistry was used to detect GFP expression in hippocampus for (A) NeuN-positive cells (neurons, white arrows), and striatum for
(B) GFAP-positive cells (astrocytes, white arrows) and (C) Olig2-positive cells (oligodendrocytes, white arrow).
Modiﬁed from Human Gene Therapy 23:1144–1155 (November 2012); © 2012 Mary Ann Liebert, Inc.
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be desirable in the long run to develop systems to provide FUS-induced
BBB outside of theMRI environment. Passive cavitationmonitoring and/
or mapping may be the enabling technology for this translation away
from MRI guidance. One can envision systems that use pre-treatment
MRI and CT (to delineate different tissue structures and skull density,
respectively), along with “frameless” navigation and cavitation moni-
toring to provide routine BBB disruption in an outpatient facility. A
number of technical developments, such as reducing targeting error
during transcranial sonication, ﬁnding methods to easily register the
position of the skull within the FUS device without a stereotactic
frame, and developing methods to better quantify acoustic emissions
measurements obtained through the thicker human skull, are needed
to reach this goal. In our opinion, all of these things are achievable. It
would also be desirable to remove the need to shave the head, which
is currently needed to allow for acoustic coupling. Attenuation should
not prevent this [181].
The potential of this technique to manipulate the amount of drug
delivered to each point in the brain can provide a level of control that
is not readily available with existing technologies. This control can be
achieved by modulating the acoustic parameters to control the “level”
of the disruption, by analyzing the post-sonication contrast enhancement
before injecting the drug and titrating the drug dose, or by repeating
sonication at select areas after some delay to lengthen the time the bar-
rier is disrupted [96]. It might even be possible to tailor the sonication
parameters and BBB disruption to the molecular weight of the thera-
peutic agent. These methods may enable “dose painting” that can give
clinicians new ﬂexibility in how drugs are used in the CNS to maximize
efﬁcacy and minimizing side effects. Further targeting and control can
be achieved by loading drugs into microbubbles [146,152–155] or by
using magnetic targeting after FUS-induced BBB disruption [144–146].
It will also be important to establish the feasibility and safety of
targeting very large volumes. Many promising applications of this tech-
nology (brain tumors, Alzheimer's disease, etc.) will require sonication
over large portions of the brain for greatest effect. This can be achieved
Fig. 9. Comparison of MRI signal enhancement with microbubble acoustic emissions.
(A)MRI signal enhancement afterGd-DTPA injection plotted as a function of theharmonic
emissions signal strength measured with single-element detectors. A clear relationship
between the two measurements was observed with a good ﬁt to an exponential. The
agreement appeared to hold among different animals and in cases where targets with
low-level harmonic emissions were sonicated a second time with either a higher power
level or an increased dose of microbubbles. Reprinted from PLoS ONE 7(9): e45783.
http://dx.doi.org/10.1371/journal.pone.0045783; © 2012 Arvanitis et al. (B–C) Comparison
between MRI signal enhancement and passive cavitation mapping. (B) Map showing the
enhancement relative to a pre-contrast image. (C) Fusion of passive acoustic map with
the T1-weighted MRI from (B). The red region shows the pixels in the cavitation map
within 95% of themaximumvalue. This region overlappedwith the contrast enhancement.
The pixelwith themaximumcavitation activity is notedwith a “+”. The enhancement from
other targets sonicated in the same session is visible. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
Modiﬁed from Phys Med Biol 58.14 (2013): 4749–61; © 2013 Institute of Physics and
Engineering in Medicine.
Fig. 10.UsingDCE-MRI to evaluate FUS-BBB disruption. (A–B)Mean Ktrans valuesmeasured
vs. time from DCE-MRI in regions of interest at sonicated locations and in corresponding
non-sonicated structures in the contralateral hemisphere. The decay of K, which occurred
due to restoration of the BBB, was ﬁt to an exponential decay (solid line; dotted lines:
95% CI). (A) Decay after a single sonication. (B) Time course after two sonications separated
by 120 min. The second sonication increased the amount of time the barrier was disrupted.
Values were signiﬁcantly higher than in control locations in the contralateral hemisphere
(**P b 0.01 and *P b 0.05). (C) DOX concentration achieved at the sonicated locations as
function of Ktrans measured using DCE-MRI 30 min after sonication. The DOX concentration
was measured approximately 16 h later for brain targets in single sonication (SS), single
sonication with hyperintense spots in T2* weighted image (SS (+T2*)), double sonication
with 10 min interval (DS 10 min), and double sonication with 120 min interval (DS
120 min). The solid line shows a linear regression of the data (slope: 28,824 ng/g DOX
per change in Ktrans in min−1; intercept: 377 ng/g DOX; R: 0.7).
Modiﬁed from Journal of Controlled Release 2012;162:134–142; © 2012 Elsevier B.V.
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by systematically focusing the ultrasound beam to a large number of
individual targets. It should be possible to target the hundreds or thou-
sands of focal points needed to achieve such large-scale BBB disruption
in a reasonable amount of time. Given the low duty cycle and minimal
acoustic exposure levels needed to induce the effect, many targets can
be sonicated simultaneously. For example, with the low duty cycle need-
ed to induce BBB disruption (1% or less), we can target 100 targets or
more with electronic beam steering with a phased array in the same
amount of time it currently takes to disrupt one location with the simple
systemweuse for small animal experiments.While again thiswill require
technical improvements and more safety tests, we expect that achieving
controlled, large volume BBB disruption is achievable.
It would be helpful if the physical and/or physiological mechanisms
by which the mechanical effects of FUS and microbubbles induce BBB
disruption were elucidated. Without knowledge of the mechanism,
one can only speculate on how one can optimize the procedure, and
we are left with performing time-consuming parametric studies. Given
the large parameter space in variables that can inﬂuence the magnitude
of the BBB disruption, it is possible that we have not stumbled upon
parameters that can further improve upon the safe window where BBB
disruption is possible. Multidisciplinary approaches are very likely to
prove fruitful and could potentially identify a unique physiologic mecha-
nism, perhapswith interesting implications on the structure and function
of the vasculature in the CNS.
Other tissues have barriers similar to the BBB and could beneﬁt from
similarmicrobubble-enhanced sonications or prove to be simplermodels
to study the aforementioned interactions. There is data demonstrating
that disruption of the blood–retinal [182] and blood–spinal cord [183]
barriers can be disrupted by FUS, and that the glomerular function in
the kidney can be enhanced, presumably through changes in the
“blood–urine barrier” [184]. Also, using pressure amplitudes higher than
are needed for FUS-induced BBB disruption, one can use microbubble-
enhanced sonications for ablation [185], thrombolysis [186], or
radiosensitization [187]. One can potentially combine one of these
microbubble-enhanced therapieswith BBBdisruption to produce a syn-
ergistic effect or to deliver therapeutics in the surrounding tissues.
The clinical need for new approaches to bypass the BBB in order to
increase the number of drugs that can be used effectively in the CNS is
tremendous. In addition to CNS disorders such as brain tumors, stroke,
trauma, and genetic neurodegenerative disorders, opportunities may
exist for awide range of other applications. Examples include painman-
agement, and psychological disorders such as addiction, both of which
may beneﬁt from a technology that permits drug transport to precise
targets in the brain. Existing drugs for these conditions can have severe
side effects that limit their use. With an ever-growing knowledge of
brain function and dysfunction, precise drug targeting in the CNS may
prove to be particularly important. Technical improvements that are
achievable in our view could enable FUS to be used on a wide scale for
routine targeted drug delivery to the CNS.
6. Conclusion
FUS is a unique technology that can induce BBB or BTB perme-
abilization that is targeted, noninvasive and transient. Extensive work
in preclinical studies has demonstrated that it can enable the delivery
of therapeutics that normally do not reach the brain, and enhance
their delivery to brain tumors. The sonications do not appear to have
anydeleterious effects on the brain, and themethod is readily repeatable.
MRI and acoustic methods to plan, monitor, and evaluate the treatment
offer the possibility of having control over where drugs are delivered
and in what concentration. Given the availability of clinical FUS devices
capable of focusing ultrasound through the intact human skull, along
with recent safety studies demonstrating the method can be performed
safely in nonhuman primates, it appears that the method is ready for
initial clinical tests.
References
[1] E.A. Neuwelt, B. Bauer, C. Fahlke, G. Fricker, C. Iadecola, D. Janigro, L. Leybaert, Z.
Molnar, M.E. O'Donnell, J.T. Povlishock, N.R. Saunders, F. Sharp, D. Stanimirovic,
R.J. Watts, L.R. Drewes, Engaging neuroscience to advance translational research
in brain barrier biology, Nat. Rev. Neurosci. 12 (2011) 169–182.
[2] N.J. Abbott, I.A. Romero, Transporting therapeutics across the blood–brain barrier,
Mol. Med. Today 2 (1996) 106–113.
[3] W.M. Pardridge, Molecular biology of the blood–brain barrier, Mol. Biotechnol. 30
(2005) 57–70.
[4] A.F. Eichler, E. Chung, D.P. Kodack, J.S. Loefﬂer, D. Fukumura, R.K. Jain, The biology
of brain metastases—translation to new therapies, Nat. Rev. Clin. Oncol. 8 (2011)
344–356.
[5] G. Minniti, D. Amelio, M. Amichetti, M. Salvati, R. Muni, A. Bozzao, G. Lanzetta, S.
Scarpino, A. Arcella, R.M. Enrici, Patterns of failure and comparison of different
target volume delineations in patients with glioblastoma treated with conformal
radiotherapy plus concomitant and adjuvant temozolomide, Radiother. Oncol. 97
(2010) 377–381.
[6] M.C. Dobelbower, O.L. Burnett Iii, R.A. Nordal, L.B. Nabors, J.M. Markert, M.D. Hyatt,
J.B. Fiveash, Patterns of failure for glioblastoma multiforme following concurrent
radiation and temozolomide, J. Med. Imaging Radiat. Oncol. 55 (2011) 77–81.
[7] M.C. Chamberlain, Radiographic patterns of relapse in glioblastoma, J. Neurooncol.
101 (2011) 319–323.
[8] D. Fukumura, R.K. Jain, Tumor microenvironment abnormalities: causes, conse-
quences, and strategies to normalize, J. Cell. Biochem. 101 (2007) 937–949.
[9] A. Regina, M. Demeule, A. Laplante, J. Jodoin, C. Dagenais, F. Berthelet, A. Moghrabi,
R. Beliveau, Multidrug resistance in brain tumors: roles of the blood–brain barrier,
Cancer Metastasis Rev. 20 (2001) 13–25.
[10] P.R. Lockman, R.K. Mittapalli, K.S. Taskar, V. Rudraraju, B. Gril, K.A. Bohn, C.E. Adkins,
A. Roberts, H.R. Thorsheim, J.A. Gaasch, S. Huang, D. Palmieri, P.S. Steeg, Q.R. Smith,
Heterogeneousblood–tumor barrier permeability determines drug efﬁcacy in exper-
imental brain metastases of breast cancer, Clin. Cancer Res. 16 (2010) 5664–5678.
[11] D.R. Groothuis, The blood–brain and blood–tumor barriers: a review of strategies
for increasing drug delivery, Neuro Oncol. 2 (2000) 45–59.
[12] W.M. Pardridge, Blood–brain barrier delivery, DrugDiscov. Today 12 (2007) 54–61.
[13] J.P. Blumling Iii, G.A. Silva, Targeting the brain: advances in drug delivery, Curr.
Pharm. Biotechnol. 13 (2012) 2417–2426.
[14] T. Tomita, Interstitial chemotherapy for brain tumors: review, J. Neurooncol. 10
(1991) 57–74.
[15] R.H. Bobo, D.W. Laske, A. Akbasak, P.F. Morrison, R.L. Dedrick, E.H. Oldﬁeld,
Convection-enhanced delivery of macromolecules in the brain, Proc. Natl. Acad.
Sci. U. S. A. 91 (1994) 2076–2080.
[16] C. Guerin, A. Olivi, J.D. Weingart, H.C. Lawson, H. Brem, Recent advances in brain
tumor therapy: local intracerebral drug delivery by polymers, Invest. New Drugs
22 (2004) 27–37.
[17] H. Brem, P. Gabikian, Biodegradable polymer implants to treat brain tumors,
J. Control. Release 74 (2001) 63–67.
[18] L.K. Fung, M. Shin, B. Tyler, H. Brem, W.M. Saltzman, Chemotherapeutic drugs
released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in
the rat brain, Pharm. Res. 13 (1996) 671–682.
[19] J. Voges, R. Reszka, A. Gossmann, C. Dittmar, R. Richter, G. Garlip, L. Kracht, H.H.
Coenen, V. Sturm, K. Wienhard, W.D. Heiss, A.H. Jacobs, Imaging-guided convection-
enhanced delivery and gene therapy of glioblastoma, Ann. Neurol. 54 (2003)
479–487.
[20] G. Fleischhack, U. Jaehde, U. Bode, Pharmacokinetics following intraventricular
administration of chemotherapy in patients with neoplastic meningitis, Clin.
Pharmacokinet. 44 (2005) 1–31.
[21] L. Illum, Nasal drug delivery—possibilities, problems and solutions, J. Control.
Release 87 (2003) 187–198.
[22] L. Illum, Nasal drug delivery: new developments and strategies, Drug Discov. Today
7 (2002) 1184–1189.
[23] M.I. Ugwoke, R.U. Agu, N. Verbeke, R. Kinget, Nasal mucoadhesive drug delivery:
background, applications, trends and future perspectives, Adv. Drug Deliv. Rev.
57 (2005) 1640–1665.
[24] A. Pires, A. Fortuna, G. Alves, A. Falcao, Intranasal drug delivery: how, why and
what for? J. Pharm. Pharm. Sci. 12 (2009) 288–311.
[25] W.H. Oldendorf, S. Hyman, L. Braun, S.Z. Oldendorf, Blood–brain barrier: penetration
of morphine, codeine, heroin, and methadone after carotid injection, Science 178
(1972) 984–986.
[26] N.J. Abbott, A.A. Patabendige, D.E. Dolman, S.R. Yusof, D.J. Begley, Structure and
function of the blood–brain barrier, Neurobiol. Dis. 37 (2010) 13–25.
[27] E.Y. Zhang, G.T. Knipp, S. Ekins, P.W. Swaan, Structural biology and function of
solute transporters: implications for identifying and designing substrates, Drug
Metab. Rev. 34 (2002) 709–750.
[28] W.M. Pardridge, Blood–brain barrier drug targeting: the future of brain drug devel-
opment, Mol. Interv. 3 (2003) 90–105(51).
[29] W.M. Pardridge, Drug targeting to the brain, Pharm. Res. 24 (2007) 1733–1744.
[30] P. Blasi, S. Giovagnoli, A. Schoubben, M. Ricci, C. Rossi, Solid lipid nanoparticles for
targeted brain drug delivery, Adv. Drug Deliv. Rev. 59 (2007) 454–477.
[31] J.C. Olivier, Drug transport to brain with targeted nanoparticles, NeuroRx 2 (2005)
108–119.
[32] A. Schnyder, J. Huwyler, Drug transport to brain with targeted liposomes, NeuroRx
2 (2005) 99–107.
[33] R.D. Broadwell, B.J. Balin, M. Salcman, Transcytotic pathway for blood-borne
protein through the blood–brain barrier, Proc. Natl. Acad. Sci. U. S. A. 85 (1988)
632–636.
13M. Aryal et al. / Advanced Drug Delivery Reviews xxx (2014) xxx–xxx
Please cite this article as: M. Aryal, et al., Ultrasound-mediated blood–brain barrier disruption for targeted drug delivery in the central nervous
system, Adv. Drug Deliv. Rev. (2014), http://dx.doi.org/10.1016/j.addr.2014.01.008
[34] I. Mellman, Endocytosis andmolecular sorting, Annu. Rev. Cell Dev. Biol. 12 (1996)
575–625.
[35] S. Mukherjee, R.N. Ghosh, F.R. Maxﬁeld, Endocytosis, Physiol. Rev. 77 (1997)
759–803.
[36] S.I. Rapoport, Effect of concentrated solutions on blood–brain barrier, Am. J.
Physiol. 219 (1970) 270–274.
[37] S.I. Rapoport, Advances in osmotic opening of the blood–brain barrier to enhance
CNS chemotherapy, Expert. Opin. Investig. Drugs 10 (2001) 1809–1818.
[38] R.A. Kroll, E.A. Neuwelt, Outwitting the blood–brain barrier for therapeutic
purposes: osmotic opening and othermeans, Neurosurgery 42 (1998) 1083–1099.
[39] M.A. Bellavance, M. Blanchette, D. Fortin, Recent advances in blood–brain barrier
disruption as a CNS delivery strategy, AAPS J. 10 (2008) 166–177.
[40] N.D. Doolittle, M.E. Miner, W.A. Hall, T. Siegal, E. Jerome, E. Osztie, L.D. McAllister,
J.S. Bubalo, D.F. Kraemer, D. Fortin, R. Nixon, L.L. Muldoon, E.A. Neuwelt, Safety
and efﬁcacy of amulticenter study using intraarterial chemotherapy in conjunction
with osmotic opening of the blood–brain barrier for the treatment of patients with
malignant brain tumors, Cancer 88 (2000) 637–647.
[41] W.A. Hall, N.D. Doolittle, M. Daman, P.K. Bruns, L. Muldoon, D. Fortin, E.A. Neuwelt,
Osmotic blood–brain barrier disruption chemotherapy for diffuse pontine gliomas,
J. Neurooncol. 77 (2006) 279–284.
[42] K. Jahnke,D.F. Kraemer, K.R. Knight, D. Fortin, S. Bell, N.D. Doolittle, L.L.Muldoon, E.A.
Neuwelt, Intraarterial chemotherapy andosmotic blood–brain barrier disruption for
patients with embryonal and germ cell tumors of the central nervous system,
Cancer 112 (2008) 581–588.
[43] L. Angelov, N.D. Doolittle, D.F. Kraemer, T. Siegal, G.H. Barnett, D.M. Peereboom, G.
Stevens, J. McGregor, K. Jahnke, C.A. Lacy, N.A. Hedrick, E. Shalom, S. Ference, S. Bell,
L. Sorenson, R.M. Tyson, M. Haluska, E.A. Neuwelt, Blood–brain barrier disruption
and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS
lymphoma: a multi-institutional experience, J. Clin. Oncol. 27 (2009) 3503–3509.
[44] J.A. Boockvar, A.J. Tsiouris, C.P. Hofstetter, I. Kovanlikaya, S. Fralin, K. Kesavabhotla,
S.M. Seedial, S.C. Pannullo, T.H. Schwartz, P. Stieg, R.D. Zimmerman, J. Knopman,
R.J. Scheff, P. Christos, S. Vallabhajosula, H.A. Riina, Safety and maximum tolerated
dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic
blood–brain barrier disruption for recurrent malignant glioma. Clinical article,
J. Neurosurg. 114 (2011) 624–632.
[45] D.J. Guillaume, N.D. Doolittle, S. Gahramanov, N.A. Hedrick, J.B. Delashaw, E.A.
Neuwelt, Intra-arterial chemotherapy with osmotic blood–brain barrier disruption
for aggressive oligodendroglial tumors: results of a phase I study, Neurosurgery 66
(2010) 48–58.
[46] T. Inamura, T. Nomura, K. Ikezaki, M. Fukui, G. Pollinger, K.L. Black, Intracarotid
histamine infusion increases blood tumour permeability in RG2 glioma, Neurol.
Res. 16 (1994) 125–128.
[47] M. Gutman, R. Laufer, A. Eisenthal, G. Goldman, A. Ravid, M. Inbar, J.M. Klausner,
Increased microvascular permeability induced by prolonged interleukin-2 admin-
istration is attenuated by the oxygen-free-radical scavenger dimethylthiourea,
Cancer Immunol. Immunother. 43 (1996) 240–244.
[48] K.L. Black, C.C. Chio, Increased opening of blood–tumour barrier by leukotriene C4
is dependent on size of molecules, Neurol. Res. 14 (1992) 402–404.
[49] H.E. de Vries, M.C. Blom-Roosemalen, M. van Oosten, A.G. de Boer, T.J. van Berkel,
D.D. Breimer, J. Kuiper, The inﬂuence of cytokines on the integrity of the blood–
brain barrier in vitro, J. Neuroimmunol. 64 (1996) 37–43.
[50] J.G. Lynn, T.J. Putnam, Histology of cerebral lesions produced by focused ultra-
sound, Am. J. Pathol. 20 (1944) 637–652.
[51] W.J. Fry, F.J. Fry, Fundamental neurological research and human neurosurgery
using intense ultrasound, IRE Trans. Med. Electron. ME-7 (1960) 166–181.
[52] H.T. Ballantine, E. Bell, J. Manlapaz, Progress and problems in the neurological
applications of focused ultrasound, J. Neurosurg. 17 (1960) 858–876.
[53] P.P. Lele, Effects of ultrasound on “solid”mammalian tissues and tumors in vivo, in:
M.H. Repacholi, M. Grondolfo, A. Rindi (Eds.), Ultrasound: Medical Applications,
Biological Effects and Hazard Potential, Plenum Pub. Corp, New York, 1987,
pp. 275–306.
[54] R. Meyers, W.J. Fry, F.J. Fry, L.L. Dreyer, D.F. Shultz, R.F. Noyes, Early experiences
with ultrasonic irradiation of the pallidfugal and nigral complexes in hyperkinetic
and hypertonic disorders, J. Neurosurg. 16 (1959) 32–54.
[55] R.F. Heimburger, Ultrasound augmentation of central nervous system tumor therapy,
Indiana Med. 78 (1985) 469–476.
[56] K.Hynynen, N.McDannold,MRI guided andmonitored focused ultrasound thermal
ablation methods: a review of progress, Int. J. Hyperthermia 20 (2004) 725–737.
[57] G.T. Clement, K. Hynynen, A non-invasive method for focusing ultrasound through
the human skull, Phys. Med. Biol. 47 (2002) 1219–1236.
[58] J.F. Aubry, M. Tanter, M. Pernot, J.L. Thomas, M. Fink, Experimental demonstration
of noninvasive transskull adaptive focusing based on prior computed tomography
scans, J. Acoust. Soc. Am. 113 (2003) 84–93.
[59] Y. Ishihara, A. Calderon, H. Watanabe, K. Okamoto, Y. Suzuki, K. Kuroda, A precise
and fast temperature mapping using water proton chemical shift, Magn. Reson.
Med. 34 (1995) 814–823.
[60] N. McDannold, G.T. Clement, P. Black, F. Jolesz, K. Hynynen, Transcranial magnetic
resonance imaging-guided focused ultrasound surgery of brain tumors: initial
ﬁndings in 3 patients, Neurosurgery 66 (2010) 323–332.
[61] N. Lipsman, M.L. Schwartz, Y. Huang, L. Lee, T. Sankar, M. Chapman, K. Hynynen,
A.M. Lozano, MR-guided focused ultrasound thalamotomy for essential tremor: a
proof-of-concept study, Lancet Neurol. 12 (2013) 462–468.
[62] W.J. Elias, D. Huss, T. Voss, J. Loomba, M. Khaled, E. Zadicario, R.C. Frysinger, S.A.
Sperling, S. Wylie, S.J. Monteith, J. Druzgal, B.B. Shah, M. Harrison, M.
Wintermark, A pilot study of focused ultrasound thalamotomy for essential tremor,
N. Engl. J. Med. 369 (2013) 640–648.
[63] E. Martin, D. Jeanmonod, A. Morel, E. Zadicario, B. Werner, High-intensity focused
ultrasound for noninvasive functional neurosurgery, Ann. Neurol. 66 (2009)
858–861.
[64] W.L. Nyborg, P.L. Carson, E.L. Carstensen, F. Dunn, D.L. Miller, M.W. Miller, H.E.
Thompson, M.C. Ziskin, R.E. Apfel, C.C. Church, L.A. Crum, Exposure Criteria for
Medical Diagnostic Ultrasound: II. Criteria Based on All Known Mechanisms (NCRP
Report No. 140), National Council on Radiation Protection and Measurements,
Bethesda, Maryland, 2002.
[65] T.G. Leighton, The Acoustic Bubble, Academic Press Limited, San Diego, CA, 1994.
[66] P. Dayton, A. Klibanov, G. Brandenburger, K. Ferrara, Acoustic radiation force
in vivo: a mechanism to assist targeting of microbubbles, Ultrasound Med. Biol.
25 (1999) 1195–1201.
[67] D.L. Miller, Particle gathering and microstreaming near ultrasonically activated
gas-ﬁlled micropores, J. Acoust. Soc. Am. 84 (1988) 1378–1387.
[68] P.D. Edmonds, K.M. Sancier, Evidence for free radical production by ultrasonic
cavitation in biological media, Ultrasound Med. Biol. 9 (1983) 635–639.
[69] H.G. Flynn, Generation of transient cavities in liquids by microsecond pulses of
ultrasound, J. Acoust. Soc. Am. 72 (1982) 1926–1932.
[70] R.E. Apfel, Acoustic cavitation: a possible consequence of biomedical uses of
ultrasound, Br. J. Cancer Suppl. 45 (1982) 140–146.
[71] L. Bakay, T.F. Hueter, H.T. Ballantine, D. Sosa, Ultrasonically produced changes in
the blood–brain barrier, Arch. Neurol. 76 (1956) 457–467.
[72] N. Vykhodtseva, Effects of high intensity pulsed ultrasound on brain tissues, The
5th International Symposium on Ultrasound in Biol Med. Puschino, Russia, 1981,
pp. 95–97.
[73] J.T. Patrick, M.N. Nolting, S.A. Goss, K.A. Dines, J.L. Clendenon, M.A. Rea, R.F.
Heimburger, Ultrasound and the blood–brain barrier, Adv. Exp. Med. Biol. 267
(1990) 369–381.
[74] N.I. Vykhodtseva, K. Hynynen, C. Damianou, Histologic effects of high intensity
pulsed ultrasound exposure with subharmonic emission in rabbit brain in vivo,
Ultrasound Med. Biol. 21 (1995) 969–979.
[75] A.H. Mesiwala, L. Farrell, H.J. Wenzel, D.L. Silbergeld, L.A. Crum, H.R. Winn, P.D.
Mourad, High-intensity focused ultrasound selectively disrupts the blood–brain
barrier in vivo, Ultrasound Med. Biol. 28 (2002) 389–400.
[76] N. McDannold, N. Vykhodtseva, F.A. Jolesz, K. Hynynen, MRI investigation of the
threshold for thermally induced blood–brain barrier disruption and brain tissue
damage in the rabbit brain, Magn. Reson. Med. 51 (2004) 913–923.
[77] K. Hynynen, N. McDannold, N. Vykhodtseva, F.A. Jolesz, Noninvasive MR
imaging-guided focal opening of the blood–brain barrier in rabbits, Radiology
220 (2001) 640–646.
[78] N. Sheikov, N.McDannold, N. Vykhodtseva, F. Jolesz, K.Hynynen, Cellularmechanisms
of the blood–brain barrier opening induced by ultrasound in presence of
microbubbles, Ultrasound Med. Biol. 30 (2004) 979–989.
[79] N.McDannold, C.D. Arvanitis, N. Vykhodtseva,M.S. Livingstone, Temporarydisruption
of the blood–brain barrier by use of ultrasound andmicrobubbles: safety and efﬁcacy
evaluation in rhesus macaques, Cancer Res. 72 (2012) 3652–3663.
[80] F. Marquet, Y.S. Tung, T. Teichert, V.P. Ferrera, E.E. Konofagou, Noninvasive,
transient and selective blood–brain barrier opening in non-human primates
in vivo, PLoS One 6 (2011) e22598.
[81] M.A. O'Reilly, Y. Huang, K. Hynynen, The impact of standing wave effects on
transcranial focused ultrasound disruption of the blood–brain barrier in a rat
model, Phys. Med. Biol. 55 (2010) 5251–5267.
[82] K. Hynynen, N. McDannold, N.A. Sheikov, F.A. Jolesz, N. Vykhodtseva, Local and
reversible blood–brain barrier disruption by noninvasive focused ultrasound at
frequencies suitable for trans-skull sonications, Neuroimage 24 (2005) 12–20.
[83] L.H. Treat, N. McDannold, Y. Zhang, N. Vykhodtseva, K. Hynynen, Targeted delivery
of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused
ultrasound, Int. J. Cancer 121 (2007) 901–907.
[84] R. Chopra, N. Vykhodtseva, K. Hynynen, Inﬂuence of exposure time and pressure
amplitude on blood–brain-barrier openingusing transcranial ultrasound exposures,
ACS Chem. Neurosci. 1 (2010) 391–398.
[85] N. McDannold, N. Vykhodtseva, K. Hynynen, Blood–brain barrier disruption
induced by focused ultrasound and circulating preformed microbubbles appears to
be characterized by themechanical index, UltrasoundMed. Biol. 34 (2008) 834–840.
[86] N. McDannold, N. Vykhodtseva, K. Hynynen, Effects of acoustic parameters and
ultrasound contrast agent dose on focused-ultrasound induced blood–brain barrier
disruption, Ultrasound Med. Biol. 34 (2008) 930–937.
[87] J.J. Choi, J.A. Feshitan, B. Baseri, S. Wang, Y.S. Tung, M.A. Borden, E.E. Konofagou,
Microbubble-size dependence of focused ultrasound-induced blood–brain barrier
opening in mice in vivo, IEEE Trans. Biomed. Eng. 57 (2010) 145–154.
[88] F. Vlachos, Y.S. Tung, E. Konofagou, Permeability dependence study of the focused
ultrasound-induced blood–brain barrier opening at distinct pressures and
microbubble diameters using DCE-MRI, Magn. Reson. Med. 66 (2011) 821–830.
[89] G. Samiotaki, F. Vlachos, Y.S. Tung, E.E. Konofagou, A quantitative pressure and
microbubble-size dependence studyof focusedultrasound-induced blood–brain bar-
rier opening reversibility in vivo using MRI, Magn. Reson. Med. 67 (2012) 769–777.
[90] J.J. Choi, K. Selert, Z. Gao, G. Samiotaki, B. Baseri, E.E. Konofagou, Noninvasive and
localized blood–brain barrier disruption using focused ultrasound can be achieved
at short pulse lengths and low pulse repetition frequencies, J. Cereb. Blood Flow
Metab. 31 (2011) 725–737.
[91] J.J. Choi, K. Selert, F. Vlachos, A. Wong, E.E. Konofagou, Noninvasive and localized
neuronal delivery using short ultrasonic pulses and microbubbles, Proc. Natl.
Acad. Sci. U. S. A. 108 (2011) 16539–16544.
[92] K.F. Bing, G.P. Howles, Y. Qi, M.L. Palmeri, K.R. Nightingale, Blood–brain barrier
(BBB) disruption using a diagnostic ultrasound scanner and Deﬁnity inmice, Ultra-
sound Med. Biol. 35 (2009) 1298–1308.
14 M. Aryal et al. / Advanced Drug Delivery Reviews xxx (2014) xxx–xxx
Please cite this article as: M. Aryal, et al., Ultrasound-mediated blood–brain barrier disruption for targeted drug delivery in the central nervous
system, Adv. Drug Deliv. Rev. (2014), http://dx.doi.org/10.1016/j.addr.2014.01.008
[93] F.Y. Yang, W.M. Fu, R.S. Yang, H.C. Liou, K.H. Kang, W.L. Lin, Quantitative evaluation
of focused ultrasound with a contrast agent on blood–brain barrier disruption,
Ultrasound Med. Biol. 33 (2007) 1421–1427.
[94] J.C. Weng, S.K. Wu, W.L. Lin, W.Y. Tseng, Detecting blood–brain barrier disruption
within minimal hemorrhage following transcranial focused ultrasound: a correla-
tion study with contrast-enhanced MRI, Magn. Reson. Med. 65 (2011) 802–811.
[95] J.C. Weng, S.K. Wu, F.Y. Yang, W.L. Lin, W.Y. Tseng, Pulse sequence and timing of
contrast-enhancedMRI for assessingblood–brain barrier disruption after transcranial
focused ultrasound in the presence of hemorrhage, J. Magn. Reson. Imaging 31
(2010) 1323–1330.
[96] J. Park, Y. Zhang, N. Vykhodtseva, F.A. Jolesz, N.J. McDannold, The kinetics of blood
brain barrier permeability and targeted doxorubicin delivery into brain induced by
focused ultrasound, J. Control. Release 162 (2012) 134–142.
[97] F.Y. Yang, Y.S. Lin, K.H. Kang, T.K. Chao, Reversible blood–brain barrier disruption
by repeated transcranial focused ultrasound allows enhanced extravasation,
J. Control. Release 150 (2011) 111–116.
[98] M.A. O'Reilly, A.C. Waspe, M. Ganguly, K. Hynynen, Focused-ultrasound disruption
of the blood–brain barrier using closely-timed short pulses: inﬂuence of sonication
parameters and injection rate, Ultrasound Med. Biol. 37 (2011) 587–594.
[99] N. McDannold, Y. Zhang, N. Vykhodtseva, Blood–brain barrier disruption and
vascular damage induced by ultrasound bursts combined with microbubbles can
be inﬂuenced by choice of anesthesia protocol, Ultrasound Med. Biol. 37 (2011)
1259–1270.
[100] J.E. Wang, Y.H. Liu, L.B. Liu, C.Y. Xia, Z. Zhang, Y.X. Xue, Effects of combining low
frequency ultrasound irradiation with papaverine on the permeability of the
blood–tumor barrier, J. Neurooncol. 102 (2) (2010) 213–224.
[101] Z. Zhang, C. Xia, Y. Xue, Y. Liu, Synergistic effect of low-frequency ultrasound and
low-dose bradykinin on increasing permeability of the blood–tumor barrier by
opening tight junction, J. Neurosci. Res. 87 (2009) 2282–2289.
[102] Z. Zhang, Y. Xue, Y. Liu, X. Shang, Additive effect of low-frequency ultrasound and
endothelial monocyte-activating polypeptide II on blood–tumor barrier in rats
with brain glioma, Neurosci. Lett. 481 (2010) 21–25.
[103] D.E. Goertz, C. Wright, K. Hynynen, Contrast agent kinetics in the rabbit brain
during exposure to therapeutic ultrasound, Ultrasound Med. Biol. 36 (2010)
916–924.
[104] H.L. Liu, C.H. Pan, C.Y. Ting, M.J. Hsiao, Opening of the blood–brain barrier by low-
frequency (28-kHz) ultrasound: a novel pinhole-assisted mechanical scanning
device, Ultrasound Med. Biol. 36 (2010) 325–335.
[105] N. McDannold, N. Vykhodtseva, K. Hynynen, Targeted disruption of the blood–
brain barrier with focused ultrasound: association with cavitation activity, Phys.
Med. Biol. 51 (2006) 793–807.
[106] Y.S. Tung, F. Vlachos, J.J. Choi, T. Defﬁeux, K. Selert, E.E. Konofagou, In vivo transcranial
cavitation threshold detection during ultrasound-induced blood–brain barrier
opening in mice, Phys. Med. Biol. 55 (2010) 6141–6155.
[107] C.D. Arvanitis, M.S. Livingstone, N. Vykhodtseva, N. McDannold, Controlled
ultrasound-induced blood–brain barrier disruption using passive acoustic emis-
sions monitoring, PLoS One 7 (2012) e45783.
[108] C.X. Deng, F. Sieling, H. Pan, J. Cui, Ultrasound-induced cell membrane porosity,
Ultrasound Med. Biol. 30 (2004) 519–526.
[109] N. Sheikov, N. McDannold, S. Sharma, K. Hynynen, Effect of focused ultrasound
applied with an ultrasound contrast agent on the tight junctional integrity
of the brain microvascular endothelium, Ultrasound Med. Biol. 34 (2008)
1093–1104.
[110] N. Sheikov, N. McDannold, F. Jolesz, Y.Z. Zhang, K. Tam, K. Hynynen, Brain arterioles
showmore active vesicular transport of blood-borne tracermolecules than capillaries
and venules after focused ultrasound-evoked opening of the blood–brain barrier,
Ultrasound Med. Biol. 32 (2006) 1399–1409.
[111] S.B. Raymond, J. Skoch, K. Hynynen, B.J. Bacskai, Multiphoton imaging of ultrasound/
Optison mediated cerebrovascular effects in vivo, J. Cereb. Blood Flow Metab. 27
(2007) 393–403.
[112] E.E. Cho, J. Drazic, M. Ganguly, B. Stefanovic, K. Hynynen, Two-photon ﬂuorescence
microscopy study of cerebrovascular dynamics in ultrasound-induced blood–brain
barrier opening, J. Cereb. Blood Flow Metab. 31 (2011) 1852–1862.
[113] H. Chen,W. Kreider, A.A. Brayman,M.R. Bailey, T.J.Matula, Blood vessel deformations
on microsecond time scales by ultrasonic cavitation, Phys. Rev. Lett. 106 (2011)
034301.
[114] E. Sassaroli, K. Hynynen, Resonance frequency of microbubbles in small blood
vessels: a numerical study, Phys. Med. Biol. 50 (2005) 5293–5305.
[115] B. Marty, B. Larrat, M. Van Landeghem, C. Robic, P. Robert, M. Port, D. Le Bihan, M.
Pernot, M. Tanter, F. Lethimonnier, S. Meriaux, Dynamic study of blood–brain
barrier closure after its disruption using ultrasound: a quantitative analysis, J. Cereb.
Blood Flow Metab. 32 (2012) 1948–1958.
[116] G.P. Howles, K.F. Bing, Y. Qi, S.J. Rosenzweig, K.R. Nightingale, G.A. Johnson,
Contrast-enhanced in vivo magnetic resonance microscopy of the mouse brain
enabled by noninvasive opening of the blood–brain barrier with ultrasound,
Magn. Reson. Med. 64 (2010) 995–1004.
[117] B. Baseri, J.J. Choi, Y.S. Tung, E.E. Konofagou, Multi-modality safety assessment of
blood–brain barrier opening using focused ultrasound and Deﬁnity microbubbles:
a short-term study, Ultrasound Med. Biol. 36 (2010) 1445–1459.
[118] N. McDannold, N. Vykhodtseva, S. Raymond, F.A. Jolesz, K. Hynynen, MRI-guided
targeted blood–brain barrier disruption with focused ultrasound: histological
ﬁndings in rabbits, Ultrasound Med. Biol. 31 (2005) 1527–1537.
[119] H.L. Liu, Y.Y. Wai, W.S. Chen, J.C. Chen, P.H. Hsu, X.Y. Wu, W.C. Huang, T.C. Yen, J.J.
Wang, Hemorrhage detection during focused-ultrasound induced blood–brain-
barrier opening by using susceptibility-weighted magnetic resonance imaging,
Ultrasound Med. Biol. 34 (2008) 598–606.
[120] K. Hynynen, N. McDannold, N. Vykhodtseva, S. Raymond, R. Weissleder, F.A. Jolesz,
N. Sheikov, Focal disruption of the blood–brain barrier due to 260-kHz ultrasound
bursts: a method for molecular imaging and targeted drug delivery, J. Neurosurg.
105 (2006) 445–454.
[121] H.L. Liu, Y.Y. Wai, P.H. Hsu, L.A. Lyu, J.S. Wu, C.R. Shen, J.C. Chen, T.C. Yen, J.J. Wang,
In vivo assessment of macrophage CNS inﬁltration during disruption of the blood–
brain barrier with focused ultrasound: a magnetic resonance imaging study,
J. Cereb. Blood Flow Metab. 30 (2010) 674.
[122] X. Shang, P.Wang, Y. Liu, Z. Zhang, Y. Xue,Mechanismof low-frequency ultrasound in
opening blood–tumor barrier by tight junction, J. Mol. Neurosci. 43 (2011) 364–369.
[123] A. Alonso, E. Reinz, J.W. Jenne, M. Fatar, H. Schmidt-Glenewinkel, M.G. Hennerici, S.
Meairs, Reorganization of gap junctions after focused ultrasound blood–brain
barrier opening in the rat brain, J. Cereb. Blood FlowMetab. 30 (2010) 1394–1402.
[124] J. Deng, Q. Huang, F. Wang, Y. Liu, Z. Wang, Z. Wang, Q. Zhang, B. Lei, Y. Cheng, The
role of caveolin-1 in blood–brain barrier disruption induced by focused ultrasound
combined with microbubbles, J. Mol. Neurosci. 46 (2012) 677–687.
[125] C.Y. Xia, Y.H. Liu, P.Wang, Y.X. Xue, Low-frequency ultrasound irradiation increases
blood–tumor barrier permeability by transcellular pathway in a rat glioma model,
J. Mol. Neurosci. 48 (1) (2012) 281–290.
[126] A.N. Shajahan, C. Tiruppathi, A.V. Smrcka, A.B. Malik, R.D. Minshall, Gbetagamma
activation of Src induces caveolae-mediated endocytosis in endothelial cells,
J. Biol. Chem. 279 (2004) 48055–48062.
[127] S. Jalali, Y. Huang, D.J. Dumont, K. Hynynen, Focused ultrasound-mediated BBB
disruption is associated with an increase in activation of Akt: experimental study
in rats, BMC Neurol. 10 (2010) 114.
[128] H. Zhao, R.M. Sapolsky, G.K. Steinberg, Phosphoinositide-3-kinase/Akt survival
signal pathways are implicated in neuronal survival after stroke, Mol. Neurobiol.
34 (2006) 249–270.
[129] R. Nath, K. McGinnis, S. Dutta, B. Shivers, K.K. Wang, Inhibition of p38 kinase
mimics survival signal-linked protection against apoptosis in rat cerebellar granule
neurons, Cell. Mol. Biol. Lett. 6 (2001) 173–184.
[130] J. Harada,M. Sugimoto, An inhibitor of p38 and JNKMAPkinases prevents activation
of caspase and apoptosis of cultured cerebellar granule neurons, Jpn. J. Pharmacol.
79 (1999) 369–378.
[131] A. Alonso, E. Reinz, M. Fatar, J. Jenne, M.G. Hennerici, S. Meairs, Neurons but not
glial cells overexpress ubiquitin in the rat brain following focused ultrasound-
induced opening of the blood–brain barrier, Neuroscience 169 (2010) 116–124.
[132] J. Park, Z. Fan, R.E. Kumon, M.E. El Sayed, C.X. Deng, Modulation of intracellular
Ca2+ concentration in brain microvascular endothelial cells in vitro by acoustic
cavitation, Ultrasound Med. Biol. 36 (2010) 1176–1187.
[133] J. Park, Z. Fan, C.X. Deng, Effects of shear stress cultivation on cell membrane
disruption and intracellular calcium concentration in sonoporation of endothelial
cells, J. Biomech. 44 (2011) 164–169.
[134] C. Ayata, H.K. Shin, S. Salomone, Y. Ozdemir-Gursoy, D.A. Boas, A.K. Dunn, M.A.
Moskowitz, Pronounced hypoperfusion during spreading depression in mouse
cortex, J. Cereb. Blood Flow Metab. 24 (2004) 1172–1182.
[135] A. Burgess, Y. Huang, W. Querbes, D.W. Sah, K. Hynynen, Focused ultrasound for
targeted delivery of siRNA and efﬁcient knockdown of Htt expression, J. Control.
Release 163 (2012) 125–129.
[136] J.J. Choi, S. Wang, Y.S. Tung, B. Morrison III, E.E. Konofagou, Molecules of various
pharmacologically-relevant sizes can cross the ultrasound-induced blood–brain
barrier opening in vivo, Ultrasound Med. Biol. 36 (2010) 58–67.
[137] L.L. Muldoon, M.A. Pagel, R.A. Kroll, S. Roman-Goldstein, R.S. Jones, E.A. Neuwelt, A
physiological barrier distal to the anatomic blood–brain barrier in a model of
transvascular delivery, AJNR Am. J. Neuroradiol. 20 (1999) 217–222.
[138] H.L. Liu,M.Y. Hua, P.Y. Chen, P.C. Chu, C.H. Pan, H.W. Yang, C.Y. Huang, J.J.Wang, T.C.
Yen, K.C. Wei, Blood–brain barrier disruption with focused ultrasound enhances
delivery of chemotherapeutic drugs for glioblastoma treatment, Radiology 255
(2010) 415–425.
[139] J. Mei, Y. Cheng, Y. Song, Y. Yang, F. Wang, Y. Liu, Z. Wang, Experimental study on
targeted methotrexate delivery to the rabbit brain via magnetic resonance
imaging-guided focused ultrasound, J. Ultrasound Med. 28 (2009) 871–880.
[140] H.Q. Zeng, L. Lu, F. Wang, Y. Luo, S.F. Lou, Focused ultrasound-induced blood–brain
barrier disruption enhances the delivery of cytarabine to the rat brain, J. Chemother.
24 (2012) 358–363.
[141] K.C. Wei, P.C. Chu, H.Y. Wang, C.Y. Huang, P.Y. Chen, H.C. Tsai, Y.J. Lu, P.Y. Lee, I.C.
Tseng, L.Y. Feng, P.W. Hsu, T.C. Yen, H.L. Liu, Focused ultrasound-induced blood–
brain barrier opening to enhance temozolomide delivery for glioblastoma
treatment: a preclinical study, PLoS One 8 (2013) e58995.
[142] M. Aryal, N. Vykhodtseva, Y.Z. Zhang, J. Park, N. McDannold, Multiple treatments
with liposomal doxorubicin and ultrasound-induced disruption of blood–tumor
and blood–brain barriers improve outcomes in a rat glioma model, J. Control.
Release 169 (2013) 103–111.
[143] F.Y. Yang, T.T. Wong, M.C. Teng, R.S. Liu, M. Lu, H.F. Liang, M.C. Wei, Focused ultra-
sound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced
targeted drug delivery and antitumor effect in glioblastoma multiforme, J. Control.
Release 160 (3) (2012) 652–658.
[144] H.L. Liu, M.Y. Hua, H.W. Yang, C.Y. Huang, P.C. Chu, J.S. Wu, I.C. Tseng, J.J. Wang, T.C.
Yen, P.Y. Chen, K.C. Wei, Magnetic resonance monitoring of focused ultrasound/
magnetic nanoparticle targeting delivery of therapeutic agents to the brain, Proc.
Natl. Acad. Sci. U. S. A. 107 (2010) 15205–15210.
[145] P.Y. Chen, H.L. Liu,M.Y. Hua, H.W. Yang, C.Y. Huang, P.C. Chu, L.A. Lyu, I.C. Tseng, L.Y.
Feng, H.C. Tsai, S.M. Chen, Y.J. Lu, J.J. Wang, T.C. Yen, Y.H. Ma, T. Wu, J.P. Chen, J.I.
Chuang, J.W. Shin, C. Hsueh, K.C. Wei, Novel magnetic/ultrasound focusing system
enhances nanoparticle drug delivery for glioma treatment, Neuro Oncol. 12 (2010)
1050–1060.
15M. Aryal et al. / Advanced Drug Delivery Reviews xxx (2014) xxx–xxx
Please cite this article as: M. Aryal, et al., Ultrasound-mediated blood–brain barrier disruption for targeted drug delivery in the central nervous
system, Adv. Drug Deliv. Rev. (2014), http://dx.doi.org/10.1016/j.addr.2014.01.008
[146] C.H. Fan, C.Y. Ting, H.J. Lin, C.H. Wang, H.L. Liu, T.C. Yen, C.K. Yeh, SPIO-
conjugated, doxorubicin-loaded microbubbles for concurrent MRI and focused-
ultrasound enhanced brain-tumor drug delivery, Biomaterials 34 (2013)
3706–3715.
[147] M. Kinoshita, N. McDannold, F.A. Jolesz, K. Hynynen, Noninvasive localized
delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-
induced blood–brain barrier disruption, Proc. Natl. Acad. Sci. U. S. A. 103 (2006)
11719–11723.
[148] E.J. Park, Y.Z. Zhang, N. Vykhodtseva, N. McDannold, Ultrasound-mediated blood–
brain/blood–tumor barrier disruption improves outcomes with trastuzumab in a
breast cancer brain metastasis model, J. Control. Release (2012), http://dx.doi.org/
10.1016/j.jconrel.2012.09.007.
[149] F.Y. Yang, Y.W. Chen, F.I. Chou, S.H. Yen, Y.L. Lin, T.T. Wong, Boron neutron capture
therapy for glioblastomamultiforme: enhanced drug delivery and antitumor effect
following blood–brain barrier disruption induced by focused ultrasound, Future
Oncol. 8 (2012) 1361–1369.
[150] R.D. Alkins, P.M. Brodersen, R.N. Sodhi, K. Hynynen, Enhancing drug delivery for
boron neutron capture therapy of brain tumors with focused ultrasound, Neuro
Oncol. 15 (9) (2013) 1225–1235.
[151] R. Alkins, A. Burgess, M. Ganguly, G. Francia, R. Kerbel, W.S. Wels, K. Hynynen,
Focused ultrasound delivers targeted immune cells to metastatic brain tumors,
Cancer Res. 73 (2013) 1892–1899.
[152] C.Y. Ting, C.H. Fan, H.L. Liu, C.Y. Huang, H.Y. Hsieh, T.C. Yen, K.C. Wei, C.K. Yeh,
Concurrent blood–brain barrier opening and local drug delivery using drug-
carrying microbubbles and focused ultrasound for brain glioma treatment, Bioma-
terials 33 (2012) 704–712.
[153] F. Wang, Y. Shi, L. Lu, L. Liu, Y. Cai, H. Zheng, X. Liu, F. Yan, C. Zou, C. Sun, J. Shi, S. Lu,
Y. Chen, Targeted delivery of GDNF through the blood–brain barrier byMRI-guided
focused ultrasound, PLoS One 7 (2012) e52925.
[154] Q. Huang, J. Deng, F. Wang, S. Chen, Y. Liu, Z. Wang, Z. Wang, Y. Cheng, Targeted
gene delivery to the mouse brain by MRI-guided focused ultrasound-induced
blood–brain barrier disruption, Exp. Neurol. 233 (2012) 350–356.
[155] C.H. Fan, C.Y. Ting, H.L. Liu, C.Y. Huang, H.Y. Hsieh, T.C. Yen, K.C. Wei, C.K. Yeh,
Antiangiogenic-targeting drug-loaded microbubbles combined with focused
ultrasound for glioma treatment, Biomaterials 34 (2013) 2142–2155.
[156] B. Baseri, J.J. Choi, T. Defﬁeux, G. Samiotaki, Y.S. Tung, O. Olumolade, S.A. Small, B.
Morrison, E.E. Konofagou, Activation of signaling pathways following localized
delivery of systemically administered neurotrophic factors across the blood–
brain barrier using focused ultrasound and microbubbles, Phys. Med. Biol. 57
(2012) N65–N81.
[157] S.B. Raymond, L.H. Treat, J.D. Dewey, N. McDannold, K. Hynynen, B.J. Bacskai,
Ultrasound enhanced delivery of molecular imaging and therapeutic agents in
Alzheimer's disease mouse models, PLoS One 3 (2008) e2175.
[158] J.F. Jordao, C.A. Ayala-Grosso, K. Markham, Y. Huang, R. Chopra, J. McLaurin, K.
Hynynen, I. Aubert, Antibodies targeted to the brain with image-guided focused
ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of
Alzheimer's disease, PLoS One 5 (2010) e10549.
[159] A. Burgess, C.A. Ayala-Grosso, M. Ganguly, J.F. Jordao, I. Aubert, K. Hynynen,
Targeted delivery of neural stem cells to the brain using MRI-guided focused
ultrasound to disrupt the blood–brain barrier, PLoS One 6 (2011) e27877.
[160] E. Thevenot, J.F. Jordao, M.A. O'Reilly, K. Markham, Y.Q. Weng, K.D. Foust, B.K.
Kaspar, K. Hynynen, I. Aubert, Targeted delivery of self-complementary adeno-
associated virus serotype 9 to the brain, using magnetic resonance imaging-
guided focused ultrasound, Hum. Gene Ther. 23 (2012) 1144–1155.
[161] A. Alonso, E. Reinz, B. Leuchs, J. Kleinschmidt, M. Fatar, B. Geers, I. Lentacker, M.G.
Hennerici, S.C. de Smedt, S. Meairs, Focal delivery of AAV2/1-transgenes into the
rat brain by localized ultrasound-induced BBB opening, Mol. Ther. Nucleic Acids
2 (2013) e73.
[162] P.H. Hsu, K.C. Wei, C.Y. Huang, C.J. Wen, T.C. Yen, C.L. Liu, Y.T. Lin, J.C. Chen, C.R.
Shen, H.L. Liu, Noninvasive and targeted gene delivery into the brain using
microbubble-facilitated focused ultrasound, PLoS One 8 (2013) e57682.
[163] L.H. Treat, N. McDannold, Y. Zhang, N. Vykhodtseva, K. Hynynen, Improved
anti-tumor effect of liposomal doxorubicin after targeted blood–brain barrier
disruption by MRI-guided focused ultrasound in rat glioma, Ultrasound Med.
Biol. 38 (2012) 1716–1725.
[164] J.F. Jordao, E. Thevenot, K. Markham-Coultes, T. Scarcelli, Y.Q. Weng, K. Xhima, M.
O'Reilly, Y. Huang, J.McLaurin,K. Hynynen, I. Aubert, Amyloid-beta plaque reduction,
endogenous antibody delivery and glial activation by brain-targeted, transcranial
focused ultrasound, Exp. Neurol. 248 (2013) 16–29.
[165] J.J. Choi, M. Pernot, S.A. Small, E.E. Konofagou, Noninvasive, transcranial and localized
opening of the blood–brain barrier using focused ultrasound in mice, Ultrasound
Med. Biol. 33 (2007) 95–104.
[166] M.A. O'Reilly, A. Muller, K. Hynynen, Ultrasound insertion loss of rat parietal
bone appears to be proportional to animal mass at submegahertz frequencies,
Ultrasound Med. Biol. 37 (2011) 1930–1937.
[167] S. Pichardo, V.W. Sin, K. Hynynen, Multi-frequency characterization of the speed of
sound and attenuation coefﬁcient for longitudinal transmission of freshly excised
human skulls, Phys. Med. Biol. 56 (2011) 219–250.
[168] P.J. White, G.T. Clement, K. Hynynen, Longitudinal and shear mode ultrasound
propagation in human skull bone, Ultrasound Med. Biol. 32 (2006) 1085–1096.
[169] K. Hynynen, N.I. Vykhodtseva, A.H. Chung, V. Sorrentino, V. Colucci, F.A. Jolesz,
Thermal effects of focused ultrasound on the brain: determination with MR
imaging, Radiology 204 (1997) 247–253.
[170] N. McDannold, S.E. Maier, Magnetic resonance acoustic radiation force imaging,
Med. Phys. 35 (2008) 3748–3758.
[171] N. Hosseinkhah, K. Hynynen, A three-dimensional model of an ultrasound contrast
agent gas bubble and its mechanical effects on microvessels, Phys. Med. Biol. 57
(2012) 785–808.
[172] Y.S. Tung, F.Marquet, T. Teichert, V. Ferrera, E.E. Konofagou, Feasibility of noninvasive
cavitation-guided blood–brain barrier opening using focused ultrasound and
microbubbles in nonhuman primates, Appl. Phys. Lett. 98 (2011) 163704.
[173] M.A. O'Reilly, K. Hynynen, Blood–brain barrier: real-time feedback-controlled
focused ultrasound disruption by using an acoustic emissions-based controller,
Radiology 263 (2012) 96–106.
[174] V.A. Salgaonkar, S. Datta, C.K. Holland, T.D. Mast, Passive cavitation imaging with
ultrasound arrays, J. Acoust. Soc. Am. 126 (2009) 3071–3083.
[175] M. Gyongy, C.C. Coussios, Passive cavitation mapping for localization and tracking
of bubble dynamics, J. Acoust. Soc. Am. 128 (2010) EL175–EL180.
[176] C.D. Arvanitis, M.S. Livingstone, N. McDannold, Combined ultrasound and MR
imaging to guide focused ultrasound therapies in the brain, Phys. Med. Biol. 58
(2013) 4749–4761.
[177] F.Y. Yang, H.E. Wang, G.L. Lin, M.C. Teng, H.H. Lin, T.T. Wong, R.S. Liu, Micro-SPECT/
CT-based pharmacokinetic analysis of 99mTc-diethylenetriaminepentaacetic acid
in rats with blood–brain barrier disruption induced by focused ultrasound,
J. Nucl. Med. 52 (2011) 478–484.
[178] F.Y. Yang, S.C. Horng, Y.S. Lin, Y.H. Kao, Association between contrast-enhancedMR
images and blood–brain barrier disruption following transcranial focused ultrasound,
J. Magn. Reson. Imaging 32 (2010) 593–599.
[179] P.C. Chu, W.Y. Chai, H.Y. Hsieh, J.J. Wang, S.P. Wey, C.Y. Huang, K.C. Wei, H.L. Liu,
Pharmacodynamic analysis of magnetic resonance imaging-monitored focused
ultrasound-induced blood–brain barrier opening for drug delivery to brain tumors,
Biomed. Res. Int. 2013 (2013) 627496.
[180] F. Vlachos, Y.S. Tung, E.E. Konofagou, Permeability assessment of the focused
ultrasound-induced blood–brain barrier opening using dynamic contrast-
enhanced MRI, Phys. Med. Biol. 55 (2010) 5451–5466.
[181] S.B. Raymond, K. Hynynen, Acoustic transmission losses and ﬁeld alterations due
to human scalp hair, IEEE Trans. Ultrason. Ferroelectr. Freq. Control 52 (2005)
1415–1419.
[182] J. Park, Y. Zhang, N. Vykhodtseva, J.D. Akula, N.J. McDannold, Targeted and reversible
blood–retinal barrier disruption via focused ultrasound andmicrobubbles, PLoS One
7 (2012) e42754.
[183] J. Wachsmuth, R. Chopra, K. Hynynen, Feasibility of transient image-guided blood–
spinal cord barrier disruption, Proceedings of the 8th International Symposium on
Therapeutic Ultrasound, Minneapolis, MN, AIP Conf.Proc., 1113, 2008, pp. 256–259.
[184] K. Fischer, N.J. McDannold, Y. Zhang, M. Kardos, A. Szabo, A. Szabo, G.S. Reusz, F.A.
Jolesz, Renal ultraﬁltration changes induced by focused US, Radiology 253 (2009)
697–705.
[185] N.J. McDannold, N.I. Vykhodtseva, K. Hynynen, Microbubble contrast agent with
focused ultrasound to create brain lesions at low power levels: MR imaging and
histologic study in rabbits, Radiology 241 (2006) 95–106.
[186] M.J. Borrelli, W.D. O'Brien Jr., E. Hamilton, M.L. Oelze, J. Wu, L.J. Bernock, S. Tung, H.
Rokadia, W.C. Culp, Inﬂuences of microbubble diameter and ultrasonic parameters
on in vitro sonothrombolysis efﬁcacy, J. Vasc. Interv. Radiol. 23 (2012) 1677–1684.
[187] G.J. Czarnota, R. Karshaﬁan, P.N. Burns, S.Wong, A. Al Mahrouki, J.W. Lee, A. Caissie,
W. Tran, C. Kim, M. Furukawa, E. Wong, A. Giles, Tumor radiation response
enhancement by acoustical stimulation of the vasculature, Proc. Natl. Acad. Sci.
U. S. A. 109 (2012) E2033–E2041.
[188] F.Y. Yang,W.M. Fu,W.S. Chen,W.L. Yeh,W.L. Lin, Quantitative evaluation of the use
of microbubbles with transcranial focused ultrasound on blood–brain-barrier
disruption, Ultrason. Sonochem. 15 (2008) 636–643.
[189] N. McDannold, N. Vykhodtseva, K. Hynynen, Use of ultrasound pulses combined
with Deﬁnity for targeted blood–brain barrier disruption: a feasibility study, Ultra-
sound Med. Biol. 33 (2007) 584–590.
[190] K.J. Lin, H.L. Liu, P.H. Hsu, Y.H. Chung, W.C. Huang, J.C. Chen, S.P. Wey, T.C. Yen, I.T.
Hsiao, Quantitative micro-SPECT/CT for detecting focused ultrasound-induced
blood–brain barrier opening in the rat, Nucl. Med. Biol. 36 (2009) 853–861.
[191] F.Y. Yang, H.E. Wang, G.L. Lin, H.H. Lin, T.T. Wong, Evaluation of the increase in
permeability of the blood–brain barrier during tumor progression after pulsed
focused ultrasound, Int. J. Nanomedicine 7 (2012) 723–730.
[192] Q. Huang, J. Deng, Z. Xie, F. Wang, S. Chen, B. Lei, P. Liao, N. Huang, Z. Wang, Z.
Wang, Y. Cheng, Effective gene transfer into central nervous system following
ultrasound-microbubbles-induced opening of the blood–brain barrier, Ultrasound
Med. Biol. 38 (2012) 1234–1243.
[193] A.B. Etame, R.J. Diaz, M.A. O'Reilly, C.A. Smith, T.G. Mainprize, K. Hynynen, J.T. Rutka,
Enhanced delivery of gold nanoparticles with therapeutic potential into the brain
using MRI-guided focused ultrasound, Nanomedicine 8 (7) (2012) 1133–1142.
[194] P.H. Wang, H.L. Liu, P.H. Hsu, C.Y. Lin, C.R. Wang, P.Y. Chen, K.C. Wei, T.C. Yen, M.L.
Li, Gold-nanorod contrast-enhanced photoacoustic micro-imaging of focused-
ultrasound induced blood–brain-barrier opening in a rat model, J. Biomed. Opt.
17 (2012) 061222.
16 M. Aryal et al. / Advanced Drug Delivery Reviews xxx (2014) xxx–xxx
Please cite this article as: M. Aryal, et al., Ultrasound-mediated blood–brain barrier disruption for targeted drug delivery in the central nervous
system, Adv. Drug Deliv. Rev. (2014), http://dx.doi.org/10.1016/j.addr.2014.01.008
Appendix II 
Multiple treatments with liposomal doxorubicin and ultrasound induced 
disruption of blood-tumor and blood-brain barriers improves outcomes in a rat 
glioma  
Muna Aryal, Natalia Vykhodtseva, Yong-Zhi Zhang, Juyoung Park, Nathan McDannold 
J Control Release. 2013 July 10; 169(0): 103–111  
 
Multiple treatmentswith liposomal doxorubicin and ultrasound-induced
disruption of blood–tumor and blood–brain barriers improve outcomes
in a rat glioma model☆
Muna Aryal a,b,⁎, Natalia Vykhodtseva b, Yong-Zhi Zhang b, Juyoung Park b, Nathan McDannold b
a Department of Physics, Boston College, Chestnut Hill, USA
b Department of Radiology, Brigham & Women's Hospital, Harvard Medical School, Boston, USA
a b s t r a c ta r t i c l e i n f o
Article history:
Received 2 January 2013
Accepted 10 April 2013
Available online 18 April 2013
Keywords:
Focused ultrasound
Brain
Drug delivery
Glioma
Blood–brain barrier
Chemotherapy
The blood–brain-barrier (BBB) prevents the transport of most anticancer agents to the central nervous sys-
tem and restricts delivery to inﬁltrating brain tumors. The heterogeneous vascular permeability in tumor ves-
sels, along with several other factors, creates additional barriers for drug treatment of brain tumors. Focused
ultrasound (FUS), when combined with circulating microbubbles, is an emerging noninvasive method to
temporarily permeabilize the BBB and the “blood–tumor barrier”. Here, we tested the impact of three weekly
sessions of FUS and liposomal doxorubicin (DOX) in 9L rat glioma tumors. Animals that received FUS + DOX
(N = 8) had a median survival time that was increased signiﬁcantly (P b 0.001) compared to animals who
received DOX only (N = 6), FUS only (N = 8), or no treatment (N = 7). Median survival for animals that
received FUS + DOX was increased by 100% relative to untreated controls, whereas animals who received
DOX alone had only a 16% improvement. Animals who received only FUS showed no improvement. No
tumor cells were found in histology in 4/8 animals in the FUS + DOX group, and in two animals, only a
few tumor cells were detected. Adverse events in the treatment group included skin toxicity, impaired activ-
ity, damage to surrounding brain tissue, and tissue loss at the tumor site. In one animal, intratumoral hemor-
rhage was observed. These events are largely consistent with known side effects of doxorubicin and with an
extensive tumor burden. Overall this work demonstrates that multiple sessions using this FUS technique to
enhance the delivery of liposomal doxorubicin have a pronounced therapeutic effect in this rat glioma model.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
The blood–brain barrier (BBB) and other challenges prevent the
effective use of most systemically-administered chemotherapeutic
agents in patients with brain tumors. The BBB restricts transport of
practically all agents to the brain parenchyma due to its selective per-
meability, which is based on lipid solubility, molecular size and
charge [1,2]. Inﬁltrating tumor cells andmetastatic “seeds” in the cen-
tral nervous system are protected by the intact BBB and are excluded
from the therapeutic effects of most drugs. Tumor blood vessels,
which often lack an intact BBB, will allow some agent to extravasate
and reach the vascular portion of the tumor. However, the permeabil-
ity of the tumor vasculature is heterogeneous, and factors such as in-
creased interstitial pressure [3] limit how far from the vasculature the
drugs can penetrate. Furthermore, efﬂux pumps, which are present at
the BBB and in many tumors, extrude cytotoxic drugs that usually
enter cells by passive diffusion [4]. Methods to overcome these bar-
riers to drug delivery are needed if effective brain tumor therapies
are to be developed.
Because of these challenges, the treatment of glioblastoma
multiforme (GBM), an aggressive, high-grade brain tumor, is difﬁcult
[5]. This tumor is highly inﬁltrative, and recurrence after localized treat-
ments such as conformal radiotherapy or surgery is common. This re-
lapse usually occurs within a few cm of the treated region [6–8]. The
introduction of temozolomide, a small molecule chemotherapy agent
that has some penetration across the BBB, has improved clinical out-
comes [9], but this improvement has been modest. A technique that
can deliver larger agents across the “blood–tumor barrier” (BTB) and
the BBB in the surrounding brain could enable the use of a wide range
of anticancer agents for GBM and other brain tumors.
The use of focused ultrasound (FUS) combined with a circulating
microbubble agent is an emerging technique to disrupt the BBB tempo-
rarily in a localized and non-invasive manner [10]. The microbubbles,
which are constrained to the vasculature, interact strongly with even
low-intensity ultrasound, producingmechanical forces on the endothe-
lium that result in transient disassembly of tight junctional complexes
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and the induction of active transport processes [11,12]. No signiﬁcant
adverse effects have been observed resulting from this temporary BBB
disruption [13–15]. The barrier is restored in a fewhours [10], providing
a time-window to deliver even long-circulating agents. Prior work in
animals has demonstrated delivery of awide range of imaging and ther-
apeutic agents, even large agents such as antibodies, nanoparticles, and
liposomally-encapsulated drugs [16–19]. The method can increase the
delivery of agents to brain tumors [20,21], and several studies have
shown that it can improve outcomes in animal brain tumor models
[20,22–24]. These results, along with recent work demonstrating safety
in a large animal model using a clinical brain FUS system [13] make it a
promising approach for the treatment of GBM and other brain tumors.
Volumetric BBB disruption can be achievedwith such devices by rapidly
steering the ultrasound focal point to different locations [13].
This method has several potential advantages over other ap-
proaches tested to overcome the BBB and the BTB [25]. FUS-induced
BBB disruption is a noninvasive and targeted procedure, and the ef-
fect can be localized to only desired volumes in the brain. The method
is also compatible with currently-available drugs, removing the need
to develop new agents. Importantly, since FUS is noninvasive and can
presumably be applied without general anesthesia, it is expected to
be a relatively benign procedure that can be readily repeated to
match a patient's drug schedule.
The purpose of this work was to evaluate whether multiple treat-
ment sessions can effectively improve the therapeutic effect of liposo-
mal doxorubicin in a rat glioma model. Previous work has shown that
a single treatment with FUS-enhanced delivery of this agent to
orthotopically-implanted 9L rat gliosarcoma model had a modest im-
provement in survival and tumor growth [24]. Here we examined
whether three weekly sessions can provide a more pronounced treat-
ment effect in this tumor model. We also utilized low-frequency FUS
to better match an existing clinical FUS device [26].
2. Materials and methods
2.1. Sonication system
An air-backed, single element, 690 kHz focused piezoelectric
transducer (diameter/radius of curvature: 100/80 mm) generated
the ultrasound ﬁeld. It was driven by an arbitrary waveform genera-
tor (model 395, Wavetek) and RF ampliﬁer (240L, ENI); electric
power was measured with a power meter (E4419B, Agilent) and a
dual-directional coupler (C5948-10, Werlatone). Reported exposure
levels are absolute peak negative pressure amplitudes measured in
water with a membrane hydrophone (Marconi; 0.5 mm diameter).
Attenuation by the brain and rat skull is expected to reduce the pres-
sure amplitude by ~30% at this frequency [27] with additional uncer-
tainty arising from standing waves within the skull and increases in
skull thickness as the animal ages [27]. The pressure distribution of
the transducer was mapped using a 0.2 mm needle hydrophone
(Onda, Sunnyvale, CA); its half-maximum diameter and length were
2.3 and 12 mm, respectively. The transducer efﬁciency was measured
using a radiation force-balance.
2.2. Experimental setup
The sonication system was operated within a clinical 3 T MRI scan-
ner (Signa; GE Healthcare). The transducer was immersed in a small
tank of degassed, deionized water and attached to an MRI-compatible,
manually-operated positioning system (Fig. 1A). The animal was laid
supine on a tray above this tank, with a water bag providing an acoustic
path to the dorsal surface of the head. Images were obtained with a
7.5 cm-diameter transmit/receive MRI surface coil. The animal's body
temperature was maintained with a heated water pad. Before treat-
ment, we visualized heating in a silicone phantom using temperature-
sensitive MRI to localize the acoustic focal point in the MRI space.
Accurate targeting in vivo was conﬁrmed before the tumor sonications
in select animals (typically the ﬁrst animal treated each week) by soni-
cating a spot in the brain outside the tumor and checking that the
resulting MRI contrast extravasation was at the desired target.
2.3. Animals
The experiments were approved by our institutional animal com-
mittee. Tests were performed in 40 male Sprague–Dawley rats
(Charles River Laboratories; ~250 g). Before each procedure, the ani-
mals were anesthetized via intraperitoneal injections of Ketamine
(80 ml/kg/h) and Xylazine (10 ml/kg/h). A catheter was placed in
the tail vein, and the hair on the scalp was removed with clippers
and depilatory cream.
9L rat gliosarcoma cells (passage number 3, obtained from the
Neurosurgery Tissue Bank at UCSF) were grown in Minimum Essen-
tial Medium (1×) with Earle's salts, supplemented with 10% fetal bo-
vine serum, 1% L-glutamine, 1% MEM nonessential amino acids, and
0.1% gentamicin in a 5% CO2 chamber held at 37 °C. After preparing
the skin, a 5-mm skin incision was made and a 1-mm burr hole was
drilled into the skull 1 mm anterior to the bregma and 2 mm lateral
to the midline. A 4 μl volume of cell suspension (1 × 105 cells) was
injected into the right caudate putamen at a depth of 3.5 mm relative
to the dural surface using a 10 μl gas-tight syringe (Hamilton). Cells
were injected over ﬁve minutes; two minutes later the needle was
retracted slowly over another 5 min, and the skin was sutured. The
sutures were removed 5 days later, and treatment began on day 7
or 8, at which point the tumor had an MRI-evident diameter between
1 and 3 mm.
The animals were monitored regularly to evaluate the treatment ef-
fects on survival and tumor growth. Animals surviving 6 weeks after
treatment were considered long-term survivors. However, some were
followed for longer periods for later histological examination, as they
appeared healthy. The animals were euthanized if they exhibited se-
verely impaired activity, weight loss exceeding 20% within one week,
tumor dimensions exceeding 10–11 mm, or if treatment-related severe
adverse events occurred that caused pain or distress and that could not
be ameliorated. The animals were euthanized via transcardial perfusion
with saline followed by 10% phosphate-buffered formalin while
under deep anesthesia. The brain was removed and immersed in 10%
phosphate-buffered formalin for histological preparation. To avoid
skin infections that were observed in two animals (see below), animals
receiving FUS and chemotherapywere treatedwith an antibiotic Baytril
(Bayer; 2.5 mg/kg).
2.4. Treatment
The rats were randomly assigned to one of four groups: (1) no
treatment (Control) (N = 7), (2) three weekly treatments with
FUS-induced BBB/BTB permeabilization (FUS-Only) (N = 8), (3) three
weekly treatments with liposomal doxorubicin (DOX-only) (N = 6),
and (4) three weekly treatments with FUS and concurrent chemother-
apy (FUS + DOX) (N = 8). After determining the coordinates of the
focal pointwithin theMRI space, treatment planningMRI was acquired,
and the focal regionwaspositionedwithin the tumor. Ultrasoundbursts
were then applied at multiple points in and around the tumor at pres-
sure amplitudes ranging from 0.55 to 0.81 MPa (burst length: 10 ms,
pulse repetition frequency: 1 Hz, duration: 60 s). The pressure ampli-
tude was initially set based on a prior study in rats with this device
[28]. It was increased based on the age and weight of the animals to
achieve a consistent level of BBB disruption. This observation was
made in our initial treatments and is similar to previous reports [27].
Before each sonication, ultrasonic contrast agent (DEFINITY, Lantheus
Medical Imaging; 0.01 ml/kg) was administered intravenously. To
facilitate the injections of such a small volume, the agent was diluted
to 0.1× normal concentration in PBS. It was injected as a bolus
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approximately 9 s before each sonication, followed by a 0.2 ml saline
ﬂush. The sonicationswere delivered at 5 min intervals in a grid pattern
(spacing: 1 or 1.5 mm, depending on tumor volume) to 5–20 targets
with the number of locations increasing over the three weeks as the
tumor volume increased. We aimed to permeabilize the BTB in the en-
tire tumor and the BBB in a surrounding rim of at least 1 mm.
For chemotherapy, 5.67 mg/kg of doxorubicin hydrochloride en-
capsulated in long-circulating pegylated liposomes was administered
intravenously. This dosage was selected based on prior work testing
this agent in rats [29]. In our initial experiments (5 rats in
DOX-Only group; 5 in FUS + DOX group), we used DOXIL (Centocor
Ortho-Biotech). Due to a national shortage of this agent that occurred
during these experiments, we used Lipo-Dox (TTY Biopharm) for the
remaining animals (1 rat in the Dox-Only group; 3 in the FUS + DOX
group). Previous work has shown that doxorubicin can be released
from liposomes by ultrasound if microbubbles are in close vicinity
[30], and we speculated that such may occur in these treatments.
Thus for the FUS + DOX group, chemotherapy was administered
over multiple slow injections administered just before each sonica-
tion. This scheme aimed to ensure a high drug concentration in the
bloodstream during every sonication. For the DOX-only group, the
agent was administered over 5 slow injections at 5 min intervals.
Each injection was followed by a 0.2 ml saline ﬂush.
2.5. Magnetic resonance imaging
T2-Weighted imaging was used to plan the treatments and mea-
sure tumor volumes. BBB/BTB disruption was evaluated using
T1-weighted imaging acquired before and after administration of
the MRI contrast agent gadopentatate dimeglumine (Magnevist
Gd-DTPA; Bayer Healthcare; 0.25 ml/kg). T2*-Weighted imaging
was used to conﬁrm that petechiae, which are produced by excessive
FUS exposures, did not occur [10] and to evaluate hemorrhagic re-
gions in the tumors. Detailed imaging parameters are listed in Supple-
mental Methods.
2.6. Image analysis
Non-contrast MRI imaging was performed weekly (±1–3 days
depending on MRI availability). Tumor boundaries were manually seg-
mented in axial T2-weighted images using ImageJ; the volumewas cal-
culated by the sum of the areas multiplied by the image thickness. In
weeks 1–2, the tumors appeared as clearly circumscribed volumes
which were sometimes surrounded by hyperintense regions (presum-
ably edema). These boundaries were sometimes not evident at later
times in the FUS + DOX group, and it was not clear whether MRI
abnormalities were residual/recurring tumor or treatment-related ef-
fects. To be conservative, such cases were included in the volume
calculations.
2.7. Histology
Representative examples from the Control (4/7 animals) and
FUS-Only (5/8 animals) groups were selected for histological examina-
tion. The treatment response varied for animals in the DOX-Only and
FUS + DOX groups (see below), and all brains from these animals
were examined. Tissue blocks containing the tumor were embedded
Fig. 1. Experimental setup and treatment overview. (A) Schematic of the MRI-guided
focused ultrasound system used in this work. The function generator, ampliﬁer, and
power meter were located outside the MRI room (B). Axial images acquired before
(left) and after (right) the ﬁrst FUS + DOX treatment showing the signal enhancement
in T1-weighted MRI after Gd-DTPA injection. Before FUS, the tumor was a small en-
hancing area (arrow). The magnitude and extent of this enhancement were increased
after FUS. (C) Signal enhancement in this example as a function of time. (D) T2-weighted
imaging (T2WI) used for treatment planning, contrast-enhanced T1-weighted imaging
(CE-T1WI) used to verify the BBB/BTB permeabilization, and post-FUS T2*-weighted imag-
ing (T2*WI) acquiredduring threeweekly FUS+DOX treatments. (D) T2-weighted imaging
(T2WI) used for treatment planning, contrast-enhanced T1-weighted imaging (CE-T1WI)
used to verify the BBB/BTB permeabilization, and post-FUS T2*-weighted imaging
(T2*WI). The location of the tumor in treatment planning is indicated by the solid line,
and the extent ofMRI contrast enhancement is indicated by the dotted line. The coordinates
of the sonication targets are also noted (white circles). Two hypointense spots (arrows)
were evident after the third treatment in T2*-weighted imaging. The enhancing area evident
in the other hemisphere in (B) and (D) (asterisk) was a location in the brain that was son-
icated before the ﬁrst Gd-DTPA injection to conﬁrm the accurate targeting of the FUS beam.
Bars: 5 mm.
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in parafﬁn and cut into 4–6 μm serial sections perpendicular to the di-
rection of ultrasound propagation. Sections with the largest evident
tumor were stained with Hematoxylin and Eosin (H&E) for examina-
tion in light microscopy.
2.8. Statistical analysis
Tumor volumes for the four groups were compared using one-way
ANOVA. The Kaplan–Meier method was used to compare survival of
animals in each group. Signiﬁcance was calculated by using log-rank
test with Yates' correction. These analyses were performed using
Matlab (MathWorks) and Microsoft Excel. The Bonferroni method
was used to comparemultiple pairs of groups [31]. With four treatment
groups (including controls) and with six possible paired comparisons,
pair-wise P values less than the Bonferroni-corrected threshold of
0.05/6 = 0.0083 were considered statistically signiﬁcant.
3. Results
3.1. Tumor progression
BBB/BTB permeabilization and a lack of signiﬁcant FUS-induced
tissue damage were conﬁrmed using contrast-enhanced and
T2*-weighted MRI, respectively (Fig. 1B). A higher pressure ampli-
tude (0.81 vs. 0.55 MPa) was needed for the third treatment to induce
consistent BBB/BTB permeabilization, presumably because of an in-
crease in skull or dura thickness as the rats grew [27]. To conﬁrm
that the sonications increased the vascular permeability in the
tumor, we performed contrast-enhanced imaging before and after
the sonications in several animals (Fig. 1B-C). Sonication targets
were applied in a grid to cover the tumor evident in T2-weighted im-
aging plus a surrounding margin (Fig. 1D). Weekly MRI examination
was used to monitor the tumor progression. Representative examples
from each experimental group over the ﬁrst three weeks and the
tumor volume measurements are shown in Fig. 2.
In most animals in the three control groups, the tumor grew rap-
idly over this time (Fig. 2A), resulting in signiﬁcant midline shift
and compression of the lateral ventricles. Hypointense regions were
often evident within the tumor in T2*-weighted imaging in all groups.
Eleven of ﬁfteen rats (73%) in these groups either died or were eutha-
nized before the third treatment due either to tumor dimensions ex-
ceeding 10–11 mm or poor health conditions (weight loss exceeding
20% or severely impaired activity). The rest died or were euthanized
for these reasons before week 4. One rat in the DOX-Only group
was euthanized before the third treatment; the rest were euthanized
shortly after week 3.
All animals in the FUS + DOX group received all three treatments,
and no rat in this group was euthanized before week 4 (Fig. 2B–C).
The tumor volume reached a maximum at weeks 3 or 4, after which
Fig. 2.MRI appearance of the tumors and their growth over time. (A) MRI for the three
control groups for weeks 1–3. The rapid growth that was observed in most of the rats
in these groups is evident in T2-weighted imaging (T2WI). Hypointense areas were
often observed within the tumor in T2*-weighted MRI (T2*WI). (B) Serial MRI for a
long-term survivor in the FUS + DOX group (Rat 4 in Table 1) showing rapid tumor
growth and subsequent resolution. The volume was maximum at week four, at
which time it covered a signiﬁcant portion of one hemisphere. It then began to shrink,
and from week 8 onwards it was no longer evident. Brain tissue loss at the former site
was evident, and the lateral ventricle was enlarged and ﬁlled much of this space. Tissue
adjacent to the former tumor mass was highly hyperintense in T2-weighted imaging,
and presumably damaged. A hypointense region was observed at the former tumor
site in T2*-weighted imaging starting at weeks 6–7, which slowly shrunk over time.
Imaging between weeks 8 and 20 was mostly similar. Note that the T2*-weighted im-
aging in the FUS-Only and FUS + DOX animals was acquired after Gd-DTPA in weeks
1–3; contrast enhancement was observed in the tumor and surrounding brain. Bar:
5 mm. (C) MRI-measured tumor volumes as a function of time for each experimental
group. Tumors were implanted at week 0. The number of surviving animals at each
week is noted below the plot (†MRI from two animals in the FUS-Only group was not
included in this analysis due to poor image quality). Mean ± S.E. is shown.
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they began to shrink. The outcomes for the eight animals in this group
varied and are summarized in Table 2. The maximum tumor volume
varied substantially, with some tumors reaching volumes similar to
the control group, and others never reaching 100 mm3. The mean
tumor volume in the FUS + DOX group was less than in the three
control groups at weeks 2–3 (Fig. 2C). However the differences
were not signiﬁcant.
The ﬁrst two rats treated in the FUS + DOX group (Rats 1 and 2 in
Table 1) exhibited local skin toxicity (inﬂammation, peeling; minor
bleeding) on the scalp and the front and hind paws beginning on or
after week two. These two animals developed a skin infection and
were euthanized at days 34 and 35. In their last imaging session, one of
these animals had no tumor evident in MRI, and the other had a small
tumor that appeared to be responding to the treatment. Subsequent an-
imalswere treated prophylacticallywith antibiotics.While skin irritation
or mild inﬂammation was observed, they did not develop infections.
Three animals (Rats 3, 4 and 8 in Table 1) did not exhibit any ev-
ident morbidity. They gained weight and behaved normally. These
animals were followed for 9 or more weeks, at which time they
were euthanized for histological examination. One of these
long-term survivors was euthanized at day 66; the other two were
observed for longer periods (136 and 142 days). Tumors in these an-
imals grew to a substantial volume (greater than 300 mm3) before
they began to resolve. MRI from one of these animals is shown in
Fig. 2B. After the tumors disappeared, brain tissue loss at the former
tumor site was evident in MRI, along with damage in adjacent tissues
and enlarged ventricles. Tissue damage appeared as highly
hyperintense regions in T2-weighted imaging. In some regions, with-
in this damaged area, discrete hyperintense zones in both T2* and
T2-weighted imaging were seen.
Two animals in the FUS + DOX group (Rats 5 and 7 in Table 1)were
euthanized due to poor health at days 32 and 36, respectively. At the
time of sacriﬁce, one of these animals exhibited only a small
hyperintense region in T2-weighted imaging, and no tumor was evi-
dent in histology (see below). The other had an extensive hyperintense
area in T2-weighted imaging, but only a small cluster containing a few
tumor cells was found in histology. Finally, in one animal (Rat 6 in
Table 1), a large hypointense region was observed in T2*-weighted im-
aging at week 4 that was assumed to be intratumoral hemorrhage. This
animal also exhibited impaired activity andwas euthanized at this time.
3.2. Histological ﬁndings
Tumors in the Control and FUS-Only groups appeared at days 15–
23 as solid masses that replaced large amounts of brain tissue
(Fig. 3A). The tumor bulk consisted of viable and rapidly dividing
spindle-shaped cells interspersed with multiple small necrotic sites.
Microvessels that were necrotic, dilated, and congested with erythro-
cytes were observed throughout and were surrounded by necrotic
zones (Fig. 3B). Small hemorrhagic regions were also found. Blood
cells in these regions and in congested blood vessels were consistent
with the hypointense regions observed in T2*-weighted imaging. In
the largest tumors, numerous necrotic and hemorrhagic areas accom-
panied by cell necrosis and apoptosis were found scattered through-
out the tumor mass. Rapid tumor growth and invasion displaced
and compressed the surrounding brain tissue, resulting in ischemia
and cell death (infarction) in some adjacent brain regions (Fig. 3C).
A narrow (0.5–1 mm) band of invading/inﬁltrating cells was evident
at the tumor margin (Fig. 3D).
The tumor appearance in the DOX-only group varied. Although viable
and dividing cells were generally present, a reduced cellularity compared
to the other control groups, along with unhealthy-appearing tumor cells
and an intensely vacuolated matrix was evident in this group (Fig. 3E).
Large regions of necrosis were observed in some cases, but some viable
tumor cells were always found within these necrotic areas. Substantial
hemorrhage was evident at the periphery of some tumors, accompanied
by infarction in the surrounding brain. Tumor cell invasion along
perivascular tracts and tumor cell clusters were observed at sites as far
as 1–2 mm from the edge of the solid tumormass (Fig. 3F). In one animal
(euthanized at day 26 due to impaired activity), no tumor cells were
found in histology.
Table 1
Outcomes in FUS + DOX group.
Rat Survival
(days)
Maximum
vol. in MRI
(mm3)
Vol. in MRI at
euthanasia
(mm3)
Tumor
found in
histology
Outcome
1 34 244 63 Yes Skin infection, euthanized
2 35 52 0 No Skin infection, euthanized
3 66 358 0 No Long-term survivor
4 142 365 0 No Long-term survivor
5 32 4242 4242 Yes1 Poor health, euthanized
6 31 312 312 Yes Intratumoral hemorrhage,
euthanized
7 36 96 40 No Poor health, euthanized
8 136 312 0 Yes1 Long-term survivor
1 Only a small cluster containing a few tumor cells was found.
2 A well-deﬁned tumor margin was not evident in T2-weighted MRI at weeks 3–4 in
this animal; only a large hyperintense region was observed (see Fig. 4F). The volume of
this hyperintense region was included in the volume measurements, as we could not
determine if this region was tumor or edema.
Fig. 3. Appearance of 9L gliosarcoma in the three control groups in histology. Animals
receiving no treatment or FUS-Only (A–D) all had a similar appearance. The tumor
appeared as a solid mass that replaced large volumes of brain tissue (A). The bulk of
the tumors consisted of viable and rapidly dividing spindle-shaped cells (inset in A).
Congested blood vessels were observed throughout, surrounded by necrotic tissue
(B). Some regions of adjacent brain tissue were severely damaged, presumably from is-
chemia (C). There was a rim of inﬁltrating cells at the margin (D). Most tumors in the
DOX-Only group (E–F) were also large masses of tumor cells with an inﬁltrating mar-
gin (E). However, unlike the other two control groups, they had a lower cellularity, un-
healthy tumor cells, and intensely vacuolated matrix (inset in E). Tumor cell invasions
along perivascular tracts and tumor cell clusters were observed at distant sites up to
2 mm from the edge of the solid tumor. The vacuolation evident in the tumor mass
was often not observed in the inﬁltrating margin (* in F).
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In contrast to the controls, all but one of the animals in the
FUS + DOX group exhibited a strong treatment response, with no
tumor mass detected in 6/8 animals. However, in two of these ani-
mals a few residual or recurrent tumor cells were found in the for-
mer tumor site. In one rat, which was euthanized due to skin
infection at day 34, a tumor was found to be shrunken compared
to its maximum size in MRI and partly destroyed. The central area
contained a viable tumor mass, and a surrounding rim of tissue
appeared to be damaged. Only one animal (Rat 6 in Table 1) had a
large tumor like most rats in the control groups. This animal, in
which intratumoral bleeding was suspected in MRI, was euthanized
at week 4. Histological examination conﬁrmed hemorrhagic infarc-
tion in a region of tumor necrosis. This region was restricted to the
tumor mass; no blood was found inside the adjacent ventricular
space.
Example histological ﬁndings from the FUS + DOX group are
shown in Fig. 4. In the three long-term survivors, where the tumors
grew to a substantial volume before beginning to resolve, brain tissue
loss was evident at the former tumor site (Fig. 4A). The adjacent lat-
eral ventricle was signiﬁcantly enlarged and ﬁlled this missing area.
A region in the adjacent brain was necrotic, with an appearance con-
sistent with infarct (Fig. 4B). A small cyst was observed within this
necrotic zone. The hypointense regions evident in MRI contained
hemosiderin — either in clusters or taken up by macrophages (inset
in Fig. 4B). In one long-term survivor, a small cluster of recurring or
residual tumor cells was found.
Findings from two animals from the FUS + DOX group that were
euthanized for impaired activity are shown in Fig. 4C–H. In one case
(euthanized at day 36) only a small necrotic area with macrophage
inﬁltration was found at the former tumor site (Fig. 4C–E). In the sec-
ond animal (euthanized at day 32), a larger necrotic area was found at
the former tumor site, and affected or damaged tissue was observed
in the surrounding brain that was hyperintense in T2-weighted MRI
(Fig. 4F–H). A tiny cluster of tumor cells was found in this example
(inset in Fig. 4G).
3.3. Survival analysis
Kaplan–Meier survival analysis is shown in Fig. 5; the correspond-
ing statistical data are summarized in Table 2. The median survival
time for the animals in both the Control and FUS-Only groups
was about 18 days. For animals in the DOX-only group, it was
20.3 days — a 16% improvement over the animals in the Control
group. However, this difference was not signiﬁcant (P = 0.16). In
contrast, the animals in the FUS + DOX group showed a signiﬁcant
survival beneﬁt (P b 0.001) compared to the other three groups.
The median survival time was 35 days, a 100% and 72% improvement
over the Control and DOX-Only groups, respectively. Note that this
analysis did not censor the two animals euthanized early due to
skin infection. If one assumes those animals did not die from their
tumor and censors them, the estimated median survival of the
FUS + DOX group would be longer than 142 days, as more than
50% of the remaining animals survived until this time.
4. Discussion
Doxorubicin is a commonly-used anticancer drug for treatment of
a wide range of cancers. While its effectiveness against glioma has
been shown in vitro [32] and in vivo when injected directly into the
tumor [33,34], systemic administration has not been effective clini-
cally [35], presumably reﬂecting insufﬁcient delivery [2]. A number
of drug formulations have been developed to enhance the delivery
of doxorubicin in animal glioma models [36–40] and at least one clin-
ical trial is ongoing with such an agent [41]. Here, we demonstrated
that ultrasound and microbubbles can effectively improve outcomes
in a rat glioma model using an existing liposomal agent, removing
the need to develop and test new drug formulations. The method is
noninvasive and restricts the drug delivery only to desired brain re-
gions. While more work is needed to optimize the treatment and to
better understand its safety proﬁle, these results are promising for
the development of new treatment options for glioma patients.
They join several other studies that showed this FUS method can en-
hance drug delivery and improve outcomes in brain tumor models
[18,20–24,42].
This study also demonstrates the importance of multiple treat-
ments. Previously, a modest survival improvement (24%) compared
to untreated controls was observed with a single treatment in this
tumor model [24]. With three weekly treatments, median survival
Fig. 4. Histological appearance of the brain in three of the animals from the FUS + DOX
group. (A–B) Long-term survivor (see Fig. 2B for MRI). No tumor cells were found.
Brain tissue loss at the former tumor site was evident, and the lateral ventricle was en-
larged and ﬁlled this space. Tissue necrosis (infarct) was observed in the adjacent tissue,
presumably from ischemia. Hemosiderin, either in clusters or insidemacrophageswas ob-
servedwithin the necrotic area. A small cyst (*)was also observed. (C–E) Example froman
animal, whose tumor was resolved, but the animal was euthanized at day 36 due to poor
health. (C) T2-weighted MRI showing tumor growth and shrinkage. At week 4, only a
small hyperintense regionwas visible. (D–E) A small necrotic areawithmacrophage inﬁl-
trationwas found at the former tumor site. (F–H) Another animal with a strong treatment
response, but that was euthanized due to poor health at day 32. In this animal, the tumor
grew to a relatively large size over weeks 1–2. At week 4, an extensive hyperintense area
was observed in T2-weighted imaging (F). A necrotic area with micro-hemorrhages was
found in histology at the former tumor site (G–H). Damaged or necrotic brain tissue was
evident in the area that was hyperintense in T2-weighted imaging. A small cluster of
tumor cells remained (inset in G).
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was increased by 100% compared to the controls, and we observed a
72% survival improvement compared to treatment with chemothera-
py only. While the drug alone produced some treatment effects, it did
not signiﬁcantly improve survival or stop tumor proliferation in most
cases. Histological examination of the tumors in this group showed a
heterogeneous response to the treatment, with necrotic areas inter-
spersed with viable tumor cells — perhaps consistent with heteroge-
neous vascular permeability and insufﬁcient drug delivery to some
regions. It also appeared that perhaps the drug did not reach the inﬁl-
trating tumor cells, as the matrix vacuolation evident in the tumor
mass was not seen around the tumor cells at the tumor margin. In
contrast, all but one of the tumors in the FUS + DOX group exhibited
a strong treatment effect.
Several adverse events were observed. Three rats with little or no
tumor evident in histology – one in the DOX-Only group and two in
the FUS + DOX group – were euthanized due to impaired activity
after three treatments. This ﬁnding may suggest that we used an ag-
gressive treatment schedule that may not be tolerated by all subjects.
Doxorubicin, even when encapsulated, has multiple known side ef-
fects, some of them severe. Use of medications to reduce the symp-
toms of these side effects may help to avoid the impairment we
observed. In one animal (shown in Fig. 4F–H), damaged brain tissue
was evident over a large portion of the treated hemisphere. We also
observed brain tissue loss and necrosis in the surrounding brain in
the three long-term survivors in the FUS + DOX group. We do not
know whether these effects were due to the FUS + DOX treatment
or to the extensive tumor burden that could have damaged the sur-
rounding brain due to mass effects. While previous work did not
ﬁnd severe damage after one FUS + DOX treatment in normal rat
brain [19], it is possible that cumulative effects from the three treat-
ments, along with known neurotoxic effects of doxorubicin [43,44],
produced this damage. If that is the case, attempting to aggressively
target inﬁltrating tumor cells with this agent may be contraindicated,
and it may be necessary to either reduce the dosage delivered to the
surrounding brain or to only target the vascular part of the tumor. Fu-
ture work should evaluate the effects of multiple FUS + DOX treat-
ments in the brain.
A potentially signiﬁcant adverse eventwas the extensive intratumoral
hemorrhagic area that occurred in one animal one week after the last
FUS + DOX treatment. While we did not observe frank bleeding (such
as into the ventricles), vascular risks associated the treatment should be
examined inmore detail. This hemorrhagemayhave resulted fromnecro-
sis of the vessel wall in a large tumor vessel. Others have reported hemor-
rhages in this tumor model with different doxorubicin formulations
[40,45].We also observed skin toxicity, a ﬁnding that may not be surpris-
ing since such toxicity, particularly in the hands and feet, is a known side
effect of doxorubicin [46]. However, it might be prudent to conﬁrm that
the sonications do not increase drug delivery into the scalp. The focal re-
gion of our transducer overlapped the small rat skull, and the intensity on
the scalpmayhavebeen relatively high.While the intensity on the scalp is
expected to be less in humans, this issuemight still be important, as large
tumors may require sonication at hundreds of individual targets, and any
low-level effects may accumulate. Reﬂections from the skull bone can ex-
acerbate this effect.
This study had several limitations. First, due to a national short-
age of DOXIL, we used a different drug formulation in some animals.
While they had similar liposome properties, there may have been
differences unknown to us that may have impacted our results.
The sample size was also relatively small, and more work is needed
to better characterize the effectiveness of the treatment and the
rate of adverse events. More consistent results may be obtained
using online methods to optimize the exposure levels. While we
did modify the exposure levels based on the animal age and weight,
we did not go back and re-treat regions where MRI contrast en-
hancement was poor to attempt to achieve a uniform level of
enhancement. We anticipate that monitoring the microbubble dy-
namics in real-time using online acoustic emission monitoring
[47,48] and re-treating areas with poor contrast enhancement can
improve the local delivery and perhaps allow for a reduced systemic
dose. Here, we evaluated only one dose of liposomal doxorubicin.
We expect that by utilizing post-treatment MRI contrast imaging,
which can be correlated to drug concentrations [19,49], along with
online methods to control the exposures, we can optimize the
drug dose delivered to the tumor and the surrounding brain tissue.
Since liposomal doxorubicin has a long circulation time, we can son-
icate regions where a higher dose is desired (such as the vascular por-
tion of the tumor) repeatedly after a delay to extend the duration of
BBB/BTB permeabilization [49] without increasing the dose to the sur-
rounding brain tissue. It would also be interesting to investigate wheth-
er the sonications can release the doxorubicin from the liposomes, as
has been observed by others with liposome-coated microbubbles [30].
Another limitation was our tumor model. While the 9L rat
gliosarcoma model is highly aggressive and the robust survival im-
provement observed here is certainly encouraging, future work is
needed with models that are genetically similar to human GBM and
that have similar growth patterns. The 9L glioma model is not consid-
ered to be highly inﬁltrating [50] and we observed only a relatively
narrow inﬁltrating zone. The disruption of the BBB in the surrounding
brain tissue may not have played as large a role in our outcomes as
might be anticipated clinically. Targeting inﬁltration is anticipated
to be critically important with human GBM, and based on clinical pat-
terns of recurrence [6–8], a margin extending several centimeters
into the “normal” brain may require BBB disruption for effective ther-
apy. Additional work in a more inﬁltrating tumor model is needed to
ensure that we can safely and effectively target such regions. Finally,
this model has been reported to be immunogenic [50], which may
have led to more improved outcomes than would be achieved in
non-immunogenic tumor model.
Fig. 5. Kaplan–Meier survival curves for the four experimental groups. Three long-term
survivors, who did not exhibit impaired activity, were euthanized at different times
(tick marks). Afterwards they were censored.
Table 2
Survival analysis.
Treatment
group
N
animals
Max.
survival
(days)
Median
survival
(days)
ISTmedian
(%)
Mean
survival ±
S.D. (days)
P-Value,
hazard
ratio
Control 7 23 17.5 … 18.6 ± 3 …
FUS-Only 8 21 18.0 2.9 18.9 ± 1 0.85, 1.16
DOX-Only 6 27 20.3 16.2 22.5 ± 3 0.16, 1.18
FUS + DOX 8 >142 35.0 100.0 64.0 ± 48 0.00031, 5.36
Note — Increase in Survival Time [ISTmedian (%)], P-value, and Hazard ratio are relative
to the Control group.
P-Value and Hazard ratio from Log-Rank test between FUS + DOX and Dox-Only group
are 0.00057 and 4.52 respectively.
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Despite these limitations, the favorable outcome of these tests
continues to support the development of this drug delivery technolo-
gy for brain tumors and conﬁrms the notion that a signiﬁcant im-
provement in outcome can be achieved using multiple treatments.
Going forward, we aim to validate these results in an inﬁltrating
human GBM line and to integrate advanced methods for treatment
planning, online monitoring, and post-treatment evaluation to maxi-
mize both the treatment efﬁcacy and safety proﬁle.
5. Conclusions
This work demonstrates that multiple sessions using this FUS
technique to enhance the delivery of liposomal doxorubicin to tumors
and the surrounding brain can have a pronounced therapeutic effect
in this rat glioma model. A strong treatment effect was observed in
7/8 animals in our FUS + DOX group, with no tumor mass found in
histology in six of the animals. Median survival was increased by
100% and 72% compared to control animals that received no treat-
ment and DOX-Only, respectively. Adverse events, including damage
to surrounding brain tissue, impaired activity, skin toxicity, and in
one case, an extensively hemorrhagic tumor, were observed along
with these treatment effects. While these events are consistent with
known side effects of doxorubicin and with an extensive tumor bur-
den, future work should be performed to examine the effects of mul-
tiple FUS + DOX sessions.
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